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Pain management is often one of the most difficult aspects of treatment for 
patients suffering from acute or chronic pain.  The mu-opioid receptor (MOR) agonist, 
morphine, and its derivatives are highly used in pain management strategies. However, 
these medications have many side effects including respiratory depression, 
gastrointestinal problems, as well as dependence and addiction liabilities.  For these 
reasons, innovative new modalities for pain management continue to be needed. One new 
approach to the design of opioid therapies for chronic pain with reduced liabilities is a 
targeted-gene therapy strategy developed by the lab of Dr. Ping-Yee Law at the 
University of Minnesota.  This strategy makes novel use of a MOR S4.54A mutant at 
which the classical opioid antagonist, naloxone, acts as a partial agonist. Targeted gene 
therapy studies using this mutant have shown that naloxone becomes an antinociceptive 
agent at the S4.54A mutant both in vitro and in vivo. Because expression of the mutant 
MOR is targeted to the spinal cord injection site region, systemic administration of 
naloxone results in antagonism of all other (native) MOR’s. The reduced number of 
receptors activated in this paradigm results in no measurable dependence/addiction as 
seen with traditional mu agonists like morphine.  
Despite the clear success of basing this strategy on the S4.54A MOR mutant, the 
origins of this unusual phenotype are not yet understood. It was therefore the overall goal 
of this dissertation to identify the molecular basis for the agonism of naloxone at this 
novel S4.54A mutant. To this end, a model of the wild-type and S4.54A mu opioid 
receptor was developed and ligand docking studies were used to probe this model.  
The opioid receptors, delta, kappa and mu, belong to the Class A subfamily of G-
Protein Coupled Receptors (GPCRs).   These are integral membrane proteins that possess 
seven transmembrane helices (TMHs) arranged to form a closed bundle with loops that 
extend both extracellularly and intracellularly.  The N-terminus is extracellular and the C-
terminus is intracellular.  In recent years, X-ray crystallography studies have yielded 
structures of numerous GPCRs. In 2012, the nociception/orphanin FQ receptor and the 
mu, delta and kappa opioid receptor crystal structures were published.  Prior to the 
release of the MOR crystal structure, we developed a homology model of WT MOR 
using the β2-AR crystal structure
2,3
 as a template with substitutions for TMH 1, 2, 4 and 
7 based on sequence divergences, as described in methods.  This model was then used for 
studies of the MOR including analyzing the receptor for cholesterol and palmitoylaiton 
interactions as well as modeling a homodimer interface for the MOR based on 
experimental data.   
In 2012, new models of WT MOR and the S4.54A/L mutants were developed 
using the MOR crystal structure. The conformational change in TMH4 that would be 
created upon the S4.54A mutation was examined using the simulated annealing/Monte 
Carlo method, Conformational Memories, and the result was incorporated into the model. 
The S4.54A mutant model was then used for naloxone docking studies using Glide. 
These studies revealed that in the crystal structure, Y3.34 forms a hydrogen bond with the 
sidechain of S4.54; however, in the S4.54A MT MOR, this interaction is broken as there 
is no polar partner for Y3.34.  The breaking of this interaction allows the extracellular 
end of TMH4 to kink away from TMH3 and towards TMH5, which leads to changes in 
the packing of the receptor binding pocket.  In the wild type MOR, naloxone interacts 
with D3.32 and sits in close proximity to the binding pocket “toggle switch” residue, 
W6.48, restricting its movement. However, in the S4.54A MT MOR, naloxone sits higher 
in the binding pocket, away from W6.48 and interacts with D3.32 and E5.35.  In this 
higher location, naloxone exerts no effect on W6.48, permitting W6.48 to assume an 
active state conformation.  This shift in binding pocket location for naloxone may be the 
origin of naloxone’s partial agonism in the S4.54A MOR mutant. 
We also explored additional experimental data generated in Dr. Ping Law’s lab 
for other mutations at the 4.54 locus. Mutating S4.54 to Phe or Gly results in the same 
phenotype as the S4.54A mutation. On the other hand, for Ile or Val mutants, naloxone 
behaves as in WT MOR. We propose that in the case of the S4.54 I / V, an increase in 
hydrophobic interactions between W4.50 and I/V4.54 allow TMH4 to maintain its wild 
type conformation.  However, while the S4.54F is also able to increase hydrophobic 
interactions, its size prevents the helix from maintaining the wild type shape.  In the 
S4.54L mutant, there is no increase in hydrophobic interactions and the orientation of the 
leucine gives rise to a straighter TMH4, as seen in the S4.54A MT MOR.  The S4.54G 
mutant offers additional flexibility and a higher turn ratio, with 5 residues per turn in that 
region such that the extracellular end of TMH4 moves away from TMH3 and towards 
TMH5. 
Additionally, Law and coworkers have published studies using a 
S4.54L/T7.44A/C7.47S triple mutant MOR that gives rise to naloxone acting as a full 
agonist.
4
  While this gene therapy has been shown in cells and in spinal cord, the 
underlying mechanism is unknown.  A triple mutant MOR model was developed and 
analyzed to determine the molecular mechanism for which naloxone acts as an agonist.  
The binding pocket for mu opioid ligands is formed by TMHs 3, 5 and 6 in the wild type 
receptor, as seen in the crystal structure with β-FNA
5
 and in our glide dock of naloxone 
(see Chapter 3).  As studied in the single mutant MOR, S4.54 is a lipid facing residue.  
Interestingly, both of the mutated residues on TMH7 (T7.44 and C7.47) in the triple 
mutant MOR also face lipid.  We report here that the combination of the S4.54L mutation 
on TMH4 along with TMH7 face shift changes occur upon mutation of T7.44 and C7.47 
produce overall packing changes that give rise to a different binding pocket than seen in 
the wild type or single mutant MORs.  These changes result in naloxone’s ability to fully 
activate the S4.54L/T7.44A/C7.47S MOR. 
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CHAPTER I 
PALMITOYLATION AND MEMBRANE CHOLESTEROL STABILIZE µ-OPIOID 
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Introduction 
 
A cholesterol–palmitoyl interaction at C7.68(341) has been reported to occur in 
the crystallographic dimeric interface of transmembrane helix (TMH) 1 and Helix 8 in a 
β2-adrenergic receptor (β2-AR) crystal structure 
3
. Because palmitoylation of the 
rhodopsin sub-family of G protein-coupled receptors (GPCR) has been universally 
reported, similar cholesterol–palmitoyl interactions may exist with other GPCRs. 
Palmitoylation is a covalent attachment of palmitic acid to cysteine residues of membrane 
proteins. Sequence alignment has identified cysteine residues in the carboxy termini as 
potential palmitoylation sites in about 78% of the 74 GPCRs examined 
6
. However, these 
 
2 
 
cysteines are not the only palmitoylation sites. For example, although rat μ-opioid 
receptor (OPRM1) has two cysteines [C7.63(346) and C7.68(351)] in its C terminus, 
mutating these cysteines did not decrease the palmitoylation of OPRM1 
7
, suggesting that 
C3.55(170) (the only other intracellular cysteine of rat OPRM1) may be the 
palmitoylation site. Similarly, V1A vasopressin receptor also has palmitoylation sites 
outside its C terminus domain 
8
. Normally, palmitoylation facilitates the membrane 
targeting and signaling of GPCRs 
9
. For instance, palmitoylation-dependent receptor–G 
protein interaction is observed with both β2-adrenergic receptor and M2 muscarinic 
acetylcholine receptor
10
. 
Although there is no definitive answer to how receptor palmitoylation contributes 
to GPCR signaling, the cholesterol–palmitoyl interaction at the β2-AR crystallographic 
dimeric interface suggests that facilitation of homodimerization may be one possible 
scenario. Because of the enrichment of many GPCRs in lipid raft (cholesterol-rich) 
microdomains in cell membranes
11
, cholesterol within such microdomains can be easily 
incorporated into the receptor dimer. In addition, because the interaction surface appears 
to be too small for the GPCR monomer to interact with G proteins
12
, dimerization may 
facilitate G protein coupling. Actually, dimerization of many GPCRs, including OPRM1 
and β2-AR, regulates receptor signaling
13
. In the work described here, we tested the 
hypothesis that a specific cholesterol–palmitoyl interaction at the OPRM1 signaling 
complex may affect its signaling by facilitating homodimerization and G protein coupling.  
Cholesterol, an important component of lipid raft microdomains on cell membrane, 
is critical for GPCR signaling
14
. The localization of some GPCRs in lipid raft 
 
3 
 
microdomains has been suggested to contribute to the downstream signaling 
11
. For 
example, OPRM1 locates in the lipid raft microdomains on cell membrane in the absence 
of agonist 
15
. Extracting cholesterol from the cells disrupts the entirety of lipid raft 
microdomains and inhibits the ability of OPRM1 to transducer signaling, such as 
morphine-induced adenylyl cyclase inhibition and ERK phosphorylation 
15
. Thus if 
cholesterol-palmitoyl interaction could be identified in the interface of OPRM1 
homodimer, the cholesterol and cholesterol-enriched lipid raft microdomains may be 
linked to the receptor palmitoylation during the regulation of receptor signaling. 
Especially, the receptor dimerization and G protein couple may also be involved, which 
can extend our understanding the mechanisms underlying GPCR signaling. 
The palmitoylation site on OPRM1 was identified, and the ability of the cholesterol–
palmitoyl interaction to contribute to receptor homodimerization, G protein coupling, and 
signaling was examined. In addition, a computational model of OPRM1 was developed to 
calculate the contribution of the cholesterol–palmitoyl interaction to the total interaction 
energy at the homodimer interface. 
 
Methods 
 
Palmitoylation Assay 
The palmitoylation assay was carried out as reported by Drisdel et al. 
16
. Briefly, 
receptor was immunoprecipitated with Protein G agarose beads. The beads were then 
sequentially incubated with 50 mM NEM to block free sulfhydryl groups, 1 M 
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hydroxylamine to remove thioester-linked palmitic acid, and 40 M btn-BMCC to 
conjugate biotin to the depalmitoylated cysteines. To assess the receptor palmitoylation 
level, the amount of conjugated biotin was determined by immunoprecipitation and 
immunoblotting 
15, 17
. Protein concentrations and receptor expression levels were 
measured to ensure that equal amounts of receptor were loaded in each lane of the gel. 
   
Membrane Purification and Cholesterol Assay 
Cells were homogenized in 0.32 M sucrose and 10 mM HEPES (pH 7.7). The 
crude lysate was then centrifuged at 1,000 x g for 10 min at 4°C, the supernatant was 
collected, and the pellet was re-homogenized. These processes were repeated until the 
pellet appeared translucent. The collected supernatant was centrifuged at 100,000 x g for 
60 min at 4°C. The pellet was re-suspended and used to determine the cholesterol content 
in cell membranes. The results were normalized against cholesterol levels in cells under 
control condition.  
Cholesterol concentrations were determined by using the Amplex Red Cholesterol 
Assay Kit (Invitrogen, Carlsbad, CA) on the cell membrane preparation following the 
instruction provided by the company.  
To determine the amount of cholesterol associated with OPRM1 complex, a new 
method was used. Cell was treated with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 0.25% sodium deoxycholate, 0.1% Nonidet P-40, 0.5% Triton X-100, 0.1% 
digitonin, 50 mM NaF, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 50 
mM sodium pyrophosphate, 10 mM sodium vanadate, and 1X protease inhibitor cocktail; 
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Roche, Indianapolis, IN). The supernatants from the cells lysate was divided into three 
equal aliquots. These aliquots were used to perform co-immunoprecipitation with PBS 
(control), HA antibody (OPRM1 and C170A were tagged with HA, Convance, 1:1000), 
or FLAG antibody (Sigma, 1:1000). After antibody incubation, Protein G agarose 
(Invitrogen, Carlsbad, CA) was added for additional overnight incubation. The resulted 
agarose was used to determine the amount of precipitated cholesterol with Amplex Red 
Cholesterol Assay Kit (Invitrogen, Carlsbad, CA). The FLAG antibody was used as 
control antibody to exclude the possible influence from antibody usage. The higher 
amount of cholesterol precipitated by HA antibody compared with PBS or FLAG 
antibody reflects the cholesterol associated specifically with OPRM1 signaling complex. 
Although this method could not determine the cholesterol interact with receptor directly, 
but could detect the cholesterol specifically interacted with receptor signaling complex. 
 
FRET (Fluorescence Resonance Energy Transfer) 
CFP and YFP were fused to the C terminus of wild-type OPRM1 or the C170A 
mutant of OPRM1. YFPGαi2 has YFP inserted between residues 91 and 92 of Gαi2 
18
. 
Throughout the studies, all FRET values are expressed as the normalized net FRET by 
the following formula: IFRET =[(ICFP×CoA) – (IYFP×CoB)] / [the square root of 
(ICFP×IYFP)]. IFRET is the fluorescence intensity when a CFP-YFP (excitation-emission) 
filter set is used, ICFP is the fluorescence intensity when a CFP-CFP filter set is used, and 
IYFP is the fluorescence intensity when a YFP-YFP filter set is used. CoA was determined 
in the cells transfected with only CFP constructs by the following formula: CoA= IFRET / 
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ICFP. CoB was determined similarly. Including “square root” in the formula eliminates the 
influence from the differential expression of CFP- and YFP-conjugated protein. Briefly, 
more than twenty individual regions on the cell membrane of a single cell were analyzed, 
and more than twelve individual cells were analyzed for each sample.  
 
OPRM1 Binding Assay 
The amounts of receptor on cell membrane and the affinity of agonists to 
receptors were determined by binding assay 
19
.  Briefly, purified cell membrane was 
incubated with [
3
H]-diprenorphine and agonists/antagonists. After incubation, PEG8000 
and NaCl were added to trapped the receptors on Whatman GF/B filters for final 
radioactive reading. Scatchard analyses were carried out to determine the level of wild-
type or mutant OPRM1 expressed on cell membranes. To determine the affinities of 
various ligands, the cell membranes were incubated with 2 nM [
3
H]-diprenorphine and 
various concentrations of morphine, naloxone, and CTOP (0.01 nM – 10 μM). These 
competition binding studies were analyzed with one- or two-site curve-fitting models in 
GraphPad 5.0.  
 
Transient Transfection 
The pCMV-shuttle vector (Stratagene) was used in current studies. cDNA of 
receptor, Gαi2 and their fluorescence-conjugated constructs were controlled by the CMV 
promoter. The transient transfection was performed with Lipofectamine 2000 (Invitrogen) 
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following the instruction provided by the company. Cells were allowed to rest for 24 
hours before further treatment.  
 
Assays based on antibodies  
Immunoblotting and co-immunoprecipitation assays were performed as described 
previously 
17
. The same Confocal Imager used for FRET was used to analyze 
colocalization. The adenylyl cyclase inhibition was measured as previously reported 
15
. 
ERK phosphorylation was determined by immunoblotting 
17
.  
Colocalization studies were performed as reported previously 
15
. Briefly, cells 
were cultured on poly-lysine-coated coverslip in six-well plates. After transient 
transfection and various treatments, cells were fixed with 2% formaldehyde for 30 min. 
HA antibody, Flag antibody, and Gαi2 antibody were used as primary antibody (1:1000). 
The confocal images were captured with a BD CARV II Confocal Imager and a Leica 
DMIRE2 fluorescence microscope. Colocalization of the fluorescence pixels was 
calculated with IPlab 4.0 software (BD Biosciences-Bioimage) and the following formula:  
2 × Nyellow / (Nred + Ngreen). N represents the number of pixels with fluorescence intensity 
over a pre-defined threshold. 
 
Model development of the OPRM1 homodimer  
A computational model of the OPRM1 inactive state was first developed using a  
β2-AR crystal structure template 
3
 with two major modifications. First, the TMH 
7/elbow/Hx8 region of the β2-AR was replaced with that of the adenosine A2A crystal 
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structure 
20
 because the “elbow region” between TMH7 and the C terminus Helix 8 
contains only two residues (P7.57 D7.58). This results in an elbow region of β2-AR that 
is stretched.  The OPRM1 would not have a similar conformation since it has three elbow 
residues (D7.57 E7.58 N7.59).  We therefore used in the OPRM1 model, the elbow 
conformation in the A2A crystal structure 
20
 which also has three residues. 
 Second, the Monte Carlo/simulated annealing technique CM 
21
 was used to study 
the conformations of three OPRM1 TMHs with important sequence divergences from the 
β2-AR template: TMH2 (P2.58 OPRM1 vs. P2.59 β2-AR), TMH4 (P4.59 OPRM1 vs. 
P4.60 β2-AR), and TMH6 (CWTP OPRM1 vs. CWLP β2-AR).  
 The CM technique explores the low free energy conformations possible for a 
helix of interest using Monte Carlo simulated annealing. The method of CM, developed 
by Guarnieri and Wilson 
22
 and extended by Guarnieri and Weinstein 
23
, efficiently and 
completely explores the dihedral conformational space of a molecule, independent of the 
dihedral conformation of the initial molecular structure. The CM method combines 
Monte Carlo exploration of the dihedral angle space with simulated annealing (MC/SA) 
to determine the range of values that each dihedral angle is capable of exploring in a 
broad temperature range.  The CM method has been expanded to allow the variation of of 
bond angles in addition to dihedral angles 
21
.  In the CM calculations reported here, the 
backbone dihedrals of each helix were set to the standard φ (-63°) and ψ (-41.6°) for 
transmembrane helices.  Our established protocol is to allow all torsion angles to vary 
±10°, and to allow a larger variation of ±50° in regions containing flexible areas.  These 
flexible areas are regions where there are known helix bending residues such as prolines, 
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glycines, serines and/or threonines 
24
.  The OPRM1 TMH regions considered flexible 
were the following: TMH2: region of i (P2.58) to i-4 (T2.54); TMH4 region of i (P4.59) 
to i-4 (A4.55) and TMH6 region of  i (P6.50) to i-4 (V6.46).  Individual bond angles were 
allowed to vary ±8°.  The CM calculation is performed in two phases, an exploratory 
phase and a biased annealing phase.  In the exploratory phase, a random walk is used to 
first identify the region of conformational space most probable for each torsion angle and 
bond angle. The initial temperature for each run was 3000 K with 50,000 Monte Carlo 
steps applied to each torsion or bond angle variation with cooling in 18 steps to a final 
temperature of 310 K. Each step consists of varying two dihedral angles and one bond 
angle chosen at random from the entire set of variable angles. The torsion angles and 
bond angles are randomly picked at each temperature and each move is accepted or 
rejected using the Metropolis criterion 
25
.  Accepted conformations in the Exploratory 
Phase are used to create “memories” of torsion angles and bond angles that were accepted.  
This information provides a map of the accessible conformational space of each TMH as 
a function of temperature. In the biased annealing phase, the only torsion angle and bond 
angle moves attempted are those that would keep the angle in the “populated 
conformational space” mapped at 310K in the exploratory phase. The biased annealing 
phase for the calculations reported here began at 749.4 K with cooling to 310 K in 7 steps. 
105 structures were output at 310 K.  The output from each TMH study was 
superimposed on the corresponding template helix in the β2-AR template that had been 
mutated to the sequence of the OPRM1.  A helix was selected for inclusion in the revised 
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OPRM1 that fit in the bundle with no van der Waals overlaps with residues on other 
TMHs.  
 The CM helices chosen for substitution into the TMH bundle had the following 
helix bend angles, wobble angles, and face shifts: TMH2 (35.2, -105.8, 40.3), TMH4 
(14.8, -126.1, 25.9), and TMH6 (30.6, -129.9, 45.6). Extracellular and intracellular 
loops were then added using MODELLER v8.2 
26
. Energy minimizations were performed 
using Macromodel and the OPLS2005 all-atom force field (version 9.8, Schrödinger, 
LLC, New York, NY). A distance-dependent dielectric, 8.0 Å extended nonbonded cutoff, 
20.0 Å electrostatic cutoff, and 4.0 Å hydrogen bond cutoff were used.   
The palmitoyl was then added to C3.55(170), and a cholesterol was docked 
between palmitoylated C3.55(170) and TMH3. Interactive docking studies in Maestro 
(version 9.1, Schrödinger, LLC, New York, NY) were used to orient two 
OPRM1/cholesterol protomers at the symmetric TMH4 interface of mouse dark state 
rhodopsin 
27
.  In this orientation, the OPRM1 protomers form an interface analogous to 
that shown by Guo and co-workers to characterize the inactive state homodimer interface 
of the dopamine D2 receptor 
1
.  This interface in OPRM1 involves N4.41, I4.44, C4.48, 
I4.51, A4.55, and P4.59 on each protomer.  In the resultant dimer, cholesterol is packed 
up against the TMH4 interface and TMH3.  The palmitoyl at C3.55(170) is packed 
against the cholesterol and TMH5, blocking cholesterol from leaving the interface. The 
energy of the OPRM1 homodimer complex was minimized using the same force field, 
dielectric, and cutoffs as described above. In the first stage of the calculation, Polak-
Ribier conjugate gradient minimization was employed until a gradient of 0.1 kcal/mol·A
2
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was reached. A force constant of 250 kcal/mol was used on the loop backbone atoms.  All 
charged residues in the loop regions and at the ends of the TMHs that face toward lipid 
head groups were mutated to neutral forms. Non-moving fixed atom restraints were 
applied to the C-alpha atoms of TMH3 in both protomers, restraining the protomers from 
moving apart. The protocol was repeated with TMH3 non-moving fixed restraints 
removed.  
Macromodel was used to output the pair-wise interaction energy (van der Waals 
and coulombic) for a given pair of atoms.  The nonbonded interactions are represented in 
OPLS2005 as implemented in Macromodel through Coulomb and Lennard-Jones terms 
interacting between sites centered on nuclei. Thus, the intermolecular interaction energy 
between molecules a and b is given by the sum of interactions between the sites on the 
two molecules 
28
 as represented in the equation below: 
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a and b are collected by Macromodel as atom sets representing all atoms of a single 
residue for a and all atoms of a nearby residue for b.  The residue represented by a is 
evaluated separately against all residues within a 7.0Ǻ radius of residue a.  With 
Cholesterol A defined as Group 1 and with all of the atoms of any residue within 7.0 Å of 
Protomers A or B defined as Group 2, the pair-wise interaction energies were calculated. 
The interaction energy at the homodimer interface was calculated as the sum of the 
interaction energies between Protomers A and B at the homodimer interface plus the 
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interaction energy of Cholesterol A with Protomer B and the interaction energy of 
Cholesterol B with Protomer A. The close interaction and steric bulk of Protomer A’s 
TMH4 with Protomer B’s TMH4 blocked Cholesterols A and B from interacting with 
each other. The palmitoyls could not interact with each other for the same reason. 
This additional information has been added to the Materials and Methods section. 
 
Statistic methods 
Experiments were repeated at least four times (more than twelve individual cells 
for image analysis). Data were analyzed and compared by one-way ANOVA with 
Dunnett-test as post-hoc test for comparisons, or by two-way ANOVA with Bonferroni-
test as post-hoc test. Error bars and “*” presented the standard deviations and significant 
changes (p<0.05), respectively. 
 
List of Abbreviations  
The following abbreviations are used: 2-BP, 2-bromopalmitate; β2-AR, β2-
adrenergic receptor; btn-BMCC, 1-biotinamido-4- [4-(maleimidomethyl) cyclohexane 
carboxamido] butane; CM: Conformational Memories; CTOP, Cys2-Tyr3-Orn5-Pen7-
amide; GM1, monosialotetrahexosylganglioside; GPCR, G protein-coupled receptor; 
NEM, N-ethylmaleimide; OPRM1, μ-opioid receptor; TMH, transmembrane helix; TR, 
transferrin receptor; VDW, van der Waals. 
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Results 
 
Cys
170
 is the palmitoylation site of OPRM1 
Wild-type HEK293 cells (HEK) and HEKOPRM1 cells (HEK cells 
heterologously expressing OPRM1 with HA spliced at the amino terminus) were used to 
validate the palmitoylation assay 
16
. The HA-tagged receptor were precipitated with HA 
antibody and Protein G agarose. The following procedures were used to determine 
receptor palmitoylation: 1) The free sulfhydryl groups in precipitated receptor were 
blocked with N-ethylmaleimide (NEM). 2) The palmitoylated cysteine was and 
hydrolyzed with hydroxylamine. 3) Biotin was conjugated to the de-palmitoylated 
cysteines in the immunoprecipitated receptor with btn-BMCC (1-biotinamido-4- [4-
(maleimidomethyl) cyclohexane carboxamido] butane). The amounts of biotin linked to 
the receptor were determined by immunoblotting.  
Intensive biotin labeling was detected in HEKOPRM1 cells, but not in HEK cells, 
suggesting that the detected palmitoylation is specific to OPRM1 (Fig. 1.1a, Lanes 1-2). 
Since NEM was used to blocked the free sulfhydryl groups, the immunoreactivity of 
biotin increased when the NEM step was omitted (Fig. 1.1a, Lane 4). In addition, the 
immunoreactivity of biotin decreased when hydroxylamine step was omitted (Fig. 1.1a, 
Lanes 5), and no biotin was detected when btn-BMCC was not used (Fig. 1.1a, Lanes 6), 
suggesting that the assay is suitable for detecting the palmitoylation of OPRM1. 
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To confirm the assay used can detect the palmitoylation specifically, 2-
bromopalmitate (2-BP), a palmitoylation inhibitor, was used to block all the 
palmitoylation. A low level of receptor palmitoylation was observed when HEKOPRM1 
cells were pretreated with the 2-BP for 12 h (Fig. 1.1a, Lane 3), which also suggests the 
detected palmitoylation is on OPRM1. Since palmitoylation is important for the cell 
functions, prolonged treatment or high concentration of 2-BP will affect cell viability.  
 
Thus in the current study the treatment time and concentration of 2-BP were 
determined empirically so as to inhibit receptor palmitoylation and to have minimal effect 
Figure 1.1. Cys
170
 is the palmitoylation site of OPRM1. (a) Palmitoylation assays were performed in 
HEK and HEKOPRM1 cells. The amounts of palmitoylated receptor were normalized against that in 
HEKOPRM1 (Lane 2). 50 μM 2-BP was used to treat HEKOPRM1 for 12 h (Lane 3). Individual steps 
(treatment with NEM, hydroxylamine, or btn-BMCC) were omitted to validate the assay (Lanes 4-6). 
(b) The palmitoylation assay was performed in HEK, HEKOPRM1, HEKOPRM1 treated with 50 µM 
2-BP for 12 h, HEKC170A, HEKC346A, and HEKC351A cells. The amounts of palmitoylated receptor 
were normalized against that in HEKOPRM1 (Lane 2). (c-e) Membrane receptor levels were 
determined with immunoblotting (c), binding assay (d), and FACS (e). (f) HEKOPRM1, HEKOPRM1 
treated with 50 μM 2-BP for 12 hr, and HEKC170A cells were treated with 1 µM morphine for 5 min. 
Phosphorylated ERK and total-ERK were determined by immunoblotting. One-way ANOVA with 
Dunnett-test as post-hoc test was used for analysis. The error bars and “*” presented the standard 
deviations and significant changes (p<0.05, n>3), respectively. 
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on cell viability. Thus the current 2-BP treatment paradigm did not block receptor 
palmitoylation totally. 
Mutating the two conserved cysteine residues [C8.53(346) and C8.58(351)] in the 
C terminus of OPRM1 does not affect palmitoylation 
7
. Thus the only other intracellular 
cysteine, C3.55(170), should be the putative palmitoylation site. To confirm this 
hypothesis, these three cysteines were mutated to alanine individually, and the mutants 
were stably expressed in HEK cells to obtain HEKC170A, HEKC346A, and HEKC351A. 
Although C170A is difficult to stably express in CHO cells 
7
, we successfully expressed a 
high level of C170A in the cell membrane of HEK cells, possibly due to the differences 
between cell lines and poly-L-lysine used during the cell culture. As shown in Fig. 1.1b, 
Lanes 2 and 5-6, similar amounts of palmitoylated receptor were detected in 
HEKOPRM1, HEKC346A, and HEKC351A cells. Furthermore, the amount of 
palmitoylated receptor in HEKC170A cells was similar to that in 2-BP-pretreated 
HEKOPRM1 cells (Fig. 1.1b). Therefore, it is reasonable to suggest that C3.55(170) but 
not C8.53(346) or C8.58(351) was the palmitoylation site of OPRM1. 
Immunoblotting indicated that the overall receptor expression levels were similar 
in these cell lines (Fig. 1.1c), and a [
3
H]-diprenorphine
 
saturation binding assay with 
isolated cell membranes indicated that there was no difference in the amounts of 
receptors in the cell membranes. HEK, HEKOPRM1, HEKC170A, HEKC346A, and 
HEKC351A cells have membrane receptor expressed at 0.06±0.05, 6.87±1.14, 7.36±1.10, 
5.12±1.67, and 6.80±1.61 pmol/mg protein respectively (Fig. 1.1d). To further confirm 
that there is no difference in the amounts of membrane receptor in these cell lines, 
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antibody against the HA-tag was used for FACS analysis (Fig. 1.1e). Since the HA was 
tagged in the N-terminal of receptors and the cell membrane was not disrupted during the 
analysis, the results obtained from FACS assay should represent the actual amounts of 
membrane receptor. Thus there was no difference in membrane receptor levels, it is 
reasonable to conclude that C3.55(170) is the major palmitoylation site of OPRM1. For 
the sake of consistency, “OPRM1” is used for the wild-type OPRM1, “C170A” is used 
for the palmitoylation-deficient mutant, and “receptor” indicates both the wild type and 
mutants in subsequent studies described here.  
In addition, agonist treatment did not affect receptor palmitoylation when 
morphine and fentanyl were used to challenge the HEKOPRM1 cells (data not shown). 
Since the current studies focused on how receptor palmitoylation influenced receptor 
signaling, the effects of agonists on receptor palmitoylation or other subsequent 
observations were not discussed in depth.  
 
Receptor palmitoylation stabilizes morphine-induced signaling and receptor-Gαi2 
coupling 
To determine the influence of palmitoylation on receptor signaling, morphine-
induced adenylyl cyclase inhibition and ERK phosphorylation were monitored. 
Morphine-induced adenylyl cyclase inhibition is defined by the ability of morphine to 
inhibit the forskolin-induced increase in the intracellular cAMP level. Morphine-induced 
ERK phosphorylation was analyzed by calculating the percentage increase of 
phosphorylated ERK when compared to basal level.   
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 HEKOPRM1 HEKC170A 
Relative Affinities    
239  Morphine KH (nM) 2.8±0.56 2.2±0.42 
 KL (nM) 155±27 123±31 
  Naloxone           KI (nM) 5.1±0.71 6.2±1.2 
  CTOP                KI (nM) 11±1.4 9.5±2.1 
   
 
 
As summarized in Table 1.1, no difference in the affinities for ligands [morphine, 
naloxone, and Cys
2
-Tyr
3
-Orn
5
-Pen
7
-amide (CTOP)] was detected between OPRM1 and 
C170A. For example, the KI of CTOP was 11±1.4 nM in HEKOPRM1 cells, and was 
9.5±2.1 nM in HEKC170A cells (Table I). In addition, the expression levels of OPRM1 
and C170A in the cell membrane were similar (Fig. 1.1c-e). However, morphine induced 
less signaling in HEKC170A than in HEKOPRM1 cells. The ability of morphine to 
induce adenylyl cyclase inhibition in HEKC170A was about 75% of that in HEKOPRM1, 
when the maximum inhibition was analyzed (Table 2). The ability to induce ERK 
phosphorylation in HEKC170A was about 69% of that in HEKOPRM1 (Table 2 and Fig. 
1.1f). In addition, morphine induced receptor signaling in 2-BP-treated HEKOPRM1 
Table 1.1. Palmitoylation did not affect the binding of agonists 
The affinities of receptor for ligands were determined in HEKOPRM1 and HEKC170A cells using 
agonist binding assay. One-site (KI: naloxone and CTOP) or two-site (KH and KL: morphine) 
curve-fitting models were used in the analyses with GraphPad Prism 5.0. . Data were analyzed by 
one-way ANOVA with post-hoc Dunnett’s test. Standard deviations are provided, and “*” 
represents significant changes (p<0.05). 
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cells as did in HEKC170A cells (Table 2 and Fig. 1.1f). Thus palmitoylation blockage 
impairs receptor signaling induced by morphine.  
 
 
 HEKOPRM1 HEKOPRM1 
+2-BP 
HEKC170A 
Morphine-Induced Signaling    
 AC Inhibition KI (nM) 9.3±0.89 15±1.2* 14±1.3* 
 Max. Inh. (%) 84±2.8 56±5.1* 63±4.3* 
  pERK  (% of basal) 239±10 154±10* 164±12* 
 
Both signaling events monitored above are mediated via Gαi2 
15
; thus, the effect 
of receptor palmitoylation on Gαi2 coupling was investigated. The colocalization 
between receptor and Gαi2 in HEKOPRM1 was more obvious than in HEKC170A cells, 
when the immunoreactivity of OPRM1 and Gαi2 on the cell membrane was analyzed 
(Fig. 1.2a). Similar observations were noted in the co-immunoprecipitation experiments 
(Fig. 1.2b and 1.2c). When Gαi2 antibody was used to perform co-immunoprecipitation, 
the amount of OPRM1 co-immunoprecipitated with Gαi2 was larger than that of C170A. 
When HA antibody was used to immunoprecipitate the receptor, more Gαi2 was co-
immunoprecipitated with OPRM1 than with C170A. Thus the interaction between Gαi2 
and C170A is weaker than that between Gαi2 and OPRM1.     
Table 1.2. Palmitoylation impaired morphine-induced receptor signaling  
 
The percentage inhibition of forskolin-induced cAMP increase by various concentrations of morphine was 
analyzed with GraphPad Prism 5.0. The results are presented as the maximum inhibition (Max. Inh.) and 
the IC50 values (KI). ERK phosphorylation was indicated by the amount of phosphorylated ERK after 5 
min of treatment with 1 μM morphine (Blots were provided in Fig. 1f). The amount of total ERK and the 
results under control condition were used for normalization. Experiments were repeated at least four times. 
Data were analyzed by one-way ANOVA with post-hoc Dunnett’s test. Standard deviations are provided, 
and “*” represents significant changes (p<0.05). 
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 The interaction between receptor and Gαi2 was investigated further with FRET 
analysis. The normalized net FRET between CFPOPRM1 and YFPGαi2 was much 
higher than that between CFP and YFP, suggesting that OPRM1 and Gαi2 were in 
proximity of each other, ≤ 10 nm. The FRET analysis was performed on the cell 
membrane to exclude the possible influence from the intracellular expression of 
fluorescence constructs. The normalized net FRET between CFPOPRM1 and YFPGαi2 
was higher than that between CFPC170A and YFPGαi2 (Fig. 1.2d). Because 1) the 
expressions of the fluorescence constructs, like CFPOPRMA1 and YFPGαi2, were kept 
to the similar levels by titrating the amounts of plasmids used for transfection; 2) 
immunoblotting was also used to monitor the expression during the studies, and 3) 
overall fluorescence intensities were determined prior to FRET and colocalization studies, 
the FRET difference supports the conclusion that blockage of receptor palmitoylation in 
the C170A mutant impairs Gαi2 coupling. 
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The YFP/CFP tagged receptors had similar functions as FLAG- and HA-tagged. 
Morphine-induced adenylyl cyclase inhibition in the cells transiently expressed these 
receptor constructs with similar KIs: 9.8±1.1 nM (HA-tagged OPRM1), 10.7±1.4 nM 
Figure 1.2. Palmitoylation contributes to Gαi2 coupling.  (a) The 
colocalization between HA-tagged receptor and Gαi2 was determined in 
HEKOPRM1 and HEKC170A cells. Images were analyzed as described 
in Methods. (b) Anti-HA antibody was used to precipitate receptors in 
HEKOPRM1 and HEKC170A cells. Gαi2 precipitated with receptors 
was quantified and normalized to that in HEKOPRM1cells.  (c) Co-
immunoprecipitation was performed with Anti-Gαi2 antibody, and the 
precipitated receptor was quantified.  (d) CFPMOR or CFPC170A was 
transfected into HEK cells with YFPGαi2. FRET analysis was 
performed.  Two-tailed student t-test was used. Error bars and “*” 
represent the standard deviations and significant changes (p<0.05, n>3 
for b and c; n>10 for a and d), respectively. IP, immunoprecipitation;  
IB, immunoblotting 
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(FLAG-tagged OPRM1), 8.9±1.2 nM (CFPOPRM1), and 9.5±0.8 nM (YFPOPRM1). 
Thus the FRET experiment could indicate the function characteristics of receptors.  
 
Receptor palmitoylation facilitates homodimerization and subsequent Gαi2 coupling 
The possible contribution of OPRM1 palmitoylation to homodimerization was 
investigated by performing FRET analysis between CFPOPRM1/CFPC170A and 
YFPOPRM1/YFPC170A. As indicated in Fig. 1.3a, the normalized net FRET between 
CFPOPRM1 and YFPOPRM1 was 0.49±0.03, whereas it was 0.07±0.02 between 
CFPC170A and YFPC170A in the cell membrane. In addition, when the HEK cells were 
co-transfected with CFPOPRM1 and YFPC170A or with CFPC170A and YFPOPRM1, 
the normalized net FRETs were 0.30±0.05 and 0.27±0.05, respectively. The 
colocalization and co-immunoprecipitation assays between HAOPRM1/HAC170A and 
FLAGOPRM1/FLAGC170A confirmed the results of the FRET assay (Fig. 1.3b and 
1.3c). In summary, colocalization, co-immunoprecipitation, and FRET studies suggest 
that the amount of OPRM1-OPRM1 homodimer is larger than the amount of OPRM1-
C170A dimer, and the amount of OPRM1-C170A dimer is larger than that of C170A-
C170A homodimer, when similar levels of receptors are expressed. It is reasonable, 
therefore, to suggest that the ability of C170A to form a homodimer is lower than that of 
OPRM1.  
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Because the amounts of homodimer decreased sequentially from Lane 1 to Lane 4 
in Fig. 1.3c, we used FRET analysis to determine if the decrease affected receptor–Gαi2 
coupling (Fig. 1.4a). We transiently transfected YFPGαi2 with either CFPOPRM1 or 
CFPC170A into HEKOPRM1 and HEKC170A cells. Two caveats in these experiments 
were considered so as to ensure the success of the studies: 1) HEKOPRM1 and 
Figure 1.3.  Palmitoylation stabilizes homodimerization. (a) FRET analysis was 
performed after transfecting combinations of CFPOPRM1/CFPC170A and 
YFPOPRM1/YFPC170A into HEK cells. (b-c) FLAGOPRM1 /FLAGC170A and 
HAOPRM1/HAC170A were transfected into HEK cells. The colocalization 
between FLAG-tagged receptor and HA-tagged receptor was determined in (b). 
The amounts of HA-tagged receptor precipitated with Flag-tagged receptor were 
normalized against the amount of HAOPRM1 precipitated with FLAGOPRM1 and 
summarized in (c). One-way ANOVA with Dunnett-test as post-hoc test was used 
for analysis. The error bars and “*” presented the standard deviations and 
significant changes (p<0.05, n>3), respectively 
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HEKC170A cells expressed similar amounts of membrane receptors; 2) transient 
transfection of CFPOPRM1 and CFPC170A was tightly controlled to reach the similar 
expression levels.   
If receptor palmitoylation affects Gαi2 coupling, a similar sequential decrease in 
receptor–Gαi2 coupling should be observed between OPRM1 homodimer, OPRM1-
C170A dimer and C170A homodimer. As indicated in Fig. 4a, the normalized net FRET 
between CFPOPRM1 and YFPGαi2 was greater than that between CFPC170A and 
YFPGαi2 in both HEKOPRM1 and HEKC170A cells. The normalized net FRET 
between CFPOPRM1 and YFPGαi2 as well as between CFPC170A and YFPGαi2 was 
greater in HEKOPRM1 than in HEKC170A. These results suggest a positive correlation 
between the receptor palmitoylation and Gαi2 coupling.   
This correlation could be explained by two mechanisms. One possible explanation 
is that the homodimers affinity for Gαi2 is much higher than the monomer’s affinity for 
Gαi2; this mechanism is supported by a previous report 
12
. A second explanation is that 
the C170A monomer’s affinity for Gαi2 is much lower than the OPRM1 monomer’s 
affinity for Gαi2. If the second mechanism was the dominant one, the FRET between 
transiently transfected CFPC170A and YFPGαi2 should be smaller in HEKOPRM1 cells 
than in HEKC170A cells, because OPRM1’s higher affinity for YFPGαi2 would result in 
a higher competition for Gαi2 in HEKOPRM1 than in HEKC170A. 
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However, the FRET analysis produced the opposite result: FRET between 
CFPC170A and YFPGαi2 was higher in HEKOPRM1 cells than in HEKC170A cells 
Figure 1.4.  Palmitoylation stabilizes Gαi2 coupling.  (a) The FRET between CFPOPRM1 and 
YFPGαi2 and the FRET between CFPC170A and YFPGαi2 were determined in HEKOPRM1 and 
HEKC170A cells. (b-c) Colocalization between FLAGOPRM1 and Gαi2 (or FLAGC170A and 
Gαi2) was compared in HEKOPRM1 and HEKC170A cells after transfection (b). The amounts of 
Gαi2 precipitated with FLAGOPRM1 and FLAGC170A in the two cell lines were compared in (c). 
The amount of Gαi2 precipitated with FLAGOPRM1 in HEKOPRM1 cells was used for 
normalization. One-way ANOVA with Dunnett-test as post-hoc test was used. The error bars and 
“*” presented the standard deviations and significant changes (p<0.05, n>3), respectively. 
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(Fig. 1.4a). These observations suggest that the reduced receptor dimerization in the 
absence of palmitoylation leads to decreased Gαi2 coupling. Additional colocalization 
and co-immunoprecipitation studies further support this hypothesis (Fig. 1.4b and 1.4c). 
These results indicate a correlation between receptor homodimerization and Gαi2 
coupling.  
 
Receptor palmitoylation facilitates cholesterol association in the receptor signaling 
complex 
Although it still requires further investigation to explore the contribution of 
receptor dimerization to G protein coupling, receptor palmitoylation facilitating receptor 
dimerization and G protein coupling was established above. In order to determine the 
detailed mechanisms underlying these phenomena, the observed interaction between 
cholesterol and palmitoyl group in the crystal structure of β2-AR 
3
 was utilized. To 
determine the existence of similar cholesterol-palmitoyl interaction in OPRM1 complex, 
the cholesterol exists in the receptor complex should be quantified first. Because the 
direct detection of the cholesterol within the homodimer requires the purification of the 
receptor to homogeneity, and there is no guarantee that the cholesterol–receptor 
association will stay intact during purification, we instead examined the amount of 
cholesterol incorporated into the receptor signaling complex.  
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A new method was used to determine cholesterol association with receptor 
complex. HA-antibody was used to precipitate the HA-tagged receptor. If cholesterol did 
associate with receptor complex specifically, larger amount of cholesterol should be 
precipitated by HA antibody when compared to the immunoprecipitation with no 
antibody.  To avoid the possible influence from the usage of antibody, FLAG antibody 
(no protein was tagged FLAG in current paradigm) was used as control antibody.   
Cholesterol association with the receptor signaling complex was indicated by the 
additional amount of cholesterol precipitated by HA antibody compared with that 
Figure 1.5.  Palmitoylation facilitates 
cholesterol association. (a) 
Cholesterol associated with receptor 
complex was determined in HEK, 
HEKOPRM1, HEKC170A cells. The 
amount of cholesterol precipitated with 
PBS in HEK cells was used for 
normalization.  (b-c) HEKOPRM1 and 
HEKC170A cells were treated with 
PBS (Control), 0.5 M simvastatin 
(Simva), or 0.5 M simvastatin with 
20 ng/ml cholesterol (Simva+Chol) for 
12 h. Membrane cholesterol contents 
were determined in (b) as described in 
Materials and Methods. Cholesterol 
association with receptor complex was 
determined in (c).  One-way ANOVA 
with Dunnett-test (b) or two-way 
ANOVA with Bonferroni’s test (a, c) 
was used. The error bars and “*” 
presented the standard deviations and 
significant changes (p<0.05, n>3), 
respectively. IP, immunoprecipitation; 
IB, immunoblot; N/S, no significance. 
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precipitated by a control antibody. The extensive washing with lysis buffer containing 
Triton X-100 and digitonin ensured the removal of cholesterol that was nonspecifically 
associated with the receptor signaling complex. With this procedure, HA antibody 
precipitated more cholesterol in HEKOPRM1 cells than FLAG antibody or PBS did. 
Since receptor was HA tagged at the N-terminal, the detected cholesterol in precipitated 
receptors should be the cholesterol associated with receptor signaling complex. As 
control experiments, in HEK cells, the two antibodies and PBS precipitated similar 
amounts of cholesterol (Fig. 1.5a). These results suggest that this assay can detect the 
cholesterol associated with the receptor signaling complex.  
Decreased cholesterol association was also noted in HEKC170A cells (Fig. 1.5a). 
The amount of cholesterol precipitated with HA antibody was similar to that precipitated 
with FLAG antibody, suggesting the mutation on C3.55(170) contributes to the  
cholesterol association. Although the assay could not distinguish between cholesterol that 
associates with the receptor directly and cholesterol that associates with other proteins 
within the signaling complex, receptor palmitoylation appears to regulate the amount of 
cholesterol that associates with the complex.  
 
Cholesterol association facilitates homodimerization and Gαi2 coupling 
The cholesterol-palmitoyl interaction has been suggested in the β2-AR crystal 
structure. Receptor palmitoylation was demonstrated to facilitate receptor dimerization 
and G protein coupling from Fig. 1.2 to Fig. 1.4, thus it is possible that cholesterol has the 
same functions. To determine the contribution of cholesterol association to receptor 
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signaling, simvastatin, an HMG-CoA reductase inhibitor was used to treat the cells. 
Receptor dimerization and G protein coupling was assayed with FRET, co-localization, 
and immunoprecipitation. 
After treating HEKOPRM1 cells with 0.5 µM simvastatin for 12 h, the cellular 
cholesterol content decreased on the cell membrane. The decreases in cholesterol content 
could be prevented by the inclusion of 20 ng/ml cholesterol during the simvastatin 
treatment (Fig. 1.5b). As expected, simvastatin treatment also induced a decrease in 
cholesterol level on the membrane of HEKC170A cells (Fig. 1.5b). 
How cholesterol depletion influenced its association to receptor signaling 
complex was accessed. Simvastatin treatment decreased the association of cholesterol to 
receptor complex, which could be prevented by including 20 ng/ml cholesterol in the 
culture medium (Fig. 1.5c). Simvastatin not only decreased the amount of cholesterol 
precipitated in the “PBS” group, but also impaired the ability of HA antibody to 
precipitate more cholesterol than FLAG antibody. Since cholesterol association was not 
detected in the HEKC170A cells, simvastatin treatment had no effect in these cells (Fig. 
1.5c). 
Simvastatin decreased the cellular cholesterol content, the FRET assay was then 
used to determine whether cholesterol content affect receptor dimerization and G protein 
couping. The normalized net FRET between CFPOPRM1 and YFPOPRM1 in 
simvastatin-treated HEK cells was decreased and could be reversed by inclusion of 
cholesterol during the simvastatin treatment (Fig. 1.6a). A similar simvastatin-mediated 
decrease was also observed with CFPOPRM1 and YFPGαi2 and could also be reversed 
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by the inclusion of cholesterol during the simvastatin treatment (Fig. 1.6b). However, the 
cholesterol depletion induced by simvastatin did not affect the homodimerization (Fig. 
1.6a) and G protein coupling of C170A (Fig. 1.6b). Therefore, the presence of cholesterol 
within the receptor signaling complex is critical for receptor homodimerization and Gαi2 
coupling.   
 
 
 
Figure 1.6.  Reducing cellular cholesterol affects homodimerization 
and G protein coupling (a) HEK cells were transfected with 
CFPOPRM1 and YFPOPRM1 or transfected with CFPC170A and 
YFPC170A for 24 h. These cells were than treated with with PBS 
(Control), 0.5 M simvastatin (Simva), or 0.5 M simvastatin with 20 
ng/ml cholesterol (Simva+Chol) for 12 h.  The FRET was analyzed to 
determine the amount of homodimer.  (b) HEK cells were transfected 
with CFPOPRM1 and YFPGαi2 or transfected with CFPC170A and 
YFPGαi2 for 24 h. These cells were than treated as in (a), G protein 
coupling was determined with FRETassay.  One-way ANOVA with 
Dunnett-test was used. The error bars and “*” presented the standard 
deviations and significant changes (p<0.05, n>3), respectively.  
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The relationship between receptor palmitoylation, cholesterol association, and 
receptor dimerization was further illustrated by incubating cells with the palmitoylation 
inhibitor 2-BP. A decrease in the cholesterol associated with the OPRM1 signaling 
complex was also observed after 2-BP treatment (Fig. 1.7a). Due to the inhibitory effect 
of palmitoylation blockage on Gαi2 membrane targeting 
29
, the influence of 2-BP on 
Gαi2 coupling was not investigated. Reduction in the normalized net FRET between 
CFPOPRM1 and YFPOPRM1 was also seen after 2-BP treatment (Fig. 1.7b). In addition, 
2-BP treatment did not affect the cholesterol association with C170A or the 
homodimerization of C170A, since palmitoylation blockage in C170A already impaired 
these two function to the basal levels (Fig. 1.7).  
Figure 1.7.  Palmitoylation inhibitor impairs homodimerization 
and cholesterol association.  (a) HEKOPRM1 or HEKC170A cells 
were treated with 50 μM 2-BP or vehicle for 12 hours, the cholesterol 
associated with receptor complex was measured.  (b) HEK cells were 
transfected with CFPOPRM1 and YFPOPRM1 or transfected with 
CFPC170A and YFPC170A for 24 hours. 50 μM 2-BP or vehicle was 
used to treat the cells for additional 12 hours. FRET was then 
determined.  Two-way ANOVA with Bonferroni-test (a) or student t-
test (b) was used. Error bars and “*” presented the standard deviations 
and significant changes (p<0.05, n>3), respectively. 
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Computational modeling suggests that palmitoyl–cholesterol interaction stabilizes 
the OPRM1 homodimer  
Modeling studies were used to confirm that a specific cholesterol interaction with 
palmitoylated C3.55(170) may enhance the interactions at the homodimer interface of 
OPRM1. The OPRM1 model developed for the modeling studies reported here is a 
homology model that uses the β2-AR crystal structure as a template 
2
. As mentioned in 
Materials and Methods the OPRM1 has two TMHs that differ in the position of helix 
deforming residues from the template β2-AR (TMH2: P2.58 OPRM1 vs. P2.59 β2-AR 
and TMH4: P4.59 OPRM1 vs. P4.60 β2-AR).  Our Conformational Memories 
calculations revealed that the location of P2.58 in OPRM1 causes the pitch of TMH2 to 
change after the proline such that residue 2.60 faces into the binding pocket.  This same 
residue position in the β2-AR resides in the TMH2/3 interface. These results from 
Conformational Memories (CM) are consistent with the conformation of TMH2 in the 
CXCR4 crystal structure. CXCR4  also has a Pro at 2.58) 
30
. The TMH4 region from 4.53 
to 4.58 is SSAIGLP in OPRM1. CM calculations showed that the presence of the G2.56 
so close to P2.58 causes a wider turn in TMH4 than is seen in β2-AR.  The net result is 
that the EC end of TMH4 leans more towards TMH5.  One result of this change is the 
lipid exposure of residue 4.59, a key residue in the TMH4 dimer interface, see below.  
These two key helix changes, along with changes in helix packing due to these changes 
distinguish the OPRM1 binding pocket (and lipid face) from that of  β2-ARThe detailed 
modeling procedures are described in Materials and Methods. Fig. 1.8a illustrates the 
position of cholesterol relative to the palmitoyl and the TMH bundle. Due to the extreme 
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tilt of TMH3 in the TMH bundle, the intracellular end of TMH3 (orange) is between the 
intracellular ends of TMH4 (yellow) and TMH5 (cyan). This position of TMH3 allows 
the cholesterol to pack between the C3.55(170) palmitoyl and TMH4. Fig. 1.8b provides 
an extracellular view of the final energy-minimized OPRM1 homodimer. In the resultant 
dimer, cholesterol is packed up against the TMH4 interface and TMH3.  The palmitoyl at 
C3.55(170) is packed against the cholesterol with TMH5, blocking cholesterol from 
leaving the interface. Table III provides a summary of the resultant interaction energies 
for the palmitoylated OPRM1 homodimer/cholesterol complex. It is clear here that the 
major energetic contributions to the interaction energies between the protomers are van 
der Waals (VDW) energies.   
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Figure 1.8.  Computational modeling of the OPRM1 homodimer interface. (a) 
This figure illustrates the position of cholesterol relative to the palmitoyl and the 
OPRM1 TMH bundle.  The view is from lipid looking toward TMH4 (yellow).  The 
OPRM1 model is displayed in molecular surface view, with cholesterol (green) and 
palmitoyl (orange) contoured at their van der Waals radii. TMH3and TMH5 are in 
orange and cyan, respectively.  (b) This figure illustrates an extracellular view of 
Protomers A and B forming the OPRM1 homodimer TMH4 interface. Residues that 
form the interface (N4.41, I4.44, C4.48, I4.51, A4.55, and P4.59) are contoured at 
their van der Waals radii and colored magenta.  Also contoured at their van der 
Waals radii are the palmitoyls (orange) and cholesterols (green). In this arrangement, 
cholesterols associated with one protomer also interact with the opposite protomer. 
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The homodimer interface residues with VDW contributions are N4.41, I4.44, 
C4.48, I4.51, and I4.56, with a total energy of -14.76 kcal/mol.  The cholesterol 
associated with Protomer A interacts with Protomer B residues R4.40, N4.41, K4.43, 
I4.44, and V4.47, contributing an additional -2.44 kcal/mol, and the cholesterol 
associated with Protomer B contributes an additional -2.39 kcal/mol similarly. Thus, the 
total cholesterol interactions (-4.83 kcal/mol) contribute 24.7% to the total interaction 
energy at the homodimer interface (-19.59 kcal/mol), suggesting that interaction between 
cholesterol and palmitoyl facilitates OPRM1 homodimerization. 
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Table 1.3.  Homodimer Interface Interaction Energies 
 
Interaction Energies 
Coulombic VDW Total 
kcal/mol kcal/mol kcal/mol 
Protomer A, B 
 T4.38 -0.01 -0.03 -0.04 
 P4.39 0.08 -0.02 0.06 
 R4.40 0.30 -0.31 -0.01 
 N4.41 -0.32 -1.06 -1.38 
 I4.44 -0.02 -3.56 -3.58 
 I4.45 0.09 -1.22 -1.13 
 V4.47 -0.06 -0.24 -0.31 
 C4.48 0.11 -1.49 -1.38 
 W4.50 0.03 -0.02 0.01 
 I4.51 0.18 -2.77 -2.58 
 L4.52 0.03 -0.11 -0.08 
 S4.54 0.03 -0.06 -0.03 
 A4.55 0.21 -2.11 -1.90 
 I4.56 0.11 -2.42 -2.32 
 G4.57 -0.03 0.00 -0.04 
 P4.59 0.01 -0.07 -0.06 
  0.74 -15.50 -14.76 
  
Cholesterol A, Protomer 
B 
0.07 -2.52 -2.44 
Cholesterol B, Protomer 
A 
0.10 -2.49 -2.39 
  0.17 -5.01 -4.83 
     
Total 
kcal/mol 
 0.91 -20.51 -19.59 
 Residues in bold are residue positions shown to be involved in the TMH4 
homodimer inactive state interface of the dopamine D2 receptor 
1
. 
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Discussion 
 
In summary, a cholesterol–palmitoyl interaction was suggested to facilitate 
homodimerization and G protein coupling. This conclusion was further supported by 
computational models of the OPRM1 homodimer: palmitoyl linked to C3.55(170) can 
trap cholesterol at the interface of OPRM1 homodimer, which subsequently stabilizes the 
homodimerization. C3.55 is highly conserved in the Class A Rhodopsin GPCRs, 
especially in the families like Peptide, Opsin, Olfactory, Thyrotropin-releasing hormone 
and Melatonin 
31
. C3.55(130) on melatonin type 1 receptor contributes to G protein 
activation 
32
. The critical roles played by the homologous residues in G protein 
coupling/activation have also been confirmed with m5 muscarinic receptor, α1b-
adrenergic receptor, AT1 angiotensin receptor, and interleukin-8 receptor as summarized 
in the GPCRDB 
31
.  Although the palmitoylation of the other two opioid receptor, δ-
opioid receptor and κ-opioid receptor, has not been reported yet, the palmitoylation site in 
OPRM1 is conserved in the other two opioid receptors, C3.55(151) in δ-opioid receptor 
and C3.55(161) in κ-opioid receptor. The location of δ-opioid receptors in cholesterol-
rich lipid raft and its heterodimer formed with OPRM1 suggested the possible 
involvement of the palmitoylation on C3.55 in its signaling 
33
.  
 The palmitoylation inhibitor 2-BP decreased the normalized net FRET between 
CFPOPRM1 and YFPOPRM1 to the level of that between CFPC170A and YFPC170A 
(Fig. 1.3a and Fig. 1.7b). 2-BP also decreased the cholesterol association with signaling 
complex (Fig. 1.7a). The influences of 2-BP on receptor signaling and G protein coupling 
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were not determined, because of its inhibitory effect on the membrane targeting of the 
highly palmitoylated G proteins 
29
. Since the effects of 2-BP were consistent with the 
effects of the C3.55(170) mutation, any conformational changes other than 
depalmitoylation are not significant in current observations. 
The dimerization of GPCRs, including the higher order oligomeric state of 
rhodopsin, has been reported for a long time 
27, 34
. The interface of monomer GPCR has 
been suggested to be too small for G protein coupling 
12
. However, the interaction 
between GPCR monomer and G protein still can not be excluded. The FRET between 
CFPC170A and YFPC170A was about 13% of that between CFPOPRM1 and 
YFPOPRM1 (Fig. 1.3a), whereas the FRET between CFPC170A and YFPGαi2 was 
about 28% of that between CFPOPRM1 and YFPGαi2 (Fig. 1.4a). This difference 
suggests that the receptor monomer can still interact with Gαi2, though with a lower 
affinity than the homodimer.  
In the β2-AR crystal structure, cholesterols are found situated at the intracellular 
side of the TMH1-TMH4 bundles 
3
. Thus, it is probable that localization of OPRM1 
within cholesterol- enriched domains such as lipid rafts regulates the cholesterol content 
within the receptor complex and receptor signaling. Therefore, the cholesterol-enriched 
lipid raft microdomain may be essential for the ability of the cholesterol–palmitoyl 
interaction to stabilize receptor homodimerization and G protein coupling.  
C3.55(170) palmitoylation affected the amount of cholesterol associated with 
signaling complex. As reported previously, Gαi2 anchors OPRM1 to the lipid raft 
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microdomains. Thus by facilitating Gαi2 coupling, cholesterol associated with OPRM1 
increases the percentage of receptor in lipid raft microdomains.  
The modeling studies reported here show that the C3.55(170) palmitoylation site is 
located very near the Class A GPCR inactive homodimer interface identified by Guo and 
co-workers for dopamine D2 receptor 
35
. For an OPRM1 homodimer formed at this 
interface, the cholesterol associated with C3.55(170) is ideally placed to contribute to the 
total energy of interaction for the homodimer. As Lambert discusses in his recent review 
36
, the interaction energies at the homodimer interface are likely weak but sufficient to 
promote dimer formation transiently.  We report here that the enthalpic component of the 
interaction between OPRM1 homodimers is -14.76 kcal/mol and that the presence of 
cholesterols at the OPRM1 homodimer interface raises the total interaction enthalpy to -
19.59 kcal/mol.  This modest interaction energy is derived predominantly from VDW 
interactions, as would be expected for the hydrophobic residues, as well as the 
hydrophobic cholesterols in the homodimer interface. By identifying a consensus 
cholesterol binding motif in the TMH2-TMH4 region that predicts cholesterol binding for 
44% of human class A receptors, Hanson and co-workers suggest that specific sterol 
binding is important to the structure and stability of many GPCRs 
37
. However, this 
consensus motif is not present in OPRM1 and does not involve C3.55. 
In summary, both experimental data and computational models delineate a cascade 
from cholesterol–palmitoyl interaction to receptor homodimerization and then to G 
protein coupling/activation. Conceivably, by regulating cholesterol–palmitoyl interaction, 
either by the control of cholesterol metabolism or receptor palmitoylation, the stability of 
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GPCR homodimers is altered, leading to the uncoupling of G protein.  In this respect, the 
cellular cholesterol content, specifically the cholesterol associated with the receptor, 
represents an additional target through which the signaling of GPCRs can be regulated.   
 
Conclusions 
 
C3.55(170) is the palmitoylation site of OPRM1 
OPRM1 is highly palmitoylated. The C3.55(170) has been suggested to be the 
palmitoylation site indirectly with the fact that the only other two cysteines [C7.63(346) 
and C7.68(351)] are not the palmitoylation site 
7
. Our current studies directly proved that 
C3.55(170) was the palmitoylation site, for the first time 
 
Cholesterol-palmitoyl interaction can be identified in OPRM1 complex 
Cholesterol-palmitoyl interaction has been identified both in the β2-AR crystal 
structure 
3
 and in the OPRM1 in current studies. Although it is not the first time to 
identify cholesterol-palmitoyl interaction in GPCR, our studies suggested that such 
interaction may be observed in the signaling complexes of many GPCRs. 
 
Cholesterol-palmitoyl interaction contributes to OPRM1 signaling by facilitating 
receptor homodimerization and G protein coupling 
Our studies reported the contributions of cholesterol-palmitoyl interaction to 
receptor signaling for the first time. In addition, by the using the different assays, 
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including FRET, the mechanism underlying these contributions were illustrated. 
Understanding this mechanism provided additional information on receptor 
homodimerization and G protein coupling. 
  
Computational modeling of OPRM1 homodimer supported the conclusions listed 
above 
To support the conclusions mentioned above, a computational model of OPRM1 
homodimer was generated basing on the structure of other relevant GPCRs. The 
computational model suggested that cholesterol-palmitoyl interaction provide addition 
energy to stabilize the homodimer, which was consistent with our other observations.  
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CHAPTER II 
 
COMPARISON OF THE MOR R HOMOLOGY MODEL AND THE MOR 
CRYSTAL STRUCTURE  
 
Introduction 
 
The opioid receptors, delta, kappa and mu, belong to the Class A subfamily of G-
Protein Coupled Receptors (GPCRs).   GPCRs are integral membrane proteins with seven 
transmembrane helices (TMHs) arranged to form a closed bundle with loops that extend 
both extracellularly and intracellularly.  The N-terminus is extracellular and the C-
terminus is intracellular, but begins with a short helix (called Helix 8) that follows the 
end of TMH7, but runs parallel to the membrane. Until recently, the only Class A GPCR 
x-ray crystal structure available was that of rhodopsin.
1
  After 2007, the field exploded 
starting with x-ray structures became available for the carazolol bound beta-2-adrenergic 
(β 2-AR),
2,3
 and followed quickly by the β1 adrenergic receptor (β1-AR),
4,5
 the adenosine 
A2A receptor,
6,7
 the CXCR4 receptor,
8
 the dopamine D3 receptor,
9
 the histamine H1 
receptor,
10
 and the S1P1 receptor.
11
  In 2012, the nociception/orphanin FQ receptor
12
 and 
the mu
13
, delta
14
 and kappa
15
 opioid receptor crystal structures were published. 
Prior to the release of the MOR crystal structure, the best way to determine 
receptor structure was to build a homology model using one of the known structures as a 
template model.  Therefore, in preliminary work, an inactive, R state MOR computational 
47 
 
model was built using the β2-AR crystal structure
2,3
 as a template with substitutions for 
TMH 1, 2, 4 and 7 based on sequence divergences, as described in methods.  This model 
was then used for studies of the MOR including analyzing the receptor for cholesterol 
and palmitoylaiton interactions as well as modeling a homodimer interface for the MOR 
based on experimental data.
16
  The work described herein compares the inactive state 
MOR model with the antagonist bound MOR crystal structure. 
 
Methods 
 
Construction of the initial MOR R state model 
Initially a homology model of the MOR was built using the β2-adrenergic 
receptor crystal structure (2rh1) as the template. The model was constructed by first 
aligning the mu sequence with that of the β2-AR template using the highly conserved 
Class A GPCR sequence motifs (TMH3 E/DRY; TMH6 CWXP; TMH7 NPXXY) or 
highly conserved residues (N1.50, D2.50, W4.50, P5.50) as the alignment guides.  The 
structure of the template was mutated to the corresponding mu residues using Maestro 
(Schrodinger 2006).  Mu receptor helices that diverged from the template structure in the 
location of helix deforming residues such as prolines or glycines were then identified.   
The conformations possible for such helices (TMH2, TMH4 and TMH6) were studied 
using Conformational Memories
17,18
 (described below) and an appropriate substitute 
helix was incorporated into the model.  The TMH7 / helix 8 region was modeled using 
the adenosine A2A crystal structure
6
 based on the fact that the mu opioid and adenosine 
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A2A receptors have two residues in the elbow region of TMH7, whereas the β2-AR only 
has one residue in the elbow region.  Extracellular and intracellular loops as well as the 
N- and C- termini were added using Modeller.
19, 20, 21
  A short, 5ns molecular dynamics 
simulation of the resultant model in a POPC bilayer was performed using NAMD.
22
  The 
output was analyzed and was compared to the initial MOR model to determine any 
significant changes. 
After building the initial MOR model, new crystal structures were released that 
provided additional information about receptor structure.  A new sequence alignment 
using the CXCR4
8
 and dopamine D3
9
 crystal structures was completed.  Changes to the 
initial model were made on TMH 1, 2, 6, and 7 based on the MD output and the new 
information from the CXCR4 and dopamine D3 receptor crystal structures.  Extracellular 
and intracellular loops were added to the revised model (specifics described below) using 
Modeller.
19-21
  The N- and C- termini were preserved from the original model and 
minimally adjusted such that there were no overlaps with the new receptor. 
 
Specific Changes to Original MOR Model 
TMHs 1 and 7:  Using N1.50 as the alignment guide for TMH1 and P7.50 as the 
guide for TMH7, the sequence alignment was studied.  Originally, the β2-AR TMH1 was 
used for the MOR model since rhodopsin has a proline in TMH1 and the MOR does not.  
In the original model, the adenosine A2A TMH7/Hx 8 region was used as the template of 
the MOR model since there are two residues in the elbow region of the mu opioid 
receptor and the adenosine receptor, but only one residue in the β2-AR.  Upon further 
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examination of the CXCR4 and dopamine D3 structures, it was determined that the 
dopamine D3 receptor would be a better match for the MOR model based on receptor 
packing between TMH1 and TMH7 as there were packing issues using the Adenosine 
A2A TMH7 and β2-AR TMH1.   
TMH2:  The alignment for TMH2 centered upon the conserved D2.50 residue 
seen in Class A GPCRs.  Additionally, there is a proline at position 2.58 or 2.59 in most 
Class A GPCRs.  In the initial model, Conformational Memories was used to determine a 
structure for TMH2 since the MOR has a P2.58 whereas the β2-AR has a P2.59.  Upon 
the release of the CXCR4 crystal structure, we decided to use TMH2 from it since it also 
had a P2.58. The sequence was mutated and superimposed onto the template structure 
and incorporated into the revised MOR model. 
TMH6:  In the initial model Conformational Memories was used to select an 
appropriate TMH6 for the wild type inactive state MOR model.  The improvement to the 
model was obtained by incorporating the information from the short MD simulation.  The 
MD simulation showed that at the extreme extracellular end of TMH6, K6.58 had rotated 
to the outside of the bundle rather than pointing directly into the bundle and binding 
pocket.  An evaluation of published mutations studies showed that K6.58 was not likely 
to be pointed into the receptor.  Therefore, in the revised model of the MOR, the CM 
TMH6 was used however; the backbone dihedral values of P6.50-V6.61 were adjusted to 
match the TMH6 from the MD simulation. 
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Extracellular and Intracellular Loops 
Extracellular (EC) and intracellular (IC) loops were added to the MOR R model 
using Modeller.
19-21
  Each of the three extracellular and intracellular loops was varied in 
the presence of the transmembrane receptor region.  To preserve the binding pocket, the 
naloxone/MOR R complex was used as the model to which the loops were added.  
MODELLER is a Monte Carlo technique described by Fiser et al. in 2000 that uses a 
template library of possible side chain conformations from the Protein Data Bank for all 
amino acids.  Using the CHARMM force field, each loop is varied and assigned an 
objective function ranking value.  The objective function is based on steric interactions 
and hydrogen bonding of each possible conformation.  The 250 loops with the lowest 
objective function were used for further analysis.   
Restraints were put on the EC2 loop of the MOR such that the conserved disulfide 
bridge between C3.25 and a cysteine in the EC2 loop was intact as seen in the crystal 
structures of rhodopsin,
1
 the β2-AR,
2-3
 β1-AR,
4
 adenosine A2A,
6
 CXCR4
8
 and dopamine 
D3
9
 receptors.  Additionally, an EC2 loop was selected for the MOR model with a Cβ-Cβ 
distance between D218 in the EC2 and H7.36 consistent with experimental data which 
show a zinc binding site between the two residues.
23
  In each of the Class A GPCRs 
mentioned herein, the second residue after the cysteine in the EC2 loop that participates 
in the disulfide bridge points down into the transmembrane bundle and was therefore one 
of the criterion in selecting the EC2 loop.  After examination of the CXCR4 EC2 loop
8
 
and the MOR sequence, it was decided that the last four residues of the MOR EC2 loop 
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(trp-tyr-trp-glu) were likely a helical extension of the extracellular portion of TMH5 in 
the MOR and was modeled as such.   
Lacking structural information about the remaining five loops, Modeller output 
was assessed to ensure that each loops structurally made sense, e. g. hydrophobic residues 
close to the lipid bilayer were pointing into the receptor rather than directly positioned in 
water.  The N and C termini were added 14 residues at a time with the last 3 residues of 
the previous section being allowed to vary with the 14 residues of the new section.  Due 
to the length of the MOR N-terminus and the associated problems of correct simulation 
of long peptide segments, the first 39 residues of the MOR N-terminus were truncated, 
which has been shown experimentally to retain full activity.
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Results 
 
Comparison of the Transmembrane Region  
To compare the MOR Model and the MOR crystal structure
13
, the model was 
superimposed onto the crystal structure using the X.50 residue Cα in each helix (N1.50, 
D2.50, R3.50, W4.50, P5.50, P6.50, and P7.50).  The two receptors were then analyzed 
and important similarities and differences were observed.  As shown in Figure 2.1 from 
an extracellular view point, the MOR Model (dark purple) and the MOR crystal structure 
(magenta) overlay very similarly.  The intracellular region has been colored gray in both 
structures and the loops removed for clarity.   
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As shown, TMH 1, 2, 6 and 7 overlay very nicely in the superimposed image of 
the MOR CS and the MOR R Model.   There is a slight shift in the extreme extracellular 
end of TMH1, which can be seen in a view from lipid in Figure 2.2a.  Additionally, there 
is a small difference in the extracellular end of TMH3, which is due to the EC2 loop in 
the MOR crystal structure.  TMH4 and TMH5 have large differences in the extracellular 
end between the MOR Model and the MOR crystal structure, as shown in Figures 2.1 and 
2.2b. 
Figure 2.2a, shows TMH5, TMH6, TMH7 and TMH1 of the MOR crystal 
structure (magenta) and MOR R model (purple) in a side view from lipid.   As shown, 
there is a slight different in the extreme extracellular end of TMH1.  TMH5 is pulled 
Figure 2.1.  An extracellular view of the MOR model (dark purple) 
superimposed with the MOR crystal structure (magenta).  Significant 
differences include the EC ends of TMH 4 and 5.  Loops have been removed 
and the intracellular portions colored gray for clarity. 
53 
 
back further in the MOR R model than in the crystal structure at the extracellular end, 
after P5.50.  Both TMH6 and TMH7 are identical in the model and in the crystal 
structure.  In the MOR model, we added an additional helical turn at the extracellular end 
of TMH6, as described in Methods, based on a 5ns MD simulation.  This additional turn 
is seen in the MOR crystal structure, validating the MD simulation output structure.  
  
 
Figure 2.2b shows TMH2, TMH3 and TMH4 in the same color scheme.  As 
illustrated, it can be seen that TMH2 in the MOR model and the MOR crystal structure 
are identical matches and that TMH3 is extremely similar, the only exception being the 
extreme extracellular end of the helix.  In the MOR crystal structure, the EC2 loop pushes 
Figure 2.2.  Views from lipid of each side of the MOR CS and MOR R Model superimposed.  
2a shows TMH5, 6, 7 and 1 with the crystal structure in magenta and the MOR R model in purple.  
2b shows TMH2, 3 and 4 in the same color scheme.  
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the extracellular portion of TMH3 away from the bundle, which is the difference between 
the crystal structure TMH3 and the MOR model TMH3. 
The largest difference between the MOR crystal structure and the MOR R model 
is that of TMH4, seen in Figure 2.2b.  Using Conformational Memories, TMH4 was 
modeled starting from a perfect alpha helical helix.  The helix selected for the model was 
believed to bend into the receptor between TMH3 and TMH5, as seen in many crystal 
structures.  
 
 
However, in the published MOR crystal structure, that was not the case and TMH4 
kinked backwards and bent towards TMH3 at the extracellular end.  Upon examination of 
Figure 2.3.  Intrahelical TMH3 / TMH4 hydrogen bonding network residues seen from lipid.  3a. 
shows the intact hydrogen bonding network comprised of S3.30, Y3.34, G4.57, S4.54 and W4.50 in the 
MOR crystal structure.  3b. Residues involved in the TMH3 / TMH4 hydrogen bonding network in the 
MOR model showing the network is broken. 
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the crystal structure, an intrahelical hydrogen-bonding network between TMH3 and 
TMH4 became clear, as shown in Figure 2.3.   
The TMH3 / TMH4 hydrogen bonding network in the MOR crystal structure 
(Figure 2.4a) is comprised of S3.30, Y3.34, G4.57, and S4.54.  Here the lipid facing 
Y3.34 hydroxyl interacts with the polar sidechain of S4.54 and S3.30 forms a hydrogen 
bond with the backbone carbonyl of G4.57.  Also, S4.54 forms a hydrogen bond with the 
backbone carbonyl of W4.50.  This network pulls TMH4 towards TMH3 and away from 
TMH5.  The P4.59 provides additional kinking of TMH4 at the extreme extracellular end 
of TMH4.  In the MOR R model (Figure 2.3b) the hydrogen bonding network is broken.  
While S4.54 is interacting with the backbone carbonyl of W4.50, neither Y3.34 nor S3.30 
is interacting with residues on TMH4. 
Previously published work shows that C3.55 is the palmitoylation site on the 
MOR
16
 (see Chapter 1).  The same work also shows that cholesterol is located in the 
same vicinity of the palmitate and that cholesterol is in fact needed for maximal signaling 
and dimerization of the mu opioid receptor.  In the MOR model, we modeled the 
palmitate and a cholesterol molecule in a cavity formed by the intracellular 
transmembrane region of TMH 3, 4 and 5, consistent with experimental data.  In Figure 
2.4, the MOR model (right, dark purple) and the crystal structure (left, magenta) are 
shown along with residues Y3.51 and C3.55.  The MOR crystal structure did not have 
any cholesterol or the palmitoylation site crystallized with the receptor.
13
  As shown, in 
the MOR model, Y3.51 is behind C3.55 and the palmitate side chain towards TMH5.  
However, in the crystal structure, it can be seen that Y3.51 is blocking access to C3.55. 
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Comparison of the Loop Region 
Predicting loop regions can be very difficult since they generally have no set 
structure and are flexible in their water like environment.  The MOR model was 
comprised of an N-terminus, C-terminus and all three extracellular and intracellular 
loops.  The MOR crystal structure was crystalized without the N or C termini, and had a 
T4 lysozyme fused to the IC3 loop, which was partially missing.   
The most significant loop is the EC2 loop.  The MOR does exhibit the conserved 
disulfide bridge between a cysteine in the EC2 loop and C3.25, as seen in many Class A 
GPCRs.  We selected an EC2 loop for the MOR model also using the criterion that the 
Figure 2.4. A view from lipid showing the palmitoylation site, C3.55 of the MOR crystal structure (4a) 
and the MOR R Model (4b).  In the crystal structure, access to C3.55 is blocked by Y3.51 and the 
intracellular end of TMH4 is wound tightly.  However, in the MOR R Model, Y3.51 is behind C3.55.  The 
palmitate is attached and the cholesterol has been docked.  W4.50 and P5.50 have been displayed for 
reference purposes.  
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second residue after the disulfide cysteine (a leucine) is pointing down into the binding 
pocket.  In every Class A GPCR crystal structure thus far, the second residue after the 
disulfide cysteine has pointed into the bundle, regardless of the residue and its charge.  
This residue varies widely from isoleucine in rhodopsin and opsin, to a phenylalanine in 
the beta adrenergic receptors and an arginine in the CXCR4 receptor.  The MOR crystal 
structure proves no different; the leucine, two residues after the disulfide bridge in the E2 
loop, is pointing down into the binding pocket.  The EC2 loop in the crystal structure also 
has a parallel beta sheet before the disulfide bridge.  This beta sheet is seen in other 
receptors, like rhodopsin, but not necessarily the same residues.  Unlike the MOR model, 
the EC2 loop in the crystal structure is pushed back and out towards TMH3 such that the 
center of the receptor is uncovered and open.  While this is unusual, this behavior is also 
seen in the CXCR4 crystal structure.     
Two other loops have differences between the MOR model and the crystal 
structure.  The IC2 loop in the MOR crystal structure has a helical portion, which is 
unlike many other crystal structures.  Also, the C-terminal portion of the EC3 loop is 
helical and forms a helical extension at the top of TMH7.  In many of the available 
crystal structures (rhodopsin, adenosine A2A and CXCR4), there is a helical extension of 
the intracellular end of TMH6 from the IC3 loop.  In the MOR model, this six residue 
extension was added.  The MOR crystal structure has an intracellular TMH 6 helical 
extension, consistent with the model. However, the extension in the crystal structure is 
only three residues, not the six that were modeled.   It is impossible to know for sure 
based on this structure if the extension should be three or six residues, or possibly none at 
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all since the T4 lysozyme was fused to the IC3 loop and could be perturbing the structure 
in this area. 
 
Dimer Interface of the MOR Crystal Structure and MOR Model 
The dimer interface in the inactive MOR was predicted to be along the TMH4 / 
TMH5 interface, as discussed in the previous chapter based on experimental information 
on the dopamine D2 receptor.
25
   The residues on TMH4 involved in this dimer interface 
are N4.41, I4.44, C4.48, I4.51, A4.55 and P4.59, shown in Figure 2.5.  The cholesterol 
bound to protomer A interacts with R4.40, N4.41, K4.43, I4.44 and V4.47 on protomer 
B.  Likewise the cholesterol on protomer B interacts with residues on protomer A.  Thus 
dimer interface is enhanced by the palmitate attached to C3.55 and presence of 
cholesterol.  In the MOR model dimer interface, the cholesterol is packed between 
intracellular TMH3 and TMH4 and the palmitoyl group on C3.55 and is unable to leave 
the interface.   
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The MOR was crystallized with two dimer interfaces, TMH5 / TMH6 and a TMH 
1/TMH7/Hx interface.
13
  The TMH5 / TMH6 dimer interface is the same interface seen 
in the CXCR4 crystal structure,
8
 and was reported to be much stronger than the 
TMH1/TMH7/Hx8 interface in the MOR crystal structure paper.  Figure 2.6 is an 
extracellular view of the TMH5/TMH6 crystallized dimer interface of the MOR.   
Protomer A is on the right, with TMH5 and TMH6 shown in blue ribbon and Protomer B 
is on the left with TMH5 and TMH6 shown in lime ribbon.  In each protomer, TMH4 is 
red and TMH7 is magenta and other helices are gray.   
Figure 2.5. An extracellular view of the MOR model dimer interface.  The residues on 
TMH4 involved in the interface are N4.41, I4.44, C4.48, I4.51, A4.55 and P4.59.  The 
palmitate has been added to C3.55 on each protomer, as has the cholesterol.  The cholesterol is 
locked in position by the intracellular end of TMH3 and the palmitate group. 
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The residues involved in the reported dimer interface on TMH5 includeY5.33, 
N5.36, L5.37, I5.40, F5.43, I5.44, F5.47, I5.48, V5.51, L5.52, T5.55, Y5.58, M5.61, 
I5.62, and L5.63.  The TMH6 residues in the dimer interface include T6.34, R6.35, 
L6.38, I6.45, T6.49, I6.53, I6.56, I6.57, L6.60, and I6.61.
13
  Additionally, the crystallized 
dimer interface includes residues on the T4 lysozyme, which was fused to the IC3 loop of 
both protomers. 
 
  
Figure 2.6.  An extracellular view of the crystallized MOR TMH5/TMH6 dimer interface. TMH5/6 of 
Protomer A is shown in blue ribbon, and TMH5/6 of Protomer B is shown in lime ribbon.  Residues 
involved are shown in pink. 
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Discussion 
 
Transmembrane Region Comparison 
TMH1 & TMH7:  The MOR model was completed using TMH1 and TMH7 from 
the dopamine D3 receptor
9
 instead of using the β2-AR template.
2-3
  The β2-AR has only 
one residue in the elbow region, while the MOR has two residues and thus the placement 
of helix 8 would have been incorrect had the β2-AR TMH7 been used. Additionally, the 
β2-AR has a W7.40, which prevents TMH1 from packing closely to TMH7.  While the 
dopamine D3 receptor has this same W7.40, it has a different orientation of the residue 
and allows for much better packing of the TMH1 / TMH7 interface.  Although TMH1 
bends in slightly at the extracellular end in the MOR crystal structure, TMH1 and TMH7 
were almost identical between the MOR model and MOR crystal structure, as shown in 
Figure 2.3a.  In the MOR crystal structure, TMH7 does have an additional ½ turn at the 
extracellular end, formed by the last three residues of the EC3 loop. 
TMH2:  In the initial MOR R model, Conformational Memories was used to 
determine a suitable TMH2 since the β2-AR template structure has a P2.59 but the MOR 
has a P2.58.  The CM output helix showed that residue 2.60 would face into the binding 
pocket of the MOR, whereas in the β2-AR, this residue faces the TMH2/TMH3 interface.  
By using the CXCR4 crystal structure
8
 TMH2 instead for the MOR model, we were able 
to use a known helix with similar characteristics to the MOR TMH2 in our model.  
Compared with the crystal structure, TMH2 of the MOR model was virtually perfect in 
both shape and special position within the receptor (see Figure 2.2b).   
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TMH2 of the β2-AR and CXCR4 receptors was superimposed and the residue 
location changes due to a proline can be seen in Figure 2.7. As depicted, W2.60 in the 
CXCR4 crystal structure faces into the binding pocket, while F2.60 in the β2-AR faces 
towards TMH3.  Additionally, A2.64 in CXCR4 faces TMH7; however H2.64 in the β2-
AR is rotated away from TMH7 and towards TMH3. 
The CXCR4 and MOR also have a T2.56, 2 residues prior to the P2.58, which 
face lipid.  In the CXCR4 crystal structure, T2.56 undertakes a g- conformation.
8
  Thus, it 
was determined that in the MOR, this residue was likely in a g- conformation and that 
using the CXCR4 crystal structure TMH2 was a valid option.  The CXCR4 crystal 
Figure 2.7.  A view of TMH2 looking through TMH6 of the β2-AR (purple) 
and CXCR4 (yellow) superimposed crystal structures.  As shown, the Cα 
residues of 2.60 and 2.64 change greatly due to a P2.59 (β2-AR) vs. a P2.58 
(CXCR4). 
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structure also validates work by Ballesteros and colleagues in 2000 showing that a lipid 
facing serine or threonine can be in a g- conformation to satisfy its hydrogen bond.
26
   
TMH3:  In the MOR model, TMH3 was not pushed back at the extracellular end, 
as it is in the MOR crystal structure
13
 (see Figure 2.2b).  This pushback in the MOR 
crystal structure is due to the conformation of the EC2 loop, which leaves the 
extracellular portion of the receptor open by forcing the end of TMH3 outwards.  
Although this portion of TMH3 is different, the relative position of the helix in the bundle 
as well as D3.32, a ligand binding residue was seamless upon superimposition.   The 
position of D3.32 is important for both ligand binding as well as for a D3.32/Y7.43 
interaction.  This interaction is seen in many Class A GPCR crystal structures, including 
the β1-AR,
4
 β2-AR,
2-3
 dopamine D3,
9
 and the histamine H1
27
 receptors.  This interaction 
was incorporated into the MOR model, and is also seen in the MOR crystal structure. 
TMH4 and TMH5: The largest difference between the MOR model and the MOR 
crystal structure was the extracellular positioning of TMH4 and TMH5, as shown in 
Figures 2.1 and 2.2.  The TMH4 selected from the Conformational Memories output for 
the MOR model incorporated the belief that S4.54 could be in a g- conformation.  This 
conformation combined with G4.57 and P4.59 produced an additive effect in the TMH4 
in the model such that TMH4 bent into the bundle between TMH3 and TMH5.  Due to 
this bend into the bundle, the P5.50 allowed TMH5 to be pushed back at the extracellular 
end, as seen in Figure 2.3.   The crystallized conformation of TMH4 in the MOR shows 
that S4.54 is in a g+ conformation and is involved in an intrahelical hydrogen bonding 
network with TMH3.  This network was not able to be predicted based on the crystal 
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structures or mutation data available at the time of its development.  In the TMH3/TMH4 
hydrogen bonding network, the lipid facing Y3.34 hydroxyl interacts with the polar 
sidechain of S4.54 and S3.30 forms a hydrogen bond with the backbone carbonyl of 
G4.57.   
In the CXCR4 crystal structure,
8
 the EC end of TMH5, coming off the EC2 loop 
has an extra helical turn formed by the last four residues of the EC2 loop, Asp-Leu-Trp-
Val.  In the MOR sequence, the corresponding residues are Trp-Tyr-Trp-Glu.  Based on 
the CXCR4 crystal structure and the similarity in the EC2 loops of the CXCR4 and 
MOR, we modeled this additional helical turn at the EC end of TMH5.  This additional 
turn is seen in the MOR crystal structure and aids in validating the MOR model. 
TMH6:  Class A GPCRs have a conserved CWXP motif in TMH6.  In the β2-AR, 
the region is CWLP, while in the MOR, the region is CWTP.  While the leucine and 
threonine residues are both beta-branching residues, the threonine is slightly smaller and 
has more flexibility than the leucine. Therefore, we employed the Conformational 
Memories technique to determine a plausible structure for TMH6 in the MOR model.  As 
seen in Figures 2.1 and 2.2a, the TMH6 in our model superimposes perfectly with the 
TMH6 in the MOR crystal structure.  
 
Conformation of Specific Residues in the Inactive State Receptor 
The structural characteristics that define the GPCR inactive (R) and active (R*) 
states have been deduced primarily from biophysical studies of rhodopsin and the β2-AR 
receptor.  In the inactive or off state (R), the intracellular (IC) end of TMH6 is bent 
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towards TMH3 and a salt bridge between R3.50 and E/D6.30 on the intracellular side of 
the TMH bundle forms an  “ionic lock”.  In the activated state, TMH6 undergoes a 
conformational change, straightening in the highly conserved CWXP hinge region.
28, 29, 
30, 31, 32, 33
  This results in the intracellular ionic lock  breaking as TMH3 and TMH6 move 
away from each other.
34
   Previous studies have shown that while the MOR does not form 
an “ionic lock” at the exact same location as rhodopsin, it does form a strong hydrogen 
bond between R3.50 and T6.34
35
 that serves the same purpose for MOR.  The R3.50 and 
T6.34 interaction is indeed present in the µ-opioid crystal structure with antagonist β-
FNA present.
13
   
The ionic lock in the MOR comprised of R3.50 and T6.34, was incorporated into 
the MOR Model.  In Class A GPCR crystal structures, the ionic lock has not been intact 
in any structure except for the MOR crystal structure when a T4 lysozyme has been fused 
to the IC3 loop between TMH5 and TMH6.  While the ionic lock was intact in the MOR 
structure, it is possible that the T4 lysozyme has perturbed the structures of the 
intracellular portions of TMH5 and TMH6 in other receptors, and possibly the MOR, due 
to its size and proximity to the receptor. 
The change from the inactive to active states also results in changes within the 
ligand binding pocket. In the R state, a tryptophan residue in the CWXP motif on TMH6, 
W6.48, adopts a g+ χ
1
 dihedral angle.  This conformation in rhodopsin is due to the close 
proximity of the beta-ionone ring of rhodopsin’s covalently bound ligand, 11-cis-retinal 
to W6.48, such that the tryptophan is locked in place.
36,37,1
  W6.48 is part of the highly 
conserved TMH6 CWXP motif and has been identified as important for GPCR activation 
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through early mutagenesis studies.  A recent x-ray crystal structure of a constitutively 
active rhodopsin mutant suggests that when rhodopsin is activated and undergoes the 
isomerization of 11-cis retinal to all-trans-retinal, the beta-ionone ring is shifted 4.3Å 
towards the cleft between TMH5 and TMH6 and W6.48 is released from its locked 
position.  The indole group of W6.48 moves 3.6Å away from its ground-state position as 
a consequence of rhodopsin activation
38
 and W6.48 undergoes a change in its χ1 angle 
from g+  trans.
39
  Although this change is not seen in recent activated GPCR crystal 
structures, it is possible that such a change is transient and therefore not captured in the 
crystalline state.  In fact, in molecular dynamics simulations of cannabinoid CB2 receptor 
activation by its endogenous ligand, we observed such a transient change in W6.48.
40
  
Likewise, a rotameric change of W6.48 has been documented to occur in microsecond 
long molecular dynamics simulations
12
 of the β-2 adrenergic receptor in complex with the 
Gs protein. 
We modeled the W6.48 in the MOR in the inactive, g+ conformation.  The MOR 
was crystallized with β-FNA, a covalently bound antagonist.
13
  In the MOR crystal 
structure, W6.48 is indeed in the g+ conformation.  Upon superimposition, not only are 
the backbone residues of TMH6 in the MOR model and the MOR crystal structure 
seamless, but the conformation and relative position of W6.48, both backbone and 
sidechain, are seamless as well. 
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MOR Dimer Interface 
Experimental studies (Chapter 1) suggest that both cholesterol and palmitoylation 
of the MOR facilitates MOR homodimer formation and signaling of the MOR.
16
  These 
studies also show that the palmitoylation site of the MOR is located at C3.55, not the C-
terminus as seen in most Class A GPCRs.  This palmitoylation site may be conserved in 
the DOR and KOR, as they both have the conserved C3.55, but experimental studies of 
both receptors are needed to verify this palmitoylation site.  Using the MOR model 
described herein as well as the experimental data for cholesterol and MOR 
palmitoylation, a possible MOR homodimer interface was modeled (Figure 2.5).  This 
interface is equivalent to the one experimentally shown in the dopamine D2 receptor by 
Guo and collogues.
25
   In the MOR, the dimer interface involves N4.41, I4.44, C4.48, 
I4.51, A4.55 and P4.59.  In the dimer, cholesterol is packed against TMH3 and TMH4 
and locked in place by the palmitoyl attached to C3.55 and TMH5. 
The MOR crystal structure shows two different dimer interfaces, TMH5/TMH6 interface 
showing in Figure 2.6 and a TMH1/TMH7/helix 8 interface.
13
  The TMH5/TMH6 dimer 
interface in the MOR is the same as the dimer interface seen in the CXCR4 crystal 
structures; however the MOR dimer interface involves more residues with better packing 
than the CXCR4 dimer interface.  The residues involved in the reported dimer interface 
of the MOR on TMH5 include Y5.33, N5.36, L5.37, I5.40, F5.43, I5.44, F5.47, I5.48, 
V5.51, L5.52, T5.55, Y5.58, M5.61, I5.62, and L5.63.  The TMH6 residues in the MOR 
dimer interface include T6.34, R6.35, L6.38, I6.45, T6.49, I6.53, I6.56, I6.57, L6.60, and 
I6.61.   
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The MOR was crystallized with a T4 lysozyme fused to the intracellular 3 (IC3) 
loop region of the receptor.  In the TMH5/TMH6 dimer interface, the T4 lysozymes of 
both protomers are in close proximity and interact with each other.   Johnston and Filizola 
presented work at the Biophysical Society Conference in 2013 on the stability of the 
dimer interfaces in the MOR.
41
  Using umbrella sampling molecular dynamics 
calculations, they were able to show that the TMH5/TMH6 dimer interface in the MOR 
was favored over the TMH1/TMH7/helix 8 dimer interface.  The calculated free energy 
of dimerization of the TMH5/TMH6 interface was -11.8kcal/mol while the 
TMH1/TMH7/helix 8 interface was -4.1kcal/mol.  Additionally, it was shown in 
simulations with the MOR homodimer and T4 lysozyme, the two MOR protomers could 
be pulled apart easily but that the T4 lysozyme maintained a strong interaction.  The T4 
lysozyme interactions were substantial enough to cause a distortion in the membrane.  
Thus, it cannot be ruled out that the TMH5/TMH6 dimer interface in the MOR is initiated 
by the T4 lysozymes, not by the transmembrane MOR protomers.  Cross-linking studies 
are needed to aid in the determination of the physiological homodimer interface in the 
MOR. 
 
Conclusions 
 
The validity of computational homology modeling of GPCRs has been an area of 
debate in many circles.  However, our MOR model comparison with the MOR crystal 
structure helps to validate the usefulness and accuracy of homology modeling.  The 
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inactive state MOR model was very similar to the antagonist bound MOR crystal 
structure.  The ionic lock, D3.32/Y7.43 interaction and locations of helices relative to the 
receptor as a whole were seen in both the MOR model and the MOR crystal structure.  
The ability of lipid facing serines and threonines to undertake a g- conformation was 
confirmed with the conformation of 11 transmembrane serines/threonines in the MOR 
crystal structure in a g- conformation including T2.56.  Although the extracellular ends of 
TMH4 and TMH5 were different from the crystal structure, the underlying intrahelical 
hydrogen bonding network causing these changes could not be predicted based on known 
crystal structures.   Overall, homology modeling is a good tool to keep in the toolbox for 
determining GPCR structure.  
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CHAPTER III 
 
MOLECULAR DETERMINANTS FOR TARGETED GENE THERAPY µ-OPIOID 
RECEPTOR FOR MULTIPLE MUTANTS AT WHICH  
NALOXONE ACTS AS A PARTIAL AGONIST 
 
Abstract 
 
A targeted gene therapy strategy has recently been reported that makes novel use 
of a µ-opioid receptor (MOR) S4.54A mutant at which the classical opioid antagonist, 
naloxone, becomes a partial agonist.
1,2,3
 Despite the clear success of basing this strategy 
on the S4.54A MOR mutant, the origins of this unusual phenotype are not yet 
understood.  Therefore, the goal of the work reported here was to identify the molecular 
basis for the agonism of naloxone at this novel S4.54A mutant. To this end, we used the 
recent x-ray crystal structure of the MOR to create a WT MOR model into which 
naloxone was docked using Glide (Schrodinger, 2011). The crystal structure was also 
used to create a homology model of the S4.54A mutant MOR.  The conformational 
change in TMH4 that would be created upon the S4.54A mutation was examined using 
the simulated annealing/Monte Carlo method, Conformational Memories, and the result 
was incorporated into the model. The S4.54A mutant model was then used for naloxone 
docking studies using Glide. These studies revealed that in the crystal structure, Y3.34
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forms a hydrogen bond with the sidechain of S4.54; however, in the S4.54A MT 
MOR, this interaction is broken as there is no polar partner for Y3.34.  The breaking of 
this interaction allows the extracellular end of TMH4 to kink away from TMH3 and 
towards TMH5, which leads to changes in the packing of the receptor binding pocket.  In 
the wild type MOR, naloxone interacts with D3.32 and sits in close proximity to the 
binding pocket “toggle switch” residue, W6.48, restricting its movement. However, in the 
S4.54A MT MOR, naloxone sits higher in the binding pocket, away from W6.48 and 
interacts with D3.32 and E5.35.  In this higher location, naloxone exerts no effect on 
W6.48, permitting W6.48 to assume an active state conformation.  This shift in binding 
pocket location for naloxone may be the origin of naloxone’s partial agonism in the 
S4.54A MOR mutant. 
 
Introduction 
 
Pain management is often one of the most difficult aspects of treatment for 
patients suffering from acute or chronic pain.  The mu-opioid receptor (MOR) agonist, 
morphine, and its derivatives are highly used in pain management strategies.  However, 
these medications have many side effects including respiratory depression, 
gastrointestinal problems as well as dependence and addiction liabilities.  For these 
reasons, innovative new modalities for pain management continue to be needed. 
One new approach to the design of opioid therapies for chronic pain with reduced 
liabilities is a targeted-gene therapy strategy developed by the lab of Dr. Ping-Yee Law at 
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the University of Minnesota.  This strategy makes novel use of a MOR S4.54A mutant at 
which the classical opioid antagonist, naloxone, acts as a partial agonist.
1,2,3
  Targeted 
gene therapy studies using this mutant have shown that naloxone becomes an 
antinociceptive agent at the S4.54A mutant both in vitro and in vivo.
1,2,3
 Because the 
targeted strategy produces expression of the mutant MOR only in and around the spinal 
cord injection site region, systemic administration of naloxone results in agonism in this 
region, but antagonism at all other (native) MORs.  The reduced number of receptors 
activated in this paradigm results in no measurable dependence/addiction as seen with 
traditional mu agonists like morphine.
1
 Despite the clear success of basing this strategy 
on the S4.54A MOR mutant, the origins of this unusual phenotype are not yet 
understood.  It is therefore the goal of this paper to identify the molecular basis for the 
agonism of naloxone at this novel S4.54A mutant.  
The opioid receptors, delta, kappa and mu, belong to the Class A subfamily of G-
Protein Coupled Receptors (GPCRs).  In the past few years, x-ray crystal structures of 
Class A GPCRs have increasingly become available.  These include rhodopsin
4,5,6
 (Rho), 
meta-rhodopsin II
7
, the β2-adrenergic receptor (β2-AR),
8,9,10,11,12
 the β1 adrenergic 
receptor (β1-AR),
13,14
 the adenosine A2A receptor,
15,16
 the CXCR4 receptor,
17
 the 
dopamine D3 receptor,
18
 the histamine H1 receptor,
19
 S1P1 receptor
12
, the 
nociception/orphanin FQ receptor
20
 and the mu
21
, delta
22
 and kappa
23
 opioid receptors.  
The mu opioid receptor structure shows that residue S4.54 is part of a small network of 
interactions in the TMH3/TMH4 region of the receptor (see Figure 3.1).  This network 
includes residues S3.30, Y3.34, S4.54 and G4.57.  Here the lipid facing Y3.34 hydroxyl 
 
78 
 
interacts with the polar sidechain of S4.54 and S3.30 forms a hydrogen bond with the 
backbone carbonyl of G4.57. In the work reported here, we take advantage of the 
availability of the MOR crystal structure to develop a homology model of the S4.54A 
mutant and explore the altered binding profile of naloxone in this mutant.  We find here 
the S4.54A phenotype has its origins in the loss of the Y3.34—S4.54 interaction seen in 
the WT MOR crystal structure.   
 
We also report herein new experimental data for additional S4.54 mutants who 
also share the unique phenotype seen in the S4.54A
3,24,1,2
 and S4.54L
25
 MT MOR in 
which naloxone becomes a partial agonist as previously reported.  Mutating S4.54 to both 
a phenylalanine and a glycine share the unusual phenotype seen in the S4.54A and 
S4.54L MT MOR.  Interestingly, when S4.54 is mutated to isoleucine or valine, naloxone 
Figure 3.1. Hydrogen bonding network in the WT MOR receptor (lime). 1a. An extracellular view 
of the MOR with the backbone in lime and the location of residues on TMH3 and TMH4 that form a 
hydrogen bonding network. 1b. A view from lipid showing each of the residues in the TMH3/TMH4 
hydrogen bonding network.  S3.30 forms a hydrogen bond with the backbone carbonyl of G4.57.  The 
hydroxyl of Y3.34 forms a hydrogen bond with the polar sidechain of S4.54 which also forms a bond 
with the backbone of W4.50. 
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maintains the same activity as seen in the wild type MOR.  We propose that in the case of 
the S4.54 I / V, an increase in hydrophobic interactions between W4.50 and I/V4.54 
allow TMH4 to maintain its wild type conformation.  However, while the S4.54F is also 
able to increase hydrophobic interactions, its size prevents the helix from maintaining the 
wild type shape.  In the S4.54L mutant, there is no increase in hydrophobic interactions 
and the orientation of the leucine gives rise to a straighter TMH4, as seen in the S4.54A 
MT MOR.  The S4.54G mutant offers additional flexibility and a higher turn ratio, with 5 
residues per turn in that region such that the extracellular end of TMH4 moves away from 
TMH3 and towards TMH5. 
 
Methods 
 
Xenopus oocyte electrophysiology 
 Mutations of Ser4.54 into various amino acid mutants were carried by cloning rat 
MOR into the pAlter vector and site-directed mutagenesis carried out as described by the 
manufacturer (pAlter-Sites I in vitro Mutagenesis System, Promega). cRNAs of wild type 
and mutant MOR, and GIRK1 channel ( a gift from Dr. Henry Lester)
26
 were prepared 
for injection by the in vitro transcription kit mMessage mMachine (Ambion, Inc).  1-3 ng 
of cRNAs of each GIRK1 and various MOR in 50 nl were injected into the vegetal pole 
of the oocytes as described previously
27
.  After injection, oocytes were incubated in ND-
96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2 and 5 mM HEPES, pH7.4) 
supplemented with 2.5 mM sodium pyruvate and 5.0% heat-inactivated horse serum (Life 
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Technologies/GIBCO).  3-8 days after injection, oocytes were placed in a 100 µl 
recording chamber and were perfused at a rate of 0.5 ml/min with ND-96. The standard 
2-electrode voltage-clamp recordings were performed at room temperature using a Dagan 
TEV-200 Voltage Clamp/Amplifier.
28
  Oocytes with transmembrane potentials more 
negative than -40 mV were chosen for voltage-clamping at -80 mV.  After oocytes were 
clamped at -80 mV, the perfusion buffer was changed to a high K
+
 buffer (2 mM NaCl, 
96 mM KCl, 1 mM CaCl2, 5 mM HEPES, pH 7.4) for K
+
 current recordings and drug 
addition.  Drugs were applied for 0.25-1 min in high K
+
 buffer. Each oocyte was exposed 
to only one concentration of opioid ligand.  Statistical significance was determined using 
Statview for Macintosh (Abacus). 
 
Measurement of forskolin-stimulated intracellular [
3
H]cAMP production 
 Measurement of intracellular [
3
H]cAMP production was carried out as described 
previously.
29
 Briefly, CHO cells stably expressing wild type or mutant MOR were grown 
to confluency in 24-well plates in DMEM medium supplemented with 10% fetal calf 
serum and 1 mg/ml G418.  24 hours prior to the assay, media was changed and on the day 
of the assay, the intracellular cAMP pools were labeled by incubating the cells in DMEM 
media supplemented with 15.3 mM NaCl, 29.3 mM NaHCO3, 40 µCi/10 ml of 
[
3
H]adenine (20 Ci/mmole, Amersham) and 0.5 mM isobutylmethylxanthine (IBMX) for 
1 hr at 37
0
C, 10% CO2.  Afterwards, DMEM media was removed, and to each well, 0.5 
ml  of KRHB pH7.4 buffer containing 0.5 mM IBMX, 10 µM forskolin and various 
drugs at 1 µM was added. Cells were then incubated at 37ºC for 15 min.  The reaction 
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was terminated by the addition of 50 µl of 3.3 N perchloric acid.  [
32
P]cAMP standard 
(3000-5000 cpm/well) was added, and [
3
H]cAMP was separated from other radioactive 
nucleotides by Dowex and alumina column chromatrography as described previously 
discussed.
30
  Radioactivity was determined by scintillation counting with a Beckman 
5000 counter. 
 
Creation of WT MOR Model and Docking of Naloxone 
We designed a WT MOR model for the studies herein using the recently 
published MOR crystal structure
21
 complexed with β-FNA, a covalently bound 
antagonist.  Using Maestro (Schrodinger, 2011), hydrogen’s were added to the crystal 
structure and β-FNA was removed.  Glide (Schrodinger, 2011) was used to ascertain the 
binding region for naloxone employing D3.32 as a hydrogen bond interaction site.  The 
dock with the best Glide score was evaluated and compared to the S4.54A MT MOR 
model. 
 
Conformational Memories (CM) Technique for Calculating the Mutant TMH4s 
S4.54A/I/L/V/F/G 
We explored the TMH4 conformational results of each mutation using the CM 
technique.
31,32
  The CM method uses multiple Monte Carlo/simulated annealing random 
walks employing the CHARMM force field.  An alpha helical TMH with the WT hMOR 
sequence was used as a starting point for these calculations.  Each mutant was 
subsequently run using the same initial structure followed by a 1 step minimization to 
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alleviate backbone clashes from the newly inputted residue.  The region of I4.51 to P4.59, 
with S4.54 mutated to the appropriate residue was considered the flexible region in these 
calculations. Backbone φ and ψ torsions in regions of interest were allowed to vary ±50°, 
while all other backbone torsion angles were allowed to vary ±10°. Side chain torsions 
were allowed to vary ±180° for the alanine and glycine mutants.  For each of the leucine, 
isoleucine, valine and phenylalanine mutant TMH4, four runs were performed: 1) All 
side chain torsions were allowed to vary ±180°, 2) All side chain torsions were allowed to 
vary ±180° except the χ1 dihedral of 4.54 which was held in 2) gauche+ (-60°), 3) 
gauche- (+60°) and 4) trans (180°).   In all runs, bond angles were allowed to vary ±8° 
except for the C–S–C angles that were allowed to vary ±15°.  From each run, there were 
120 output TMH4 conformers generated in a distance-dependent dielectric at 310 K.  The 
CM output helices were subsequently evaluated in the context of the MOR TMH bundle 
and an appropriate helix was chosen for substitution into the MOR model (see next 
section). 
 
Construction of the TMH Region of the S4.54A MT MOR and Ligand Docking 
The recently reported MOR WT x-ray crystal structure
21
 was used to create a 
homology model of the S4.54A mutant MOR.  The MOR crystal structure was pulled 
apart 2Å in each direction from the center of the bundle. The selected S4.54A CM output 
helix was superimposed onto TMH4 of the crystal structure using the Cα atoms from 
R4.40 to W4.50.  The transmembrane regions of the resultant S4.54A MOR model were 
energy minimized to allow the TMHs pack such that there were no large gaps.  A 500 
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step energy minimization was performed using the OPLS2005 all atom force field in 
Macromodel 9.1 (Schrodinger, 2006), employing a distance-dependent dielectric with 
extended cutoffs.  The backbone phi/psi dihedrals of the TMHs were constrained with a 
force of 500kJ/mol to preserve their geometries.  The output structure from the 4
th
 
iteration of the minimization was selected as the model for the S4.54A MT MOR by 
comparing the TMH regions of the mutant and wild type receptors to ensure that the 
TMH region of the mutant receptor was not over-packed.  Naloxone was docked in the 
resultant S4.54A model using Glide (Schrodinger 2006) with D3.32 as the primary 
interaction site for the ligand.  The dock with the best Glide score was used for further 
study. 
To preserve the general shape of the loop regions seen in the crystal structure, 
four of the loops from the crystal structure (EC2/IC3 excluded) were added to the S4.54A 
model.  Due to the differences in the extracellular region of TMH4, MODELLER 
v9.1.
33,34,35
   was used to add the EC2 loop.  Restraints were added to the MODELLER 
run such that the disulfide bond with C3.25 and the beta sheet regions were preserved.  
The IC3 loop was not resolved in the crystal structure therefore; MODELLER was used 
to determine a likely loop conformation.  Once the loops were added, naloxone was re-
docked in the full model using Glide.  The dock with the best Glide score was used for 
the final S4.54A MOR/naloxone complex model. 
The resultant WT MOR/naloxone and S4.54A MOR/naloxone complexes were 
compared in order to investigate at the molecular level, the possible origins of naloxone’s 
partial agonist behavior in the S4.54A MT MOR.  
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Results 
 
S4.54 A Conformational Memories Results  
The biased Monte Carlo/simulated annealing technique,  Conformational 
Memories
31-
 
32
 was used here to explore the conformational consequences of the SA 
mutation at position 4.54 in the MOR.  Figure 3.2 shows the CM output for the S4.54A 
TMH4 superimposed using the Cα atoms of residues R4.40 to W4.50 on TMH4 in the 
WT MOR.  The most striking differences between the CM output and WT MOR TMH4 
was that the extracellular ends of the S4.54A CM output helices were bent towards 
TMH5 rather than towards TMH3 as seen in the WT MOR crystal structure.  The TMH4 
chosen for use in the S4.54A mutant receptor model is colored magenta in Figure 3.2, 
while TMH4 of the WT MOR crystal structure is colored yellow.  Prokink
36
 was used to 
determine the bend, wobble, and face shift angles of these two helices.   
The WT TMH4 measured 33.6°, -47.5°, and 152.4°, while the S4.54A MT TMH4 
measured 31.5°, 128.9°, and 57.2°, respectively.  Figures 3.3a and 3.3b illustrate the key 
differences between WT MOR TMH4 (lime) and the chosen S4.54A MT TMH4 
(magenta). Figure 3.3a shows an extracellular view of the WT MOR and MT MOR with 
TMH4 in the top left hand corner.  As shown, the extracellular end of TMH4 moves in 
the S4.54A MT MOR.  In Figure 3.3b the view is from within the TMH bundle looking 
from TMH1 towards TMHs3-5. The large shift in the extracellular end of TMH4 is 
evident here. Using the locations of A4.64 and M4.61 as guides, we found that the Cα 
atom of A4.64 moves 7.1 Å and the Cα of M4.61 moves 5.7 Å 
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Creation of S4.54A Mutant Model   
A homology model of the S4.54A MT MOR was developed using the recently 
published mu-opioid crystal structure (PDB Code: 4DKL)
21
 and the results of the 
Conformational Memories studies of TMH4 in the S4.54A mutant.  Once the S4.54A MT 
MOR was completed, the transmembrane regions were superimposed onto the WT MOR 
crystal structure using the most conserved residue in each respective helix.  The 
superimposed receptors are shown in Figure 3.3a, with the WT MOR in lime and the MT 
MOR in magenta.  Here it is clear that there were no large backbone changes from the 
WT to the MT MOR model, except for the extracellular region of TMH4, at the top of the 
figure.  There was some slight movement in the extracellular end of TMH5 which can be 
Figure 3.2.  Conformation Memories (CM) output of S4.54A MT TMH4.  An extracellular view (2a) 
and a view from lipid (2b) showing the WT MOR in gray, with TMH3 and TMH5 in lime and WT 
TMH4 in yellow. The CM output is shown in blue tube representation and the S4.54A MT TMH4 
selected is shown in magenta.   
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attributed to the change in conformation of TMH4 in the S4.54A MT MOR.  
Additionally, there was some slight movement at the extracellular ends of TMH1 and 
TMH7, but these movements were not found to be significant. 
 
To quantitate the movement of TMH4 relative to TMHs 3 and 5, the following 
pairs of distances were measured in both the WT MOR and MT MOR (Table 1): K3.26-
A4.64, K3.26-M4.61, K5.39-A4.64, and K5.39-M4.61. These residues can be seen in 
Figure 3.3b, where the WT is shown in lime and the MT model is shown in magenta.  As 
shown, the last helical residue of TMH4, A4.64 moves away from TMH3 and towards 
TMH5 based on the measurements in the models.  M4.61 displays the same movement, 
which is consistent with the Prokink
37
 data in Figures 3.3a and 3.3b where there is a large 
Figure 3.3.  A comparison of the WT MOR (lime) and S4.54A MT MOR (magenta) models.  3a. 
An extracellular view of the two receptors superimposed using the most conserved residue in each helix.  
There are no large backbone changes in the S4.54A MT MOR except for the extracellular end of 
TMH4. 3b. A view inside the bundle from TMH1 looking towards the TMH3, 4, 5 region of the WT 
and S4.54A MT MORs.  K3.29, M4.64, A4.61 and K5.39 are shown in the WT MOR (gray residues) 
and the S4.54A MT MOR (pink residues) to quantitate the changes of TMH4 in the WT MOR and the 
S4.54A MT MOR.  The Cα of M4.61 and A4.64 moved 5.6Å and 7.1Å, respectively.   
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change in both the wobble and face shift angles of the WT TMH4 as compared to the 
S4.54A MT TMH4.   
 
Table 1.1.  Cα distances of select residues on TMHs 3, 4 
and 5 in the WT MOR and the S4.54A MT MOR 
 
 
 
 
 
 
 
 
The hydrogen bonding network seen in the MOR crystal structure (Figure 3.1), is 
not intact in the S4.54A MT MOR model.  Although Y3.34 and A4.54 are close enough 
to make the hydrogen bond seen in the WT MOR, the Ala does not have a polar group for 
Y3.34 to interact with.  Additionally, in the WT MOR, Cα S3.30 is only 4.6Å from the 
backbone carbonyl of G4.57; however in the S4.54A MT MOR, the Cα of S3.30 is 7.3Å 
from the backbone carbonyl of G4.57.  The difference between S3.30 and G4.57 (See 
Figure 3.3b) is consistent with the Prokink data and measurements in Table 3.1. 
 
Naloxone Docking Studies   
WT MOR: The MOR was crystalized with Beta-FNA, a covalently bound 
antagonist.  This antagonist was removed from the crystal structure in order to explore 
DISTANCE 
MEASURED      
all are Cα  
WT MOR 
(Å) 
S4.54A MT 
MOR (Å) 
M4.61--K3.26  4.963 8.611 
A4.64--K3.26 5.136 10.712 
M4.61--K5.39 15.618 11.399 
A4.64--K5.39 15.538 10.145 
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naloxone’s binding site at the WT MOR.  Glide (Schrodinger, 2011) was used to identify 
docking poses for naloxone (yellow) in the WT MOR and the dock with the best score (-
8.948) was chosen, as shown in Figure 3.4a.  Shown in Figure 3.4a, both the crystallized 
ligand, β-FNA (cyan) and naloxone (yellow) form an electrostatic interaction with D3.32 
(gray), consistent with experimental data.
38
  It can be seen in Figure 3.4a that naloxone 
and β-FNA occupy the same binding pocket and same general location inside the 
receptor.  Naloxone sits slightly lower in the binding pocket than β-FNA.  This is likely 
due to the fact that naloxone does not have a covalent attachment to the receptor and can 
orient itself to optimize its binding, whereas β-FNA is locked into position by its covalent 
attachment at K5.39 (gray).  The N-allyl of naloxone and the n-methylcyclopropyl of β-
FNA sit in close proximity to W6.48 (gray).  The driving interaction for naloxone in this 
dock is with the electrostatic interaction with D3.32; however naloxone also has 
significant Van-der-Waals (VDW) interactions with Y3.34, M3.36 and W6.48.   The 
charged nitrogen of naloxone is 9.0Å away from the C-alpha carbon of W6.48 in the WT 
MOR (Figure 3.4a).  In this position, the alkaloid fused ring system of naloxone would 
restrict movement W6.48 (see Figure 3.5a).   
S4.54A Mutant:  Glide was also used to identify a binding site for naloxone in the 
S4.54A MT MOR model. The dock with the best score (-7.240) was chosen (Figure 
3.4b).  In this docked position, naloxone (sea green) sits higher in the binding pocket 
compared to naloxone in the WT MOR (yellow) (see Figure 3.4c).  Naloxone still has its 
primary electrostatic interaction with D3.32 (pink) here in the S4.54A MT MOR; 
however, naloxone also picks up a hydrogen bond with E5.35 (pink) which is not seen in 
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the WT MOR.  In the MT MOR, naloxone maintains VdW interactions with Y3.34 and 
M3.36, but loses the interactions with W6.48 seen in the WT MOR.  The charged 
nitrogen of naloxone is 12.1Å away from the C-alpha carbon of W6.48 in the MT MOR 
while only 9.0Å away in the WT MOR.   
While the alkaloid fused ring system of naloxone restricts movement of W6.48 in 
the WT MOR (Figure 3.5a), it does not restrict movement of W6.48 in the S4.54A MT 
MOR (Figure 3.5b-d).  Shown in space filling representation in Figure 3.5b, it can be 
seen that naloxone has rotated and shifted towards the extracellular part of the receptor in 
the S4.54A MT MOR model.  This movement permits W6.48 conformational freedom in 
the binding pocket (see Figure 3.5b-d).   
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Potassium Current and cAMP Results of various S4.54 Mutants  
Potassium current was tested in various S4.54 MOR mutants to determine if any 
additional mutations gave rise to the phenotype of naloxone acting as a partial or full 
agonist at the MOR as seen in the S4.54A mutant MOR (Figure 3.6a).  Surprisingly, upon 
mutation to leucine and phenylalanine, naloxone induced approximately 15% of the 
Figure 3.4.  Naloxone docked in the WT MOR (4a), S4.54A MT MOR (4b) and ligand structures 
(4d).  4a. The WT MOR (lime backbone) with the crystallized covalently bound antagonist β-FNA 
(cyan) at K5.39 and the Glide docked naloxone (yellow).  4b.  The S4.54A MT MOR (magenta 
backbone) with naloxone (sea green) docked using Glide.  The D3.32 interaction was maintained and an 
interaction with E5.35 was added in the MT MOR.  4c.  A comparison of the WT MOR  with naloxone 
(yellow) and the S4.54A MT MOR with naloxone (sea green) models. In the MT MOR naloxone has 
rotated and sits higher and more extracellularly in the binding pocket compared to the WT MOR.  4d. 
Structures of naloxone and β-FNA  
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maximal current induced by DAMGO, a full peptide agonist at the MOR. The S4.54 
mutations to glutamine, threonine, isoleucine and valine showed naloxone acting as an 
antagonist, as seen the in WT MOR. 
Subsequently, intracellular cAMP levels were tested for S4.54 mutations to 
glycine (Figure 3.6b), isoleucine (Figure 3.6c) and phenyalanine (Figure 3.6d) mutants.  
Both the glycine and phenylalanine mutants showed that naloxone and naltrexone were 
able to decrease cAMP level, indicative of agonist behavior as seen in with DAMGO.  In 
the isoleucine mutant, neither naloxone nor naltrexone inhibited cAMP level and both 
ligands acted as antagonists, consistent with their WT MOR phenotype.  CTOP, a MOR 
peptide antagonist did not have an altered phenotype in any of the mutations, including 
the S4.54G and S4.54F mutants at which the alkaloid ligands had an altered phenotype 
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Figure 3.5.  Space filling representation of naloxone and W6.48 in the WT MOR (5a) and S4.54A MT 
MOR (5b-d).  5a.  Naloxone (yellow) prohibits a change in conformation of W6.48 (gray) between the 
inactive and active conformations in the WT MOR.  A 30° change to a value of -106° in the conformation 
of W6.48 causes steric interactions with naloxone in the WT MOR and thus W6.48 cannot undergo the 
rotameric changes needed as part of receptor activation.  5b-d.  In the S4.54A MT MOR, naloxone (sea 
green) does not prevent the rotameric changes of W6.48 (lt. pink) during activation.  In the inactive state, 
W6.48 is in g+ with a χ1 dihedral value of -79° (5b).  As W6.48 flips from g+ to trans, naloxone does not 
prohibit this movement. 5c shows W6.48 with a χ1 value of -106, the same as shown in the WT MOR 
where naloxone blocks this movement (5a).  5d shows W6.48 in a fully trans conformation since naloxone 
sits too high to block its rotameric changes. 
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Figure 3.6.  Various amino acid substitution at Ser4.54 (Ser
196
) of rat MOR on receptor activities. 
In (A), Xenopus oocytes were injected with cRNAs of various Ser4.54 mutants of MOR and the maximal 
K
+
 current induced by 1 µM naloxone was compared to those induced by 1 µM DAMGO as described in 
Methods. Each bar represents the average ± SEM of 4-10 oocytes. In (B), (C) and (D), the ability of 100 
nM opioid ligand to inhibit 10 µM forskolin-stimulated intracellular [
3
H]cAMP production in CHO cells 
stably expressing S196G (B), S196I (C) or S196F (D) mutant was determined as described in Method.  
Bars represent average±SEM from 4-6 wells. Statistical significance was determined by ANOVA and 
Fisher PLSD post-hoc analyses. In (A), statistical analyses were carried out by comparing the relative K
+
 
current induced by naloxone in oocytes injected with mutant cRNAs to those injected with wild type 
MOR cRNAs.  In (B) to (D), statistical analyses were carried out by comparing the forskolin-stimulated 
[
3
H]cAMP level in the presence of drug to that of control.  * denotes p <0.05.    
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Conformational Memories Results 
A representative MT TMH4 was selected from the CM output for each of the 
mutants and superimposed onto the intracellular end of the WT MOR crystal structure 
TMH4, as shown in Figure 3.7a.  This figure shows the MOR crystal structure TMH4 in 
yellow, with the S4.54I (light blue), S4.54V (maroon), S4.54L (sea green), S4.54A 
(magenta), S4.54F (royal blue) and S4.54G (red) output.  The S4.54I and S4.54V mutant 
TMH4 helices match the TMH4 seen in the MOR crystal structure.  However, the 
S4.54L/F/G helices are very similar to the S.454A mutant model shown earlier.    
 
 
 
 
Figure 3.7.  Figure 3.7a shows the WT MOR TMH4 in yellow, along with each of the mutant CM 
output selected superimposed on the intracellular end of the helix.  As shown, the S4.54L (sea 
green), S4.54F (royal blue) and S4.54G (red) mutants all bend into the receptor, much like the S4.54A 
mutant helix as described in Figure 3.3.  The S4.54I (maroon)/V (lt. blue) mutants have a similar shape 
to the WT TMH4.  Figure 3.5b shows an up close picture of the methyl groups of the V4.54 (left) and 
I4.54(right) mutants and their Van-der-Waals packing with W4.50. 
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S4.54V Conformational Memories Results 
In the run without constraints on the chi1 dihedral, V4.54 preferred a g+ 
orientation in a 2:1 ratio vs g- and a 3:1 ratio with trans.  In the output, there were 66 g+, 
34 g- and 20 trans χ1 dihedrals of V4.54.  Upon examination, it was determined that 
V4.54 was able to orient itself in the g+ conformation to maximize hydrophobic 
interactions with the ring system of W4.50 as shown in Figure 3.7b (light blue, left).   
The interaction between W4.50 and V4.54 is -26kJ/mol.  Despite the loss of the 
TMH3/TMH4 hydrogen bond network, a valine sidechain at position 4.54 is able to 
mimic the shape of the WT TMH4 due to this specific interaction. 
 
S4.54I Conformational Memories Results 
In the run without constraints on the χ1 dihedral, I4.54 preferred to be g+.  Of the 
120 output, there were 94 in g+, 4 in g- and 7 in trans.  Upon inspection, it was 
determined that the I4.54 was able to point its methyl groups at the ring system of W4.50 
and increase hydrophobic interactions as shown in Figure 3.7b (right, magenta).  This 
interaction is very similar to the one seen by the S4.54V TMH4, also shown in Figure 
3.7b (left, lt. blue).  The interaction between W4.50 and I4.54 was measured to be -
22kJ/mol.  Due to this interaction, the I4.54 mutant TMH4 maintains a wild type shape 
even though there is a loss of the TMH3/TMH4 hydrogen bonding network seen in the 
crystal structure. 
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S4.54L Conformational Memories Results 
In the run without constraints on the chi1 dihedral, L4.54 preferred to be trans vs 
g+ in approximately a 2:1 ratio (77 vs 43).  There were no output with the chi1 in g-, as 
putting a leucine in g- would cause steric clashes with the backbone.  It was evident that 
the S.454L output was strikingly different from the S4.54I/V output in that the shape of 
the helix did not match the wild type TMH4 from the crystal structure.  Upon 
examination, it was determined that the leucine was unable to point its methyl groups at 
W4.50, as seen in both the valine and isoleucine output.  The interaction energy between 
W4.50 and L4.54 was a marginal -12kJ/mol, much less than the isoleucine and valine 
mutants.  With the S4.54L MT TMH4 not able to maintain the hydrogen bonding 
network seen between TMH3/TMH4 in the WT MOR, nor being able to increase 
hydrophobic interactions with W4.50 to maintain the WT TMH4 helical shape, the 
S4.54L MT TMH4 is free to straighten and give rise to naloxone’s ability to act as a 
partial agonist. 
 
S4.54G Conformational Memories Results 
Unlike the other S4.54 mutants reported herein, the S4.54G gives rise to 
additional flexibility of TMH4.  In the CM output, all 120 output structures had an 
unwound region in the helix near G4.54 that allowed for a higher turn ratio with 5 
residues per turn instead of the traditional 4 residues per turn.   This mutation prevents 
the TMH3/TMH4 hydrogen bonding network from forming and combined with the 
higher turn ratio, shifts the extracellular end of TMH4 towards TMH5, giving rise to 
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naloxone’s ability to act as a partial agonist, much like the S4.54A MT TMH4 described 
herein. 
 
S4.54F Conformational Memories Results 
In the χ1 unconstrained run with S4.54F, the phenylalanine preferred to be in 
trans by a 3:1 ratio over g+ (93 vs. 27) and there were no output in g-.   While this 
mutant gives rise to naloxone acting as a partial agonist like the alanine, glycine and 
leucine mutants, the F4.54 was able to maximize hydrophobic stacking interactions with 
W4.50, as seen in the isoleucine and valine mutants.  The interaction energy between 
W4.50 and F4.54 was calculated to be -20kJ/mol, similar to that of the isoleucine and 
valine mutants.  Upon examination, it became clear that because of size, a phenylalanine 
at 4.54 prevents TMH4 from taking the wild type conformation.  In the WT MOR, Y3.34 
is pointed directly at S4.54.  Upon mutation of the S4.54 to phenylalanine, there are 
major steric overlaps with the Y3.34.  The F4.54MT TMH4 has to undertake a straighter 
conformation, like those seen in the S4.54A and S4.54L mutants to be able to fit in the 
receptor.   
 
Discussion 
 
Geometry of TMH4 
Proline residues are the most common helix deforming residues.  In addition to leaving 
the i-4 backbone carbonyl without its normal hydrogen bond donor, the proline also 
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sterically prevents the (i-3)-carbonyl-(i + l)-amide backbone hydrogen bond from 
forming.
39
  However, other residues such as serines and threonines can induce structural 
deformations in helices as well.
40
  The hydrogen bonding capacity of serine or threonine 
residues in α-helices can be satisfied by an intrahelical hydrogen bond interaction, in 
either the g- or g+ conformation, between the O-γ atom and the i-3 or i-4 carbonyl 
oxygen.  Serine and threonine residues in the g- conformation can induce a bend in an α-
helix, and we have found that changes in wobble angle and face shift can also occur.   
 
 
 
 
Figure 3.8.  An extracellular view of the MOR (lime), DOR (orange) and 
KOR (blue) crystal structures.  The structures were superimposed using the 
most conserved residue in each helix and are very similar.  The MOR and DOR 
have a P4.59 but the KOR has a S4.59.  The Ser in the KOR is mimicking the 
behavior of a P4.59 by forming a hydrogen bond with the i-3 backbone carbonyl. 
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In many class A GPCR’s there is a proline in TMH4 at either residue position 
4.59 or 4.60.  In the cannabinoids, beta-adrenergic, sphingosine -1-phosphate 1, and 
adenosine receptors, the proline is found at position 4.60, but in the orexin, dopamine, mu 
opioid, delta opioid and chemokine 4 receptors, the proline is found at position 4.59.  The 
Pro at 4.59 contributes to a kink at the extreme extracellular end of TMH4 in the MOR 
and DOR structures.  The kappa opioid receptor lacks the Pro at 4.59, but has a Ser at this 
position.  Figure 3.8 illustrates that the geometry of TMH4 in the MOR (lime), DOR 
(orange), and KOR (blue) are very similar.  The KOR TMH4 is able to mimic the proline 
kink in MOR and DOR because S4.59 can from a hydrogen bond with the backbone 
carbonyl of V4.56, the i-3 residue, and bend the helix.  
A hydrogen bonding network on TMH3 and TMH4 also contributes to the relative 
positions of these two helices in the opioid receptor bundles.  In each of the three opioid 
receptors, there are three lipid facing residues that need to satisfy their hydrogen bonding 
capabilities: S4.54, S3.30 and Y3.34. These three residues along with the backbone 
carbonyls of W4.50 and G4.57 form a series of interactions that appear to pull TMH4 to 
keep it packed close to TMH3, while contributing to the kinking of the extracellular end 
of TMH4, as seen in Figure 3.1.  Y3.34 forms a hydrogen bond with S4.54, which pulls 
TMH4 close to TMH3.  S3.30 also forms a hydrogen bond with the backbone carbonyl of 
G4.57 which aids in pulling TMH4 towards TMH3.  Additionally, P4.59 provides further 
kinking of the extreme extracellular end of TMH4 away from TMH5.   
When the S4.54 is mutated to an alanine in the MOR, the hydrogen bond with 
Y3.34 is eliminated.  Because this interaction is lost, TMH4 is not held close enough to 
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TMH3 for the S3.30/G4.57 interaction to take place.  Consequently, the overall shape of 
TMH4 in the S4.54A mutant receptor is altered such that TMH4 is less kinked and moves 
its extracellular end away from TMH3 towards TMH5 (see Figure 3.3).   
 
Ligand Binding Pocket Changes During R to R* Transition   
The striking phenotype of the S4.54A mutant is that naloxone changes from an 
antagonist to a partial agonist.  This change is likely due to a structural change in the 
alkaloid binding pocket.  The structural characteristics that define the GPCR inactive (R) 
and active (R*) states have been deduced primarily from biophysical studies of rhodopsin 
and the β2-AR receptor.  In the inactive or off state (R), the intracellular (IC) end of 
TMH6 is bent towards TMH3 and a salt bridge between R3.50 and E/D6.30 on the 
intracellular side of the TMH bundle forms an  “ionic lock”.  In the activated state, 
TMH6 undergoes a conformational change, straightening in the highly conserved CWXP 
hinge region.
41, 42, 43, 44, 45, 46
  This results in the intracellular ionic lock  breaking as TMH3 
and TMH6 move away from each other.
47
   Previous studies have shown that while the 
MOR does not form an “ionic lock” at the exact same location as rhodopsin, it does form 
a strong hydrogen bond between R3.50 and T6.34
36
 that serves the same purpose for 
MOR.  The R3.50 and T6.34 interaction is indeed present in the µ-opioid crystal structure 
with antagonist β-FNA present.
21
   
The change from the inactive to active states also results in changes within the 
ligand binding pocket. In the R state, a tryptophan residue in the CWXP motif on TMH6, 
W6.48, adopts a g+ χ
1
 dihedral angle.  This conformation in rhodopsin is due to the close 
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proximity of the beta-ionone ring of rhodopsin’s covalently bound ligand, 11-cis-retinal 
to W6.48, such that the tryptophan is locked in place.
6,5,4
  W6.48 is part of the highly 
conserved TMH6 CWXP motif and has been identified as important for GPCR activation 
through early mutagenesis studies.  A recent x-ray crystal structure of a constitutively 
active rhodopsin mutant suggests that when rhodopsin is activated and undergoes the 
isomerization of 11-cis retinal to all-trans-retinal, the beta-ionone ring is shifted 4.3Å 
towards the cleft between TMH5 and TMH6 and W6.48 is released from its locked 
position.  The indole group of W6.48 moves 3.6Å away from its ground-state position as 
a consequence of rhodopsin activation
48
 and W6.48 undergoes a change in its χ1 angle 
from g+  trans.
49
  Although this change is not seen in recent activated GPCR crystal 
structures, it is possible that such a change is transient and therefore not captured in the 
crystalline state.  In fact, in molecular dynamics simulations of cannabinoid CB2 receptor 
activation by its endogenous ligand, we observed such a transient change in W6.48.
50
  
Likewise, a rotameric change of W6.48 has been documented to occur in microsecond 
long molecular dynamics simulations
20
 of the β-2 adrenergic receptor in complex with the 
Gs protein. 
In the MOR crystal structure, the antagonist, β-FNA is covalently bound to K5.39 
via an alkyl chain on the C ring of the fused ring structure (see Figure 3.4d).  The N-
substituent, a methylcyclopropyl is wedged between W6.48 and Y7.43.  The A ring of the 
backbone structure of β-FNA sits above W6.48 and restricts its movement.  To determine 
the location of naloxone in the MOR, we removed β-FNA and used Glide, a ligand 
docking program, to dock naloxone in the WT MOR.  As illustrated in Figure 3.4a, the 
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Glide dock of naloxone in the MOR crystal structure
21
 mimics the placement of β-FNA.  
Here, the naloxone C-ring (see Figure 3.4d) restricts the movement of W6.48.  Figure 
3.5a illustrates that even a 30° change in conformation of W6.48 is not possible due to 
steric clashes with naloxone.  Further movement of W6.48 towards an active 
conformation would increase these steric clashes between W6.48 and naloxone in the WT 
MOR model.   
Figure 3.9 presents a comparison of the recently released DOR crystal structure
22
 
complexed with naltrindole, the MOR crystal structure with β-FNA and our dock of 
naloxone in WT MOR.   
 
Figure 3.9.  A comparison of the MOR crystal structure with β-FNA 
(cyan) and DOR crystal structure with naltrindole (purple), and the 
Glide docked naloxone (yellow) in MOR.  All three ligands occupy the 
same general binding area of the receptors and interact with D3.32.  
Naloxone sits slightly lower and closer to D3.32 and is likely able to do 
so since there is no large side chain or indole ring off of its C-ring 
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This figure illustrates that all three ligands occupy the same general receptor 
region.  Of the three ligands, naloxone (yellow) is shifted closest to the primary 
interaction site, D3.32 (gray).  Naltrindole (purple) has a large indole ring attached to the 
C-ring of the opioid backbone structure which prevents naltrindole from binding deeper 
in the binding pocket, very similar to the covalent attachment of β-FNA (cyan) in the 
MOR crystal structure.  Naloxone, which does not have a large sidechain or ring system 
off of the C-ring, is free to shift towards D3.32.   
Our Glide docking studies suggest that the conformational changes produced by 
the S4.54A mutation on TMH packing (see Figure 3.3) results in naloxone sitting higher 
in the binding pocket (see Figure 3.4c).  One important consequence of this new position 
is that naloxone has rotated to include an interaction with E5.35, therefore moving away 
from W6.48 such that W6.48 movement is no longer blocked by naloxone.  This change 
is likely the reason why naloxone can act as a partial agonist in the S4.54A MOR mutant. 
 
S4.54X MOR Mutations  
Using a potassium current assay, we were able to identify two additional S4.54 
mutations (S4.54L, S4.54F) that give rise to the unusual phenotype of naloxone acting as 
a partial agonist at the MOR.  Subsequent cAMP assays identified an additional mutant, 
S4.54G, upon which naloxone also acted as a partial agonist.  Surprisingly, upon 
mutation of S4.54 to an isoleucine or valine, naloxone remained acting as an antagonist, 
as seen in the wild type receptor.  Each of these mutations results in the loss of the 
TMH3/TMH4 hydrogen bonding network seen in the wild type MOR.  Along with 
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naloxone, naltrexone, DAMGO and CTOP were tested in the cAMP assays of the 
S4.54G, S4.54I and S4.54F mutants (see Figure 3.6b-d).  Naltrexone is structurally very 
similar to naloxone, and would be expected to behave similarly.  Both DAMGO and 
CTOP are peptide ligands and do not share a binding pocket with the alkaloid ligands 
such as naloxone and naltrexone.  Therefore, their behavior may or may not be affected 
by various mutations on TMH4 and would not be expected to behave the same as the 
alkaloid ligands. 
Upon examination of the S4.54I and S4.54V Conformational Memories output, 
we have determined that the isoleucine and valine mutant MORs are able to point their 
methyl groups directly at the ring system of W4.50, as seen in Figure 3.7b.  In doing so, 
the hydrophobic interactions between W4.50 and I/V4.54 are maximized and the mutant 
TMH4 helix is able to maintain the wild type conformation even though the hydrogen 
bonding network seen in the crystal structure is disrupted.  
Although the S4.54I and S4.54V mutant TMH4s are able to point their methyl 
groups at the ring system of W4.50, the S4.54L mutant is unable to do so without 
undertaking a g- conformation. Undertaking a g- conformation would cause a steric clash 
with the backbone, and thus a leucine at position 4.54 would have to remain in g+ or 
trans.   The interaction energy between W4.50 and L4.54 is -12kJ/mol, compared to -
22kJ/mol for the S4.54I and -26kJ/mol for the S4.54V mutants. As shown in Figure 3.7a, 
the S4.54L mutant TMH4 adopts the same conformation seen in the S4.54A MT MOR 
due to its inability to maximize interactions with W4.50 and disruption of the 
TMH3/TMH4 hydrogen bonding network seen in the wild type MOR.   
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Unlike the S4.54L mutant MOR, the S4.54F mutant is able to maximize 
interactions with W4.50 and yet, the phenylalanine mutant also gives rise to naloxone 
acting as a partial agonist.  The offset parallel stack between F4.54 and W4.50 gives rise 
to an interaction energy of -20kJ/mol between the two residues, similar to that of the 
valine and isoleucine mutants.  The TMH3/TMH4 hydrogen bonding network residue, 
Y3.34 points directly at S4.54 in the WT MOR, as shown in Figure 3.1b.  Thus, a S4.54F 
mutation involves a large steric clash between the two residues if the receptor cannot 
adjust to the mutation.  Therefore, we find that a S4.54F mutation and the loss of the 
hydrogen bonding network causes TMH4 to undertake a straighter conformation such 
that the helix is closer to TMH5, much like the S4.54A MT MOR model. 
Upon mutation of S4.54 to glycine, naloxone displayed a partial agonist 
phenotype (Figure 3.6b).  We find that although this mutation disrupts the TMH3/TMH4 
hydrogen bonding network, it also allows for extra flexibility in the helix.  The output 
structures for the S4.54G mutant MOR had an unwound region near G4.54.  This region 
of the helix had a higher turn ratio of 5 residues per turn as opposed to the traditional 4 
residues per turn seen in an alpha helix.  The unwound region with a higher turn ratio 
shifts the extracellular end of S4.54G TMH4 towards TMH5, thus giving rise to 
naloxone’s ability to act as a partial agonist. 
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Conclusions 
 
The work presented here suggests that the origin of the unusual phenotype of the 
S4.54A mutant lies in the loss of a single key hydrogen bond between S4.54 and Y3.34 
and the ensuing geometrical changes in the binding pocket which prevent naloxone from 
restricting the motion of W6.48 in the mutant MOR.  We also propose that the S4.54I and 
S4.54V mutant MORs are able to maintain a wild type TMH4 conformation due to 
increased hydrophobic interactions with W4.50; accordingly naloxone maintains wild 
type activity.  Upon mutation of S4.54L, S4.54G or S4.54F, the TMH3/TMH4 hydrogen 
bonding network is broken and each of the mutants are unable to maintain a wild type 
conformation.  Consequently, naloxone displays partial agonist activity at these MORs 
much like the S4.54A mutant MOR described previously and herein.   
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CHAPTER IV 
 
MOLECULAR STUDIES OF A S4.54L/T7.44A/C7.47S TRIPLE MUTANT MOR AT 
WHICH NALOXONE ACTS AS A FULL AGONIST 
 
Introduction 
 
For centuries the most consistent treatment for chronic and acute pain has been 
agonists of the opioid receptors.
1
  Although there are three known opioid receptors, mu, 
delta and kappa, only mu receptor agonists, such as morphine and hydrocodone, 
consistently produce analgesic effects.
1,2
  According to the IMS Health study of 
prescriptions in 2010, the number one prescribed medication was Vicodin® 
(hydrocodone and Tylenol) with 131 billion prescriptions filled.  While these medications 
are effective at treating pain, they are also widely abused and can be addictive.  Thus, the 
need for effective pain management without addiction and lessened side effects is 
essential.  
Targeted gene therapy of opioids can be used to attenuate pain, as mentioned in 
the previous chapter using a single mutant of the mu-opioid receptor along with the 
traditional antagonist, naloxone.
3,4,5
  However, the single mutant MOR described 
previously only provides naloxone with the ability to act as a partial agonist.  Law and 
coworkers have published additional studies using a S4.54L/T7.44A/C7.47S triple mutant 
MOR that gives rise to naloxone acting as a full agonist.
6
  While this gene therapy has 
been shown in cells and in spinal cord, the underlying mechanism is unknown and thus 
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the goal of this paper is to determine the molecular mechanism by which naloxone can 
act as a full agonist at the triple mutant MOR. 
The binding pocket for mu opioid ligands is formed by TMHs 3, 5 and 6 in the 
wild type receptor, as seen in the crystal structure with β-FNA
7
 and in our glide dock of 
naloxone (See Chapter 3).  As discussed previously, S4.54 does not face into the receptor 
or the binding pocket; rather it is on the outer lipid interface of TMH4.  Interestingly, 
both of the mutated residues on TMH7 (T7.44 and C7.47) in the triple mutant MOR also 
face lipid.  We report here that the combination of the S4.54L mutation on TMH4 along 
with TMH7 face shift changes occur upon mutation of T7.44 and C7.47 produce overall 
packing changes that give rise to a different binding pocket than seen in the wild type or 
single mutant MORs.  These changes result in naloxone’s ability to fully activate the 
S4.54L/T7.44A/C7.47S MOR. 
 
Methods 
 
Conformational Memories Technique  
We explored the wild type TMH7 sequence of the MOR as well as the 
T7.44A/C7.47S mutant TMH7 using Conformational Memories
8
, as described 
previously.  Briefly, an alpha helical TMH with the WT hMOR sequence was used as a 
starting point for this calculation.  The region of A7.40 to P7.50 was considered the 
flexible region in both the WT calculations and the T7.44A/C7.47S mutant calculations.  
Backbone φ and ψ torsions in regions of interest were allowed to vary ±50°, while all 
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other backbone torsion angles were allowed to vary ±10°. Side chain torsions were 
allowed to vary ±180°.  The exploratory phase starts at 3000K with 50,000 Monte Carlo 
steps applied to each torsion or bond angle variation, with cooling to 310K over 18 steps.  
The biased annealing phase starts at 749K and cools to 310K in 7 steps.  There were 120 
output TMH7 conformers generated in a distance-dependent dielectric at 310 K.  The CM 
output helices were subsequently evaluated in the context of the MOR TMH bundle and 
an appropriate helix was chosen for substitution into the MOR model (see next section).   
 
Construction of the TMH Region of the S4.54L/T7.44A/C7.47S MT MOR and 
Ligand Docking 
The recently published MOT WT x-ray crystal structure
7
 was used to create a 
homology model for the S4.54L/T7.44A/C7.47S triple mutant MOR model.  As reported 
for the S4.54A single mutant MOR, the MOR crystal structure was pulled apart 2Å in 
each direction from the center of the bundle.  The S4.54A TMH4 from the single mutant 
model was substituted in place of the WT TMH4.  The selected T7.44A/C7.47S CM 
output helix was superimposed onto TMH7 of the crystal structure using the Cα atoms 
from L7.48 to F7.55.  The transmembrane regions of the resultant 
S4.54L/T7.44A/C7.47S MOR model were energy minimized to allow the TMHs to pack 
such that there were no large gaps.  The minimization protocol used included a 500 step 
energy minimization using the OPLS2005 all atom force field in Macromodel 9.1 
(Schrodinger, 2006) and a distance-dependent dielectric with extended cutoffs.  The 
backbone phi/psi dihedrals of the TMHs were constrained with a force of 500kJ/mol to 
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preserve their geometries.  The minimization was set to converge to 0.05kJ/mol·Å
2
.  The 
converged output structure was selected as the model for the S4.54L/T7.44A/C7.47S MT 
MOR by comparing the TMH regions of the mutant and wild type receptors to ensure 
that the TMH region of the mutant receptor was not over-packed.  Naloxone was docked 
in the resultant triple mutant model using Glide (Schrodinger 2006) with D3.32 as the 
primary interaction site for the ligand.  The dock with the best Glide score was used for 
further study. 
Due to the differences in the extracellular region, and overall changes in the 
receptor packing, all loops were calculated in MODELLER v9.1.
9,10,11
  Restraints were 
added to the MODELLER run such that the disulfide bond with C3.25 and the beta sheet 
regions of the EC2 loop were preserved.  The helical portion of the IC2 loop was also 
preserved.  The IC3 loop was not resolved in the crystal structure therefore MODELLER 
was used to determine a likely loop conformation.  Once the loops were added, naloxone 
was re-docked in the full model using Glide.  The dock with the best Glide score was 
used for the final S4.54L/T7.44A/C7.47S MT MOR/naloxone complex model.  The 
resultant WT MOR/naloxone and S4.54L/T7.44A/C7.47S MOR/naloxone complexes 
were compared in order to investigate the possible origins of naloxone’s full agonist 
behavior in the S4.54L/T7.44A/C7.47S MT MOR at the molecular level. 
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Results 
 
WT MOR Conformational Memories Results 
CM calculations were used to determine the flexibility of WT TMH7, as well as that of 
the T7.44A/C7.47S MT TMH7.  After superimposing on the intracellular end, the CM 
output from the WT and T7.44A/C7.47S were compared.  As shown in Figure 4.1, the 
WT CM output (magenta) are clustered together tightly, while the T7.44A/C7.47S MT 
TMH7 CM output (blue) have a larger spread.   
 
Figure 4.1. An extracellular view of Conformational Memories 
(CM) output of WT TMH7 (magenta) and T7.44A/C7.47S MT 
TMH7 (blue).   
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T7.44A/C7.47S Conformational Memories Results 
The biased Monte Carlo/simulated annealing technique, Conformational 
Memories was used here to explore the conformational consequences of the 
T7.44A/C7.47S mutations in the MOR.  Figure 4.2 shows the CM output for the 
T7.44A/C7.47S TMH7 superimposed using the Cα atoms of residues L7.48-F7.55 on 
TMH7 of the WT MOR.  The most striking difference between the CM output and WT 
MOR TMH7 was that the extracellular end of the CM output bends towards the center of 
the receptor.  Additionally, none of the output looks like the WT TMH7 seen in the 
crystal structure with many of the CM output kinking towards TMH1 or TMH6.  The 
TMH7 chosen for use in the S4.54L/T7.44A/C7.47S mutant receptor is colored in red 
with the WT TMH7 colored yellow.  The S4.54A MT TMH4 used is shown in magenta 
as well.  Prokink
12
 was used to determine the bend, wobble and face shift angles of the 
WT TMH7 (B=45.3°, W=46.3°, FS=-106.2°) and the MT TMH7 (B=37.1°, W=-60°, 
FS=116.6°).  As shown in Figure 4.2, the extracellular end of the MT TMH7 moves 
inward slightly and toward TMH6. 
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Creation of S4.54L/T7.44A/C7.47S Triple Mutant MOR Model   
A homology model of the S4.54L/T7.44A/C7.47S triple mutant MOR was 
developed using the published mu-opioid crystal structure (PDB Code: 4DKL)
7
 and the 
results of the Conformational Memories studies of TMH4, as well as TMH7.  Once the 
triple mutant MOR model was completed, the transmembrane regions were superimposed 
onto the MOR crystal structure template using the most conserved residue in each 
respective helix.   
 
Figure 4.2.  Conformational Memories (CM) output of T7.44A/C7.47S MT TMH7.  An 
extracellular view (a) and a view from lipid (b) showing the WT MOR in gray (TMH2, 3, 5) 
and lime (TMH 1 and 6), the S4.54A MT TMH4 in magenta and WT TMH7 in yellow.  The 
CM output is shown in blue tube displays with the T7.44A/C7.47S TMH7 selected in red. 
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The superimposed receptors are shown in Figure 4.3, with the WT MOR in lime 
and the triple mutant (TMT) MOR shown in lavender.   As shown, there are significant 
changes in the backbone structure of TMHs 1, 2, 4 and 7, with a minor shift in TMHs 3 
and 5 and no changes in TMH6 between the WT MOR and the TMT MOR.  The 
extracellular movement of TMH3 was found to not be significant.  The changes in TMH4 
and TMH5 are the same in the TMT as in the S4.54A SMT MOR model and thus the 
Figure 4.3.  An extracellular view of the WT MOR (lime) and the 
S4.54L/T7.44A/C7.47 triple mutant, TMT, (lavender) MOR models.  There were 
significant changes in TMHs 1, 2, 4, and 7 and minor changes in TMHs 3 and 5.  
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hydrogen bond network between TMH3 and TMH4 in the S4.54L/T7.44A/C7.47S TMT 
MOR is disrupted. 
The movement of TMHs 1, 2 and 7 can be seen Figures 4.4(a) (TMH2 and 7) and 
4.4(b) (TMH1).  As shown, TMH7 moves into the bundle and towards TMH6, TMH2 
moves away from TMH1 and towards TMH3 and pulls back away from the center of the 
receptor.  In the triple mutant model, TMH1 pulls back significantly when compared to 
the WT MOR (Figure 4.4(b)).  The Cα of A1.32 at the extracellular end of TMH1 moves 
10.89Å, Cα Y2.64 moves 5.35Å, and Cα W7.35 moves 6.59Å between the two models.   
 
 
Figure 4.4. A zoomed in extracellular view of the WT MOR (lime /gray) and the TMT 
MOR model in lavender.  (a) TMH2 and TMH7 are compared on the left. (b) The TMH1 
difference is shown on the right. 
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Upon visual inspection it can be seen that in the triple mutant MOR, TMH1 and TMH7 
are further apart than in the WT MOR (see Figures 4.3 and 4.4).  A measurement of the 
distance between the Cα’s atoms of A1.32 and W7.35 indicates that these two 
extracellular residues move apart by almost 6Å.  In the WT MOR, the Cα’s are 12.4Å 
apart, but in the TMT MOR they are 18.3Å apart.  Interestingly, there is no gap between 
TMH1 and TMH7 as shown in Figure 4.5.   
 
  
In Figure 4.5 (a), TMH1, 6 and 7 are shown in lavender with other helices in gray 
in the TMT MOR model.  As shown, there are a significant number of bulky residues on 
the TMH1/2/7 interface that prevent a hole from opening between the two helices.  These 
Figure 4.5.  A view from lipid of the packing of TMH1 and TMH7 in the triple mutant 
MOR model. (a) shows residues involved in the packing of TMH1/7 in VdW representation and 
include I1.35, Y1.39, V1.42, Y2.64, W7.35, H7.36, I7.39 and Y7.43.  (b) shows a surface 
representation of the triple mutant MOR model.  It can be seen that there are no holes where a 
lipid could penetrate the receptor in the TMH2-7 region. 
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residues include I1.35, Y1.39, V1.42, Y2.64, W7.35, H7.36, I7.39 and Y7.43 in the triple 
mutant MOR.  Shown in surface representation in Figure 4.4 (b), it can be seen that 
although these helices are far apart, there are no holes where a lipid could possibly 
penetrate and disrupt the receptor. 
In all three (mu, delta and kappa) opioid crystal structures there is a hydrogen 
bond interaction between Y7.43 and D3.32, as shown in Figure 4.6 for the WT MOR 
crystal structure (lime backbone, yellow residues).  In our triple mutant model, this 
interaction has been broken due to the rotation and movement of TMH7.  As shown, 
while there is slight movement of TMH3, the Cα atom of D3.32 remains in the same area 
with only minimal movement (1.01Å) in the TMT model compared to the MOR crystal 
structure. 
As depicted in the WT MOR (lime backbone, yellow residues) D3.32 and Y7.43 
are pointed towards each other and form a hydrogen bond.  However, in the TMT MOR 
(lavender backbone, pink residues), TMH7 has moved and rotated such that Y7.43 does 
not point into the receptor; rather it is on the TMH1/7 lipid interface.  Interestingly, 
TMH6 does not change shape between the WT MOR and TMT MOR models shown in 
Figure 4.3.  Seen in Figure 4.6, W6.48 has minimal movement in the TMT MOR model 
(Cα moves by less than 1Å) and is in the same conformation in the WT MOR and the 
TMT MOR.  Since both W6.48 and D3.32 move only a minimal amount, these two 
residues were used in measurements with Y7.43 to quantitate the movement of the central 
area of TMH7.  The Cα distance between D3.32 and Y7.43 in the WT MOR was 9.8Å 
124 
 
and increased to 12.1Å in the TMT MOR.  The Cα distance between W6.48 and Y7.43 in 
the WT MOR was 8.7Å and increased to 12.6Å in the TMT MOR. 
 
 
  
Figure 4.6.  An extracellular view of the WT MOR (lime) and TMT MOR (lavender) 
models superimposed with D3.32, W6.48 and Y7.43 highlighted in yellow (WT) and pink 
(TMT).  TMH7 rotates in the TMT and the D3.32/Y7.43 hydrogen bond interaction is 
broken as Y7.43 rotates away from the center of the receptor.  TMH1 is omitted here for 
clarity. 
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Naloxone Docking Studies 
S4.54L/T7.44A/C7.47S Triple Mutant MOR.  Glide was used to identify a 
binding site for naloxone in the triple mutant MOR model (Figure 4.7) and the dock with 
the best score (-5.673) was chosen for naloxone docking studies.  In this docked position, 
naloxone (pink) maintains the hydrogen bond interaction with D3.32 that has been shown 
experimentally and in the naloxone dock in the WT MOR (see Chapter 2 and Figure 4.7).  
Naloxone maintains VdW interactions with Y3.34 and M3.36 in the TMT MOR, but 
loses the W6.48 interaction.  Also, in the TMT MOR model, naloxone picks up 
significant interactions with I3.29, W7.35 and C7.38.  In addition to these interactions, 
naloxone also interacts with L155 in the E2 loop.  In Figure 4.7 (a), naloxone can be seen 
in a space filling representation looking from lipid through TMH1 along with some of the 
residues it interacts with in gray.  In Figure 4.7 (b), naloxone is seen with a view from 
TMH6 so that the residues on TMH3 can be visualized. 
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Naloxone binds higher and in a different location in the triple mutant MOR than it 
does in the WT MOR crystal structure as shown in Figure 4.8.  In the WT MOR crystal 
structure dock of naloxone, the alkaloid backbone of naloxone is located between TMH 
3, 5, and 6 (as discussed previously) but in the TMT MOR, naloxone has re-oriented in 
the binding pocket and docks with the alkaloid backbone between TMH 2, 3, 6 and 7.    
In a view from between TMH1 and TMH7 (cut away for clarity), it can be seen that the 
alkaloid backbone of naloxone in the TMT model (pink) has rotated towards TMH2 and 
is higher in the binding pocket than in the WT MOR dock (yellow naloxone).   
  
Figure 4.7. The docked position of naloxone in the S4.54L/T7.44A/C7.47S MT MOR model.  
(a). A view of naloxone’s (pink, space filling) binding pocket looking through TMH1 in the TMT 
MOR model.  Naloxone maintains a hydrogen bond interaction with D3.32 and picks up 
interactions with L155, I7.39 and W7.35.  (b) A cut away view from TMH6 showing naloxone’s 
interactions with I3.29, Y3.33 and M3.36 in gray. 
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As shown in Figure 4.8, the A-ring hydroxyl of the alkaloid backbone of naloxone 
moves 6.7Å extracellularly, away from TMH6 towards TMH3 in the TMT MOR dock 
(pink naloxone—see blue dashed line which references the position of naloxone (yellow) 
in the WT MOR).  Additionally, the C-ring carbonyl oxygen flips 180° away (7.3Å) from 
TMH5 and towards TMH2 in the TMT dock of naloxone, as shown by the red dashed 
line in Figure 4.8. The alkaloid fused ring system of naloxone restricts movement of 
W6.48 in the WT MOR, but does not restrict movement of W6.48 in the TMT MOR.  
Figure 4.8.  A lipid view from TMH7 of the WT MOR (lime, yellow residues) and TMT 
MOR (gray, pink residues) models superimposed with naloxone docked.  The A-ring 
hydroxyl of the alkaloid backbone of naloxone moves extracellularly 6.7Å (blue line) and the 
C-ring carbonyl moves 7.3Å in the TMT MOR backbone, as indicated by the red dashed line. 
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The charged nitrogen of naloxone is 11Å away from the Cα carbon of W6.48 in the TMT 
MOR but only 9Å away in the WT MOR. 
 
Discussion 
 
Geometry of TMH7 
As previously discussed, while proline residues are the most common helix 
deforming residues, glycines, serines and threonines can also deform helices.
13
  In 
addition to leaving the i-4 backbone carbonyl without its normal hydrogen bond donor, 
the proline also sterically prevents the (i-3)-carbonyl-(i + l)-amide backbone hydrogen 
bond from forming.
13
  The hydrogen bonding capacity of serine or threonine residues in 
α-helices can be satisfied by an intrahelical hydrogen bond interaction, in either the g- or 
g+ conformation, between the O-γ atom and the i-3 or i-4 carbonyl oxygen.  Serine and 
threonine residues in the g- conformation can induce a bend in an α-helix, and we have 
found that changes in wobble angle and face shift can also occur.
14
  For example, in the 
kappa opioid receptor (KOR) crystal structure, there is no proline at position 4.59 as seen 
in both the mu and delta opioid receptors.  Interestingly, the shape of TMH4 in the KOR 
is the same as the shape in the MOR and DOR.  The KOR TMH4 is able to mimic the 
proline kink seen in the MOR and DOR because it has a S4.59 which can form a 
hydrogen bond with the backbone carbonyl of V4.56, the i-3 residue and bend the helix. 
In the MOR crystal structure, C7.47 faces lipid on the TMH1/7 interface and is in 
a g- conformation with a χ1 dihedral value of 82°.  Although a relatively weak 
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interaction, C7.47 forms a hydrogen bond with the backbone carbonyl of T7.44, the i-3 
residue.  In both the delta and kappa opioid receptors, the residue at position 7.47 is a 
serine and undertakes the g- conformation in the crystal structure.   
 
 
By mutating C7.47 in the MOR to a serine, the hydrogen bond is strengthened and 
thus the new residue may aid in deforming TMH7.  Also, the cysteine to serine mutation 
allows for greater flexibility of TMH7 since the large sulfur atom has been replaced by a 
smaller oxygen atom in the serine as shown in Figure 4.9.  Additionally, the T7.44A 
Figure 4.9.  A close up picture of TMH7 in the WT 
MOR (left, lime) and the TMT MOR (right, lavender) 
in the region of the T7.44A/C7.47S mutations.  As 
shown, both the alanine and serine are smaller than the 
threonine and cysteine and allow for extra flexibility of 
TMH7. 
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mutation results in the loss of steric bulk of the threonine to just the methyl group of the 
alanine, also shown in Figure 4.9. 
 
 
Taken together, both the C7.47S and T7.44A mutations give TMH7 greater 
flexibility than seen in the WT, as shown in Figure 4.1.  The WT TMH7 CM output 
helices are clustered together, while the T7.44A/C7.47S MT TMH7 CM output helices 
have a much larger spread.   
In Class A GPCRs, residues 7.34 and 7.38 are located out of the TMH6/TMH7 
interface, facing lipid.  These residues are generally hydrophobic, however in the opioids 
Figure 4.10.  An extracellular view of the WT MOR (lime) and TMT 
MOR (lavender) displaying S7.34 and C7.37 in both receptors.  In the 
TMT MOR model, these residues point into the binding pocket rather than 
staying on the lipid side of TMH7 as seen in the crystal structure. 
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they are generally a S7.34 and C7.37.  The exception to this is in the DOR, where 7.34 is 
an alanine.  Given that these residues face lipid, they will form hydrogen bonds with the 
backbone of the TMH to satisfy their hydrogen bond capability.  In the MOR crystal 
structure, S7.34 is in g- with a χ1 dihedral of 59° and can hydrogen bond to both the i-3 
and i-4 carbonyl oxygen.  As shown in Figure 4.10, both S7.34 and C7.38 are on the lipid 
interface of TMH6/TMH7 in the MOR crystal structure (lime).  However, as a result of 
the additional flexibility and movement of the T7.44A/C7.47S TMH7 both S7.34 and 
C7.38 have rotated and are on the inside of the bundle in the triple mutant MOR model 
(Figure 4.10, lavender backbone).  In the WT MOR, the Cα of W6.48 and S7.34 are 
13.7Å apart, but come closer together in the TMT MOR, with a distance of 11.7 Å.  
Additionally, the Cα of D3.32 and S7.34 are 20Å apart in the WT MOR, but that distance 
decreases to 14.6 Å in the TMT MOR.  As a result of the additional flexibility and 
movement of TMH7, there is a large face shift and bend difference in the T7.44A/C7.47S 
TMH7. The face shift in the WT TMH7 is -106.2°, compared with 116.6° in the MT 
TMH7.  The wobble in the WT TMH7 is 46.3° and is -60° in the MT TMH7.  
 
Binding pocket changes in the S4.54L/T7.44A/C7.47S triple mutant MOR 
In the TMT MOR, naloxone maintains its strong salt bridge interaction with 
D3.32, while also forming strong interactions with W7.35, C7.38 and I3.29.  These 
interactions are made possible by the changes in the receptor binding pocket due to the 
movement of TMH7 and subsequently the position change of naloxone.  As a result of 
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sitting higher in the binding pocket on the opposite side of the receptor, naloxone also 
picks up interactions with L155 in the E2 loop, Q2.60 and Q7.31. 
As discussed in the previous chapter, as a GPCR undergoes activation, W6.48 changes its 
χ1 dihedral from g+ to trans.  For W6.48 to be able to shift in the MOR naloxone cannot 
be preventing that movement by either the alkaloid backbone or the N-allyl tail.  As 
indicated by our Glide dock of naloxone, the fused ring system of the alkaloid backbone 
prevents the movement of W6.48 in the WT MOR.  However, in the 
S4.54L/T7.44A/C7.47S triple mutant MOR, the nitrogen that hydrogen bonds with D3.32 
is slightly higher in the binding pocket and the fused alkaloid backbone rotates away 
from TMH6 and towards TMH2 and TMH7.  This rotation moves the hydroxyl of the A-
ring of the alkaloid backbone 6.7 Å higher in the binding pocket as shown in Figure 4.8.  
Shown in Figure 4.11, in the TMT MOR, naloxone does not prohibit movement of 
W6.48.  In Figure 4.11 (a), the χ1 dihedral of W6.48 is in g+ at -88°.  Figures 4.11(b-d) 
show the movement of W6.48χ1 dihedral as it rotates from g+ to trans, -110° (11b), -
140° (11c) and -180° (11d).  As depicted, W6.48 is free to move without being blocked 
by naloxone in the TMT MOR.  Distance measurements indicate that during the rotation 
of W6.48, no atom of W6.48 or naloxone come closer together than a distance of 3.5Å at 
any point in time, including hydrogen atoms. 
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Binding pocket changes in the S4.54A SMT MOR and S4.54L/T7.44A/C7.47S TMT 
MOR 
 
In both the S4.54A SMT and S4.54L/T7.44A/C7.47S TMT MOR models, 
naloxone maintains interactions with D3.32 and M3.36 as seen in the dock of naloxone in 
the WT MOR crystal structure (see previous chapter).  However, naloxone binds higher 
in both the SMT MOR and the TMT MOR as indicated by the difference in the distance 
between the Cα atoms of W6.48 and the N
+
 on naloxone in each of the 3 models (9.0Å in 
the WT, 12Å in the SMT, and 12.5Å in the TMT).  Additionally, as mentioned before, 
Figure 4.11.  Movement of W6.48 in the TMT MOR Model.  This figure shows the 
progression of W6.48 (gray, VdW) from a χ1 dihedral of g+  (-80°) to trans (180°).  
This movement of W6.48 is unimpeded by naloxone which is shown in VdW display 
and pink.  
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naloxone rotates in the TMT model towards TMH2 such that the alkaloid backbone is 
shifted when compared to the WT MOR or the SMT MOR models.  The difference of the 
Cα atom positions of D3.32 in the two mutant MOR models is very small (1.0Å), as is 
the difference in Cα atom positions of W6.48 (0.7Å). In the S4.54A SMT MOR model, 
naloxone is able to bind higher in part due to the face shift of TMH5 (see previous 
chapter) and a new hydrogen bond with E5.35.  
 
  
The protonated N atom of naloxone in the S4.54A SMT MOR is approximately 
2Å from the protonated N atom of naloxone in the S4.54L/T7.44A/C7.47S TMT MOR 
Figure 4.12.  The S4.54A SMT MOR (magenta backbone, sea 
green residues) and the S4.54L/T7.44A/C7.47S TMT MOR 
(lavender backbone, pink residues) models with naloxone.  
Naloxone maintains the D3.32 interaction in both models but picks 
up an interaction with E5.35 in the SMT MOR and with S7.34 in the 
TMT models. 
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model.  Also, in the TMT MOR, the C-ring carbonyl of naloxone moves 8.9Å when 
compared to the SMT MOR with naloxone.  However, in the S4.54L/T7.44A/C7.47S 
TMT MOR, the shape of the receptor is altered such that naloxone is able to pick up 
interactions with W7.35 and C7.38, which is not seen in either the SMT MOR or the WT 
MOR.  Due to the changes in the TMH7 region and naloxone’s orientation, in the TMT 
MOR naloxone does not interact with E5.35, but instead interacts with W7.35.   Figure 
4.12 shows the S4.54A SMT MOR model (magenta helices, green residues) and the 
S4.54L /T7.44A/ C7.47S TMT MOR (lavender helices, pink residues) model with 
naloxone docked in both models.  As shown, TMH7 in the TMT MOR (lavender) is 
pulled into the receptor towards TMH3 more than what is seen in the SMT (magenta) 
TMH7.  Additionally, the A-ring hydroxyl of naloxone, which hydrogen bonds with 
E5.35 in the SMT, moves 7.0Å in the TMT model when compared with its location in the 
SMT model and the C-ring carbonyl oxygen moves 8.9Å in the TMT model.      
 
Conclusions 
 
In the S4.54A SMT MOR, the new position of naloxone allows it to bind higher 
and form a hydrogen bond with E5.35, therefore moving away from W6.48 such that 
W6.48 movement is no longer blocked by naloxone.  This change is likely the reason 
why naloxone can act as a partial agonist in the S4.54A MOR mutant.  Naloxone binds 
higher and in a different location in the S4.54L/T7.44A/C7.47S TMT MOR.  In this new 
binding pocket where the alkaloid backbone is in the pocket formed by TMH2, 3 and 7 in 
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the TMT MOR, naloxone does not come close to W6.48.  Upon activation in the TMT 
MOR, the χ1 dihedral of W6.48 can rotate from g+ to trans, and the carbon atoms of the 
indole ring come no closer to any carbon of naloxone than 6Å at any point during the 
rotation.  Additionally, in the TMT MOR, TMH7 rotates such that Y7.43 is on the 
TMH1/7 interface and its interaction with D3.32 is broken.  The breakings of this 
interaction, as well as the changes in the overall packing of the receptor, together with 
naloxone’s altered binding position are likely the underlying reasons for naloxone’s full 
agonism in the triple mutant MOR. 
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CHAPTER V 
 
PARAMETERIZATION DEVELOPMENT OF THE N-ALLYL TAIL OF NALOXONE 
 
Introduction 
 
The mu opioid receptor is a Class A G-protein coupled receptor (GPCR) that is 
widely expressed throughout the peripheral and central nervous systems.  Traditionally, 
drugs used for pain management activate the mu-opioid receptor (MOR) and include 
medications such as morphine and oxycodone.  Antagonists of the mu-opioid receptor, 
such as naloxone and naltrexone are used in cases of opioid overdose to reverse the 
actions of MOR agonists.  While it has been known for many years that these drugs work 
in the body, their exact mechanism and interactions have not been discovered.  
Computational studies and simulations can be used to determine exactly how opioid 
ligands behave in the receptor.  Although there have been previous molecular dynamics 
simulations of the opioid receptors and their ligands,
1,2
 parameters for these ligands have 
not been published. 
In the work described here, we developed parameters for naloxone for use in 
molecular dynamics simulations employing a CHARMM force field.
3,4
  These parameters 
were developed using an established parameterization method which compares molecular 
mechanical and quantum mechanical data, as previously published.
3,4,5
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The published CHARMM General Force Field (CGenFF) database
6
  was used as a 
starting point due to its extensive list of atom types and parameters for organic 
compounds.  Subsequently, a model compound was used to develop novel parameters for 
the N-allyl region of naloxone and is described herein.   
 
Methods 
 
The potential energy function applied by CHARMM is given in equation (1) 
below.  
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where Kb, Kθ, KUB, Kφ, Kψ  are respectively the bond, angle, Urey-Bradley, dihedral, and 
improper dihedral force constants; b, θ, s, φ, ψ are respectively the bond length, bond 
angle, Urey-Bradley distance, dihedral angle, and improper dihedral angle, where the 
subscript zero represents the equilibrium value of each. The dihedral value also 
incorporates n, the periodicity, and δ, the phase. In the CHARMM force field nonbonded 
interactions, including attractive Van der Waals dispersion as well as short range 
repulsion, are included via the Lennard Jones 6-12 potential.  Electrostatic interactions 
are included using the Coulombic potential. In equation 1, Rmin is the distance between 
atoms at the Lennard-Jones minimum and ε is the well depth. The partial atomic charges, 
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q, and the effective dielectric constant, l, are both included in the Coulombic 
contribution. Lastly, rij is the distance between atoms i and j.
3
 
Force field parameters for naloxone were calculated by comparison to quantum 
mechanical (QM) calculated data. The structure of naloxone is displayed in Figure 5.1 
along with the atomic naming convention used in this work.  Atom types in naloxone 
were assigned according to those used in the CGenFF database
6
 and are listed in Table 
5.1 for each atom number which is labeled in Figure 5.1.  The CGenFF types,
6
 that the 
current naloxone parameters were derived from, are listed in Table 5.2. 
 
 
 
 
 
Figure 5.1.  The structure of Naloxone is illustrated here along with the 
atomic numbering convention used in this work.  Atom labels were assigned 
based upon atom types from the CGenFF library.  Atom names were changed 
from six characters to three or four to be compatible with CHARMM27 
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Table 5.1. Listing of Atom Names, Types and Partial Charges for Naloxone  
(See Figure 5.1 for atom numbering system) 
 
Atom Type 
Partial 
Charge Atom Type 
Partial 
Charge 
O1 O11 -0.53 H1 HP1 0.42 
O2 O351 -0.40 H2 HP1 0.42 
O3 OD3 -0.48 H3 HP2 0.32 
O4 O11 -0.64 H4 H61 0.12 
N1 NP1 -0.40 H5 H61 0.12 
C1 C61 -0.12 H6 HG1 0.09 
C2 C61 -0.12 H7 HG2 0.09 
C3 C61 0.11 H8 HG2 0.09 
C4 CC0 0.13 H9 HG2 0.09 
C5 C3C1 0.12 H10 HG2 0.09 
C6 CO5 0.48 H11 HG1 0.09 
C7 C21 -0.18 H12 HG2 0.09 
C8 C21 -0.18 H13 HG2 0.09 
C9 C14 0.21 H14 HG2 0.09 
C10 C21 -0.18 H15 HG2 0.09 
C11 CC0 0.00 H16 HG2 0.09 
C12 CC0 0.00 H17 HG2 0.09 
C13 C3C1 0.00 H18 HG2 0.09 
C14 C01 0.22 H19 HG2 0.09 
C15 C21 -0.18 H20 HG4 0.15 
C16 C24 0.21 H21 HG5 0.21 
C17 C24 0.21 H22 HG5 0.21 
C18 CD1 -0.15   
  C19 CD2 -0.42   
   
Model Compound 
 The major portion of naloxone for which there were no parameters is the N-allyl 
portion of the molecule.  A model compound was used to represent this N-allyl portion 
during the parameterization of torsion angles.  This model compound, PIPA, was chosen 
such that the atom types in it were as similar as possible to the atom types in the N-allyl 
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portion of naloxone.  Figure 5.2 shows the model compound, PIPA (piperdine amine) 
with its atomic numbering convention. 
 
 
Non-bonded Parameters   
Partial charges for naloxone atoms were taken from chemically similar atoms 
present in the CGenFF database.
6
  The CGenFF database applies a charge of -0.115q to 
all aromatic carbons not bonded to heteroatoms and an equal and opposite charge to their 
hydrogen atoms. It also applies a charge of 0.09q to all aliphatic hydrogen atoms and an 
opposite charge that is the sum of all hydrogen atoms bonded to an aliphatic carbon if 
that carbon atom is not bonded to a heteroatom. In the model compound and naloxone, all 
atoms that fell under these guidelines were restricted to those charges.  Charges not in 
these categories, such as O1, O2, C18 and C19 in naloxone were taken from various  
Figure 5.2.  PIPA: Model compound for naloxone N-allyl torsion 
parameters.  The model compound used for torsion parameters of 
the N-allyl portion of Naloxone, PIPA (piperdine amine) as well as 
its atomic numbering convention. 
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compounds with known charges including propene, phenol, 2,3 epoxy or N-benzyl 
piperidine in the CGenFF database. 
Internal Parameters 
Many of the bond and angle parameters needed for naloxone were already present 
in the CGenFF database.
6
 If a parameter for a bond or angle was missing, force constants, 
equilibrium bond lengths and bond angles listed for similar atom type interactions were 
used as a substitute.   Torsion parameters for the rigid alkaloid backbone of naloxone 
were also substituted in this manner.  However, because of the larger implication of the 
torsional force constants on the flexible N-allyl tail of naloxone, the remaining missing 
dihedral parameters were calculated according to the published CHARMM 
parameterization procedure.
7
 This process compares the QM potential energy surface 
with the CHARMM calculated surface for each dihedral and using a Monte Carlo 
simulated annealing approach provides parameters that optimize the fit of the molecular 
mechanics dihedral surface to the quantum mechanical one.   
The energy surfaces of each model compound were determined by rotating a 
subject torsion angle 360 degrees in increments of 10 degrees (or 180 degrees when the 
model compound was symmetric), thus creating 36 separate conformers (or 18) of the 
compound. Each of these conformers was optimized using HF/6-31G* in NWChem 5.1.1 
with the rotated torsion held constant. A single-point energy calculation using MP2/6-
31G* was then performed on each conformer. These energies were used to create a 
potential energy surface for each missing torsion angle. For model compounds with more 
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than one torsion angle missing, such as in PIPA, a separate potential energy surface was 
calculated for each dihedral. 
In order to create an MM potential energy surface, each conformer was 
minimized using CHARMM with the missing torsion held constant. The potential energy 
surface created by CHARMM must reproduce the QM calculated surface for each torsion 
angle of interest. By using Guvench and MacKerell’s Monte Carlo simulated annealing 
method 
7
 and their provided script (fit_dihedral.tar.gz and is available for downloading at 
http://mackerell.umaryland.edu/CHARMM_ff_params.html) the QM and MM potential 
energies were compared and the dihedral parameters were optimized. By testing different 
periodicity values, torsion parameters that generate a potential energy surface equivalent 
to the QM values were produced.  
In the case of the N-allyl tail, multiple dihedrals that involved different rotatable 
bonds were missing in the model compound. Therefore, the torsion parameter closest to 
the least flexible part of the molecule was varied and determined first (e.g. the torsion 
closest to a piperdine ring), then the next closest dihedral was varied and determined. An 
iterative process was used to return to the first dihedral tested after determining values for 
the second dihedral until agreement of all missing dihedrals’ potential energy surfaces 
were as accurate as possible.  
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Results & Discussion 
 
In this section, we present the optimized CHARMM force field parameters for use 
with the CGenFF database.  Table 5.2 lists all the atom names and types for naloxone.  
Table 5.3 provides a list of CGenFF atom types that were used as starting points for the 
development of the naloxone CHARMM parameters. 
 
Table 5.2.  CGenFF Atom Types Initially Assigned to Naloxone 
naloxone Atom 
Type 
CGENFF Atom 
Type  
O351 OG3C51 
OD3 OG2D3 
O11 OG311 
NP1 NG3P1 
C21 CG321 
C01 CG301 
C14 CG314 
C24 CG324 
C61 CG2R61 
CO5 CG2O5 
CC0 CG2RC0 
CD1 CG2D1 
CD2 CG2D2 
C3C1 CG3RC1 
HP1 HGP1 
HP2 HGP2 
H61 HGR61 
HG1 HGA1 
HG2 HGA2 
HG4 HGA4 
HG5 HGA5 
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Charge Parameters 
Charge calculations were not necessary for naloxone, or the model compound, 
PIPA.  As mentioned in methods, the CGenFF database
6
 applies a charge of -0.115q to all 
aromatic carbons not bonded to heteroatoms and an equal and opposite charge to their 
hydrogen atoms. It also applies a charge of 0.09q to all aliphatic hydrogen atoms and an 
opposite charge that is the sum of all hydrogen atoms bonded to an aliphatic carbon if 
that carbon atom is not bonded to a heteroatom.  In the model compound and naloxone, 
all atoms that fell under these guidelines were restricted to those charges.  Charges not in 
these categories, such as O1, O2, C18 and C19 in naloxone were adapted from various 
compounds with known charges including propene, phenol, 2,3 epoxy or N-benzyl 
piperidine in the CGenFF database.  Charges for naloxone are shown in Table 5.1, and 
for PIPA, the model compound, in Table 5.3.  Also in Table 5.3 are the atom names and 
types for PIPA. 
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Internal Parameters 
The bond and angle and torsion parameters were initially assigned by substituting 
with already existing parameters from the CGennFF database.
6
  Torsion parameters have 
a direct effect on the energy minima that the molecule will occupy.  However, the fused 
ring system backbone of naloxone is rigid, so torsion parameters in this area were 
substituted with already existing parameters.  A full listing of all bond angle and torsion 
parameters for naloxone is provided in Appendix A.  The model compound used for 
parameter development of the N-allyl portion of naloxone, PIPA is shown in Figure 5.2.   
The missing sections of torsion angles for the N-allyl substituent were C16-N1-
C17-C18 and N1-C17-C18-C19 of naloxone.  Using the model compound, PIPA, shown 
in Figure 5.2, the two torsions mentioned and seven other missing torsions involving the 
Atom 
Name 
Type 
Partial 
Charge 
Atom 
Name 
Type 
Partial 
Charge 
N1 NP1 -0.4 H5 HG2 0.09 
C1 C24 0.21 H6 HG2 0.09 
C2 C24 0.21 H7 HG2 0.09 
C3 C21 -0.18 H8 HG2 0.09 
C4 C21 -0.18 H9 HG2 0.09 
C5 C21 -0.18 H10 HG2 0.09 
C6 C24 0.21 H11 HP2 0.32 
C7 CD1 -0.15 H12 HG2 0.09 
C8 CD2 -0.42 H13 HG2 0.09 
H1 HG2 0.09 H14 HG4 0.15 
H2 HG2 0.09 H15 HG5 0.21 
H3 HG2 0.09 H16 HG5 0.21 
H4 HG2 0.09       
Table 5.3.  Atom Name, Type and Partial Charges for PIPA, 
the Model Compound for the N-allyl Portion of Naloxone. 
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same rotatable bonds were calculated.  The protonated nitrogen ring of naloxone was 
mimicked by a piperidine ring and the allyl tail was reserved.  By calculating these nine 
new torsion parameters, the molecular mechanics surfaces shown in Figures 5.3 and 5.4 
resulted.  As shown, initially the molecular mechanics surfaces were vastly different from 
the MP2/6-31G* NWChem surfaces in both the C-N-C-C (Figure 5.3) and N-C-C-C 
(Figure 5.4) primary dihedrals of PIPA.  The initial CHARMM is shown in red, the final 
CHARMM in blue and the MP2/6-31G* NWChem is in black in both figures.  The final 
molecular mechanics / CHARMM parameters and energy surfaces match the MP2/6-
31G* NWChem surfaces are considerably improved.   
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Figure 5.3.  Potential energy surface of the first rotatable bond (N1-C6) of PIPA.  This 
figure shows the initial MM surface (red), initial MP2/6-31G* NWChem surface (black) and 
final MM surface (blue) after development of parameters for both rotatable bonds in PIPA.  
Inset: Structure of PIPA is illustrated with the bond rotated in red. 
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Refinement 
Previous studies in our lab
5
 have shown that an experimental solid state IR 
spectrum can be compared with a calculated in vacuo molecular dynamics simulation of a 
ligand to further refine the calculated parameters.  This type of study can also be utilized 
to refine bond and angle force constraints in CHARMM parameters.   This type of study 
was originally planned, however various constraints prevented it from being undertaken 
in the work presented here.  
Figure 5.4.  Potential energy surface of the second rotatable bond (C6-C7) of PIPA.  This 
figure shows the initial MM surface (red), initial MP2/6-31G* NWChem surface (black) and 
final MM surface (blue) after development of parameters for both rotatable bonds in PIPA.  
Inset: Structure of PIPA is illustrated with the bond rotated in red. 
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Additionally, although the alkaloid backbone of naloxone is a rigid, fused ring 
system, the CHARMM parameters in this area should be optimized for the most accurate 
behavior of the molecule.  Previous studies involving molecular dynamics simulations of 
opioid compounds have been elusive in parameters used for the ligands in the receptor-
ligand complexes or have used a different simulation platform with different parameter 
needs. 
 
Conclusions 
 
The development of CHARMM parameters for Naloxone, including the N-allyl 
tail using previously published methods for parameter development was successful.  The 
CGenFF library was used and was appropriate due to the large number of organic 
molecules and molecules with similar structure to naloxone.  The use of a model 
compound, PIPA, allowed for calculation of missing dihedral parameters of the N-allyl 
portion of naloxone.  The parameters for naloxone could be further refined and optimized 
using experimental and calculated IR spectrum to compare the developed parameters. 
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APPENDIX A 
 
 BOND, ANGLE, AND TORSION PARAMETERS FOR NALOXONE 
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BOND Kb bo Source 
C61 C61 305.00 1.3750 PROT benzene, JES 8/25/89 
C61 CC0 300.00 1.3600 INDO/TRP 
C61 O11 334.30 1.4110 PROT MeOH, EMB 10/10/89, 
C61 H61 340.00 1.0800 PROT phe,tyr JES 8/25/89 
CC0 CC0 360.00 1.3850 INDO/TRP 
CO5 OD3 700.00 1.2150 ACO, acetone adm 11/08 
CO5 C21 330.00 1.5000 
COMPDS PEDRO re-initialized from ACO 
adm 11/08-TAKEN FROM CO5 C11 4/26/10 
C01 C21 222.50 1.5380 RETINOL TMCH/MECH 
C01 O31 360.00 1.4150 
AMOL, alpha-methoxy-lactic acid, og 
all34_ethers_1a CG32A OG30A 
C14 HG1 309.00 1.1110 PROT alkane update, adm jr., 3/2/92 
C14 C21 222.50 1.5380 PROT alkane update, adm jr., 3/2/92 
C14 NP1 200.00 1.4900 
2MRB, Alpha benzyl gamma 2-methyl 
piperidine, chayan--TAKEN FROM C14/NP2 
4/26/10 
C21 C21 222.50 1.5300 PROT alkane update, adm jr., 3/2/92 
C21 C24 222.50 1.5300 FLAVOP PIP1,2,3 
C21 HG2 309.00 1.1110 PROT alkane update, adm jr., 3/2/92 
C21 O31 360.00 1.4150 diethylether, alex 
C24 NP1 200.00 1.4800 FLAVOP PIP1,2,3 
C24 HG2 284.50 1.1000 FLAVOP PIP1,2,3 
CD1 HG4 360.50 1.1000 LIPID propene, yin,adm jr., 12/95 
CD2 HG5 365.00 1.1000 LIPID propene; from ethene, yin,adm jr., 12/95 
CD1 CD2 500.00 1.3420 LIPID propene, yin,adm jr., 12/95 
NP1 HP2 403.00 1.0400 
PROT new stretch and bend; 
methylammonium (KK 03/10/92) 
O11 HP1 545.00 0.9600 
PROT EMB 11/21/89 methanol vib fit; og 
tested on MeOH EtOH,... 
CC0 O31 450.00 1.3700 
ZFUR, benzofuran, kevo--USED CC0-O50 
4/28/10 
C01 C14 222.50 1.5000 
PROT alkane update, adm jr., 3/2/92--USED 
C11-C14 4/28/10 
CC0 C21 230.00 1.4900 
PROT phe,tyr, JES 8/25/89--USED C61-C21 
4.28.10 
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Bond Kb bo Source 
CD1 C24 365.00 1.5020 
LIPID butene; from propene, yin,adm jr., 
12/95--used CD1-C21 
CC0 C01 230.00 1.4900 
NAMODEL difluorotoluene--USED C61-C11 
4/29/10 
C11 HG1 309.00 1.1110 PROT alkane update, adm jr., 3/2/92 
 
C01 O11 
 
428.00 
 
1.4200 
AMOL, alpha-methoxy-lactic acid, og par22 
OH1 CT1 
CO5 C11 330.00 1.5000 
COMPDS PEDRO re-initialized from ACO 
adm 11/08 
C11 O31 450.00 1.3710 FURA, furan--USED C51-O50 4/28/10 
C01 C11 222.50 1.5000 CA, CHOLIC ACID, chayan, 03/06 
C01 C01 222.50 1.5000 
CA, CHOLIC ACID, chayan, 03/06--USED 
C01-C11 4/30/10 
C61  C21 230.00 1.4900 PROT phe,tyr, JES 8/25/89 
C3C1 O351 350.00 1.4250 
THF, nucleotide CSD/NDB survey, 
5/30/06,viv 
C61  C3C1 230.00 1.4900 
NAMODEL difluorotoluene--USED C61-C11 
5/3/10 
CO5  C3C1 330.00 1.5000 
COMPDS PEDRO re-initialized from ACO 
adm 11/08--USED CO5-C11 5/3/10 
CC0  O351 450.00 1.3700 
ZFUR, benzofuran, kevo--USED CC0-O50 
5/4/10 
C3C1 C3C1 222.50 1.5230 CARBOCY carbocyclic sugars 
C01  C3C1 222.50 1.5240 
CARBOCY carbocyclic sugars--USED C11-
C3C1 5/4/10 
C21  C3C1 222.50 1.5240 CARBOCY carbocyclic sugars 
C3C1 HG1 309.00 1.1110 CARBOCY carbocyclic sugars 
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Angle Kϴ ϴ0 Source 
CD2 CD1 HG4 42.00 118.00 LIPID propene, yin,adm jr., 12/95 
HG5 CD2 HG5 19.00 119.00 LIPID propene, yin,adm jr., 12/95 
C24 CD1 HG4 40.00 116.00 
LIPID 1-butene; propene, yin,adm jr., 12/95-
-taken from C21-CD1-HG4 4/27/10 
CD2 CD1 C24 48.00 126.00 
LIPID 1-butene; propene, yin,adm jr., 12/95-
-taken from CD2-CD1-C21 4/27/10 
CD1 CD2 HG5 45.00 120.50 LIPID propene, yin,adm jr., 12/95 
C61 C61 C61 40.00 120.00 PROT JES 8/25/89 
C61 C61 CC0 50.00 120.00 adm,dec06 113.20 ! INDO/TRP 
C61 C61 H61 30.00 120.00 PROT JES 8/25/89 benzene 
CC0 C61 H61 30.00 120.00 122 INDO/TRP 
C61 C61 O11 45.20 120.00 PYRIDINE phenol 
CC0 C61 O11 45.20 120.00 
PYRIDINE phenol--taken from C61-C61-
O11 4/27/10 
C61 CC0 CC0 50.00 120.00 adm,dec06 110.00 ! INDO/TRP 
C61 CC0 O31 100.00 129.40 
ZFUR, benzofuran, kevo--taken from C61-
CC0-O50 4/27/10 
HG2 C21 HG 35.50 109.00 PROT alkane update, adm jr., 3/2/92 
C21 C21 HG2 26.50 110.10 PROT alkane update, adm jr., 3/2/92 
C01 C21 C21 58.35 113.50 RETINOL TMCH/MECH 
C01 C21 HG2 26.50 110.10 RETINOL TMCH/MECH 
CO5 C11 HG1 50.00 109.50 
BIPHENYL ANALOGS from PROT 
Alanine Dipeptide ab initio calc's (LK) 
consistent with adm 11/08 
O31 C11 HG1 60.00 109.50 
all34_ethers_1a HCA2 CC32A OC30A, gk 
or og (not affected by mistake) 
C11 CO5 OD3 95.00 121.30 
BIPHENYLS BF6, C36 new init guess by 
Kenno based on ACO adm 11/08 ==> re-
optimize 
C21 CO5 C11 35.00 116.00 
ACO, acetone adm 11/08--taken from C31-
CO5-C31 4/27/10 
CC0 CC0 CC0 50.00 120.00 
adm,dec06 110.00 ! INDO/TRP--taken from 
C61-CC0-CC0 4/27/10 
C21 C01 O11 75.70 110.10 
AMOL, alpha-methoxy-lactic acid, og--
USED C31-C01-O11 4/28/10 
C11 C01 C21 58.35 113.50 CA, CHOLIC ACID, chayan, 03/06 
C11 C01 C01 58.35 113.50 
CA, CHOLIC ACID, chayan, 03/06--USED 
C11-C01-C11 4/27/10 
C01 C14 HG1 34.50 110.10 PROT alkane update, adm jr., 3/2/92 
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Angle Kϴ ϴ0 Source 
C01 C14 NP1 67.70 110.00 
PROT new aliphatics, adm jr., 2/3/92--used 
C11-C14-NP3 4/27/10 
NP1 C14 HG1 45.00 102.30 
2MRB, Alpha benzyl gamma 2-methyl 
piperidine, chayan--USED NP2-C14-HG1 
4/27/10 
CO5 C21 C21 60.00 113.80 
ALDEHYDE propionaldehyde unmodified--
USED CO4-C21-C31 4/27/10 
C24 C21 HG2 26.50 110.10 FLAVOP PIP1,2,3 
C14 C21 HG2 33.43 110.10 PROT alkanes 
NP1 C24 HG2 45.00 102.30 FLAVOP PIP1,2,3 
HG2 C24 HG2 35.50 109.00 PIP1,2,3 
CC0 O31 C11 65.00 108.00 
ETOB, Ethoxybenzene, chayan--USED 
C61-O31-C21 4/27/10 
C01 O11 HP1 50.00 106.00 AMOL, alpha-methoxy-lactic acid, og 
C61 O11 HP1 65.00 108.00 PROT JES 8/25/89 phenol 
C24 NP1 HP2 30.00 110.80 FLAVOP PIP1,2,3 
C14 NP1 HP2 30.00 110.80 FLAVOP PIP1,2,3 
C01 C11 HG1 34.60 110.10 CA, CHOLIC ACID, chayan, 03/06 
CO5 C11 O31 45.00 109.00 
CC321 CC3163 OC3C61 optimize on 
PROA, gk (not affected by mistake)--used 
CO3-C11-O31 4/27/10 
C61 CC0 C21 45.80 119.00 
PYRIDINE pyridines--USED C61-C61-C21 
4/28/10 
CC0 CC0 C01 45.80 121.00 
NAMODEL difluorotoluene--USED C61-
C61-C11 4/28/10 
CC0 CC0 C21 45.80 119.00 PYRIDINE pyridines 
CC0 C21 HG2 49.30 107.50 
PYRIDINE pyridines--USED C61-C21-
HG2 4/28/10 
CC0 C21 C14 51.80 107.50 
PROT PARALLH19 (JES)--USED C61-
C21-C14 4/28/10 
C21 C24 NP1 67.70 110.00 
RETINOL SCK1, protonated Schiff's base 
#eq# 
CO5 C11 C01 52.00 108.00 
PROT adm jr. 4/05/91, for asn,asp,gln,glu 
and cters--USED CO3-C11-C11 4/28/10 
C01 C11 O31 110.00 120.00 
BIPHENYL ANALOGS--USED C61-C61-
O31 4/28/10 
CC0 C01 C11 51.80 107.50 
NAMODEL difluorotoluene--USED C61-
C11-C21 4/30/10 
C21 C01 C14 58.35 110.50 
FLAVOP PIP1,2,3--USED C21-C11-C24 
4/30/10 
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Angle Kϴ ϴ0 Source 
C01 C01 C21 58.35 113.50 
CA, CHOLIC ACID, chayan, 03/06--USED 
C01-C11-C21 4/30/10 
CC0 C01 C01 58.35 113.50 
CA, CHOLIC ACID, chayan, 03/06--USED 
C11-C01-C11 4/30/10 
C14 C01 C01 53.35 111.00 
PROT alkane update, adm jr., 3/2/92--USED 
C14-C11-C21 4/30/10 
C14 C01 O11 75.70 112.10 
FLAVOP PIP1,2,3--USED C24-C11-O11 
4/30/10 
C01 C01 O11 75.70 110.10 
PROT MeOH, EMB, 10/10/89--USED C11-
C11-O11 4/30/10 
C14 NP1 C24 45.00 115.50 
2MRB, Alpha benzyl gamma 2-methyl 
piperidine, chayan--USED C14-NP2-C24 
4/30/10 
C24 NP1 C24 45.00 115.50 FLAVOP PIP1,2,3 
CC0 CC0 O31 110.00 110.60 
ZFUR, benzofuran, kevo--USED CC0-CC0-
O50 4/30/10 
C21 CO5 OD3 95.00 121.30 
BIPHENYLS BF6, C36 new init guess  
based on ACO adm 11/08 --USED C11-
CO5-OD3 4/30/10 
CO5 C21 HG2 33.00 109.50 
PALD, propionaldehyde from PROT adm jr. 
5/02/91, acetic acid pure solvent. Consistent 
with adm 11/08. 
C21 C14 NP1 40.00 110.00 
2MRB, Alpha benzyl gamma 2-methyl 
piperidine, chayan--USED C21-C14-NP2 
4/30/10 
C01 C14 C21 58.35 113.50 
2MRB, Alpha benzyl gamma 2-methyl 
piperidine, chayan--USED C21-C14-C21 
4/30/10 
C21 C14 HG1 34.50 110.10 PROT alkane update, adm jr., 3/2/92 
CC0 C01 C21 51.80 107.50 
NAMODEL difluorotoluene--USED C61-
C11-C21 4/30/10 
C01 C21 C24 58.35 113.50 
RETINOL TMCH/MECH--USED C01-
C21-C21 4/30/10 
C21 C24 HG2 26.50 111.80 FLAVOP PIP1,2,3 
C61  C21  HG2 49.30 107.50 PYRIDINE pyridines 
C61  C21  C14 51.80 107.50 PROT PARALLH19 (JES) 
C3C1 C21  HG2 34.60 110.10 TF2M viv--USED C351-C21-HG2 5/4/10 
C21  C3C1 C3C1 58.00 115.00 TF2M viv--USED C21-C351-C351 5/4/10 
O351 C3C1 HG1 70.00 107.30 THF 10/21/05, viv 
C3C1 C3C1 O351 45.00 111.10 
THF 10/21/05, viv--USED C351-C351-
O351 5/4/10 
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Angle Kϴ ϴ0 Source 
C3C1 CO5  OD3 95.00 121.30 
BIPHENYLS BF6, C36 new init guess by 
Kenno based on ACO adm 11/08  used c11-
co5-od3 5/4/10 
C3C1 CO5  C21 35.00 116.00 
ACO, acetone adm 11/08--USED C31-CO5-
C31 5/4/10 
C61  CC0  C61 50.00 120.00 
adm,dec06 110.00 ! INDO/TRP--USED 
C61-CC0-CC0 5/4/10 
C61  CC0  O351 100.00 129.40 
ZFUR, benzofuran, kevo--USED C51-CC0-
O50 5/4/10 
C61  C61  C21 45.80 119.00 PYRIDINE pyridines 
C61  C61  C3C1 45.80 121.00 NAMODEL difluorotoluene 
C21  C11  C3C1 53.35 108.50 
BAM1, bile acid steroidal C-D ring, chayan, 
02/08--USED C31-C11-C351 5/4/10 
C21  C01  C3C1 53.35 103.70 
CARBOCY carbocyclic sugars--used C21-
C11-C3C1 5/4/10 
C3C1 C01  O11 75.70 110.10 
CARBOCY ncarbocyclic sugars--USED 
C3C1-C11-O11 5/4/10 
C3C1 C3C1 HG1 34.50 110.10 CARBOCY carbocyclic sugars 
C24  C01  C3C1 53.35 111.00 
CARBOCY carbocyclic sugars--USED C21-
C21-C3C1 5/4/10 
C14  C01  C3C1 53.35 103.70 
CARBOCY carbocyclic sugars--USED C11-
C11-C3C1 5/4/10 
C01  C3C1 C3C1 53.35 108.00 
CARBOCY carbocyclic sugars--USED C11-
C3C1-C3C1 5/4/10 
C61  C3C1 C01 51.80 107.50 
NAMODEL difluorotoluene--USED C61-
C11-C21 5/4/10 
C61  C3C1 C21 51.80 107.50 
NAMODEL difluorotoluene--USED C61-
C11-C21 5/4/10 
C61  C3C1 C3C1 51.80 107.50 
NAMODEL difluorotoluene--USED C61-
C11-C21 5/4/10 
C3C1 O351 CC0 95.00 111.00 
THF 10/21/05, viv--USED C351-O351-
C351 5/4/10 
O351 C3C1 CO5 52.00 112.30 
TAKEN FROM CO1 C351 C352 P=64 EAP 
3/9/12 
C3C1 C3C1 CO5 70.00 113.70 
TAKEN FROM C3C1 C3C1 N61 P=48 
EAP 3/9/12 
CO5  C3C1 HG1 50.00 109.50 
BIPHENYL  from PROT Alanine Dipeptide 
consistent with adm 11/08--USED CO5-
C11-HG1 5/5/10 
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Angle Kϴ ϴ0 Source 
C01  C3C1 C21 53.35 111.00 
CARBOCY carbocyclic sugars--USED C11-
C3C1-C21 5/5/10 
C3C1 C21  C24 58.35 110.50 
FLAVOP PIP1,2,3--USED C11-C21-C24 
5/5/10 
CC0  C61  C3C1 45.80 121.00 
NAMODEL difluorotoluene--USED C61-
C61-C11 5/5/10 
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Dihedral K n δ Source 
OD3 CO5 C21 HG2 0.0000 1 0.00 
PROT Alanine Dipeptide ab initio calc's 
(LK) unmodified--USED OD3-CO5-
C11-HG1 4/28/10 
OD3 CO5 C21 C21 1.0500 1 180.00 
ALDEHYDE propionaldehyde 
unmodified--USED OD1-CO4-C21-C31 
4/28/10 
OD3 CO5 C11 C01 0.0500 6 180.00 
PROT For side chains of 
asp,asn,glu,gln, (n=6) from KK(LK)--
USED OD2-CO3-C21-C11 4/28/10 
OD3 CO5 C11 HG1 0.0000 1 0.00 
PROT Alanine Dipeptide ab initio calc's 
(LK) unmodified 
OD3 CO5 C11 O31 0.5500 2 180.00 
og amop mp2/ccpvtz--USED OD2-C03-
C11-O31 4/28/10 
C11 CO5 C21 HG2 0.0000 1 180.00 
BIPHENYL ANALOGS unmodified--
USED C61-CO5-C11-HG1 4/28/10 
C11 CO5 C21 C21 1.5850 2 180.00 
BIPHENYL ANALOGS unmodified--
USED C11-CO5-C61-C61 4/28/10 
C21 CO5 C11 C01 1.5850 2 180.00 
BIPHENYL ANALOGS unmodified--
USED C11-CO5-C61-C61 4/28/10 
C21 CO5 C11 HG1 0.0000 1 180.00 
BIPHENYL ANALOGS unmodified--
USED C61-CO5-C11-HG1 4/28/10 
C21 CO5 C11 O31 0.0000 2 180.00 
BIPHENYL ANALOGS unmodified--
USED C61-CO5-C11-O11 4/28/10 
CC0 C61 C61 H61 3.0000 2 180.00 INDO/TRP 
C61 C61 C61 H61 4.2000 2 180.00 PROT JES 8/25/89 benzene 
H61 C61 C61 H61 2.4000 2 180.00 PROT JES 8/25/89 benzene 
O11 C61 C61 H61 2.4000 2 180.00 
PROT JES 8/25/89 phenol Kenno: 4.2 -
> 2.4 
C61 C61 CC0 O31 0.0000 2 180.00 
ZFUR, benzofuran, kevo--USED C61-
C61-CC0-O50 4/28/10 
C61 C61 CC0 C21 3.1000 2 180.00 
PROT JES 8/25/89 toluene and 
ethylbenzene-USED C61-C61-C61-C21 
4/28/10 
H61 C61 CC0 CC0 3.0000 2 180.00 INDO/TRP 
C61 C61 C61 O11 3.1000 2 180.00 
PYRIDINE phenol--USED C61-C61-
C61-O11 4/28/10 
O11 C61 CC0 O31 2.4000 2 180.00 
PROT JES 8/25/89 phenol Kenno: 4.2 -
> 2.4--USED O11-C61-C61-H61 
4/28/10 
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Dihedral K n δ Source 
C21 CC0 C61 H61 2.4000 2 180.00 
PROT JES 8/25/89 toluene and 
ethylbenzene Kenno: 4.2 -> 2.4--USED 
C21-C61-C61-H61 4/29/10 
C61 C61 CC0 CC0 3.0000 2 180.00 INDO/TRP 
C61 C61 O11 HP1 0.9900 2 180.00 
PROT phenol OH rot bar, 3.37 
kcal/mole, adm jr. 3/7/92 
CC0 C61 O11 HP1 0.9900 2 180.00 
PROT phenol OH rot bar, 3.37 
kcal/mole, adm jr. 3/7/92--USED C61-
C61-011-HP1 4/29/10 
C61 CC0 CC0 CC0 3.0000 2 180.00 
INDO/TRP--USED C61-CC0-CC0-C61 
4/29/10 
CC0 CC0 CC0 O31 0.0000 2 180.00 
ZFUR, benzofuran, kevo--USED C61-
CC0-CC0-O50 4/29/10 
C61 CC0 CC0 C01 3.1000 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C61-C11 4/29/10 
CC0 CC0 C01 C11 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C11 4/29/10 
CC0 CC0 C01 C01 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C11 4/29/10 
C61 CC0 C21 C14 0.2300 2 180.00 
PROT ethylbenzene ethyl rotation, adm 
jr. 3/7/92--USED C61-C61-C21-C14 
4/29/10 
C61 CC0 C21 HG2 0.0000 2 0.00 
3ALP, nicotinaldehyde (PYRIDINE 
pyr-CH2OH)--USED C61-C61-C21-
HG2 4/29/10 
CC0 CC0 C21 C14 0.2300 2 180.00 
PROT ethylbenzene ethyl rotation, adm 
jr. 3/7/92--USED C61-C61-C21-C14 
4/29/10 
CC0 CC0 C21 HG2 0.0000 2 0.00 
3ALP, nicotinaldehyde (PYRIDINE 
pyr-CH2OH)--USED C61-C61-C21-
HG2 4/29/10 
C61 CC0 O31 C11 1.6200 2 180.00 
ETOB, Ethoxybenzene, chayan--USED 
C61-C61-O31-C21 4/29/10 
C61 CC0 O31 C11 0.1900 4 180.00 
ETOB, Ethoxybenzene, chayan--USED 
C61-C61-O31-C21 4/29/10 
CC0 CC0 O31 C11 1.6200 2 180.00 
ETOB, Ethoxybenzene, chayan--USED 
C61-C61-O31-C21 4/29/10 
CC0 CC0 O31 C11 0.1900 4 180.00 
ETOB, Ethoxybenzene, chayan--USED 
C61-C61-O31-C21 4/29/10 
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Dihedral K n δ Source 
C01 C01 C11 HG1 0.2000 3 0.00 
CA, Cholic Acid, chayan, 03/06--USED 
C01-C11-C11-HG1 4/29/10 
C21 C01 C11 O31 0.8000 3 180.00 
NA, sugar--USED C21-C11-C11-O33 
4/29/10 
C21 C01 C11 O31 0.2000 4 0.00 
NA, sugar--USED C21-C11-C11-O33 
4/29/10 
CO5 C11 C01 C21 0.2000 3 0.00 --USED CO2-C11-C11-C21 4/29/10 
CO5 C11 C01 C01 0.2000 3 0.00 --USED CO2-C11-C11-C21 4/29/10 
C01 C01 C11 O31 2.0000 3 180.00 
NA, sugar--USED C11-C11-C11-O33 
4/29/10 
C01 C01 C11 O31 0.4000 5 0.00 
NA, sugar--USED C11-C11-C11-O33 
4/29/10 
C01 C01 C11 O31 0.8000 6 0.00 
NA, sugar--USED C11-C11-C11-O33 
4/29/10 
C11 C01 C01 O11 0.1400 3 0.00 
PROT, hydroxyl wild card--USED C11-
C11-C11-O11 4/29/10 
C11 C01 C01 C14 0.5000 4 180.00 
NA bkb--USED C11-C11-C11-C21 
4/29/10 
C11 C01 C01 C21 0.5000 4 180.00 
NA bkb--USED C11-C11-C11-C21 
4/29/10 
CC0 C01 C11 HG1 0.1500 3 0.00 
CARBOCY carbocyclic sugar--USED 
CC1-C11-C11-HG1 4/29/10 
C21 C01 C11 HG1 0.1950 3 0.00 
NA, sugar--USED C21-C11-C11-HG1 
4/29/10 
CO5 C11 C01 CC0 0.0400 3 0.00 
deleteme DELETEME (we want to use 
wildcarting)--USED CO2-C11-C21-C61 
4/29/10 
CC0 C01 C01 O11 0.6000 1 0.00 
CARBOCY carbocyclic sugars--USED 
CC1-C11-C11-O11 4/29/10 
CC0 C01 C01 O11 0.7000 3 0.00 
CARBOCY carbocyclic sugars--USED 
CC1-C11-C11-O11 4/29/10 
CC0 C01 C11 O31 0.0000 2 180.00 
ZFUR, benzofuran, kevo--USED C61-
CC0-CC0-O50 4/29/10 
CC0 C01 C01 C21 0.0000 3 0.00 
NAMODEL difluorotoluene--USED 
C61-C11-C21-C11 4/29/10 
CC0 C01 C01 C14 0.1500 3 0.00 CARBOCY carbocyclic sugars 
C01 C01 C14 NP1 0.2000 3 0.00 
PROT alkane update, adm jr., 3/2/92--
USED C21-C11-C14-NP3 4/29/10 
C01 C01 C14 HG1 0.1950 3 0.00 
NA, sugar--USED C21-C11-C14-HG1 
4/29/10 
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Dihedral K n δ Source 
NP1 C14 C01 C21 0.1950 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED NP2-C14-C21-C21 4/29/10 
C21 C14 C01 C01 0.2000 3 0.00 
3MRB,Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED C21-C14-C21-C21 4/29/10 
C21 C01 C14 HG1 0.1950 3 0.00 
NA, sugar--USED C21-C11-C14-HG1 
4/29/10 
C21 C14 C01 C21 0.2000 3 0.00 
3MRB,Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED C21-C14-C11-C21 4/29/10 
NP1 C14 C01 O11 0.2000 3 0.00 
PROT alkane update, adm jr., 3/2/92--
USED NP3-C14-C21-O11 4/29/10 
HG1 C14 C01 O11 0.1950 3 0.00 
NA, sugar--USED HG1-C14-C21-O11 
4/29/10 
C21 C14 C01 O11 0.2000 3 0.00 
PROT alkane update, adm jr., 3/2/92--
USED CO3-C14-C21-O11 4/29/10 
C01 C01 C21 C21 0.2000 3 0.00 
DCA, Deoxycholic Acid, chayan, 
03/06--USED C01-C11-C21-C21 
4/29/10 
C01 C01 C21 HG2 0.2000 3 0.00 
CA, Cholic Acid, chayan, 03/06--USED 
C01-C11-C21-HG2 4/29/10 
C11 C01 C21 C24 0.1000 3 0.00 NA--USED C11-C11-C21-C21 4/29/10 
C11 C01 C21 C24 0.5000 4 0.00 NA--USED C11-C11-C21-C21 4/29/10 
C11 C01 C21 HG2 0.1950 3 0.00 
NA, sugar--USED C11-C11-C21-HG2 
4/29/10 
O11 C01 C21 HG2 0.1950 3 180.00 
NA, sugar--USED O11-C11-C21-HG2 
4/29/10 
O11 C01 C21 C21 0.5000 1 180.00 
NA elevates energy at 0 (c3'endo), adm-
-USED O11-C11-C21-C21 4/29/10 
O11 C01 C21 C21 0.7000 2 0.00 
NA elevates energy at 0 (c3'endo), adm-
-USED O11-C11-C21-C21 4/29/10 
O11 C01 C21 C21 0.4000 3 0.00 
NA abasic nucleoside--USED O11-C11-
C21-C21 4/29/10 
O11 C01 C21 C21 0.4000 5 0.00 
NA abasic nucleoside--USED O11-C11-
C21-C21 4/29/10 
C14 C01 C21 C21 0.2000 3 0.00 
PROT alkane update, adm jr., 3/2/92--
USED C14-C11-C21-C31 4/29/10 
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Dihedral K n δ Source 
C14 C01 C21 HG2 0.1950 3 0.00 
NA, sugar--USED C14-C11-C21-HG2 
4/29/10 
C01 C01 O11 HP1 1.3300 1 0.00 
PROT 2-propanol OH hf/torsional 
surface, adm jr., 3/2/93--USED C11-
C11-O11-HP1 4/29/10 
C01 C01 O11 HP1 0.1800 2 0.00 
PROT 2-propanol OH hf/torsional 
surface, adm jr., 3/2/93--USED C11-
C11-O11-HP1 4/29/10 
C01 C01 O11 HP1 0.3200 3 0.00 
PROT 2-propanol OH hf/torsional 
surface, adm jr., 3/2/93--USED C11-
C11-O11-HP1 4/29/10 
C14 C01 O11 HP1 0.5000 1 0.00 
FLAVOP PIP3--USED C24-C11-O11-
HP1 4/29/10 
C14 C01 O11 HP1 0.7000 2 0.00 
FLAVOP PIP3--USED C24-C11-O11-
HP1 4/29/10 
C21 C01 O11 HP1 0.3000 1 0.00 
CARBOCY carbocyclic sugars--USED 
C21-C11-O11-HP1 4/29/10 
C21 C01 O11 HP1 0.3000 3 0.00 
CHOLEST cholesterol--USED C21-
C11-O11-HP1 4/29/10 
NP1 C14 C21 HG2 0.2000 3 0.00 
PROT alkane update, adm jr., 3/2/92--
USED NP3-C14-C21-HG2 4/29/10 
C01 C14 NP1 HP2 0.1000 3 0.00 
PROT 0.715->0.10 
METHYLAMMONIUM (KK)--USED 
C11-C14-NP3-HP2 4/29/10 
C21 C14 NP1 HP2 0.1000 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED C21-C14-NP2-HP2 4/29/10 
HG1 C14 NP1 C24 0.1000 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED HG1-C14-NP2-C24 4/29/10 
HG1 C14 NP1 HP2 0.1000 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED HG1-C14-NP2-HP2 4/29/10 
C01 C14 NP1 C24 0.1000 3 0.00 
G3P(R/S), Gamma-3-Piperidine Glu 
Acid CDCA Amide, chayan--USED 
C11-C24-NP2-C24 4/29/10 
HG1 C14 C21 HG2 0.1950 3 0.00 NA, sugar 
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Dihedral K n δ Source 
C21 C14 NP1 C24 0.1000 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED C21-C14-NP1-C24 4/29/10 
CO5 C21 C21 HG2 0.1950 3 0.00 
deleteme DELETEME (we want to use 
wildcarting)--USED CO2-C21-C21-
HG2 4/29/10 
CO5 C21 C21 C01 0.2100 1 180.00 
LIPID methylbutyrate--USED CO2-
C21-C21-C31 4/29/10 
CO5 C21 C21 C01 0.3900 2 0.00 
LIPID methylbutyrate--USED CO2-
C21-C21-C31 4/29/10 
CO5 C21 C21 C01 0.3500 3 180.00 
LIPID methylbutyrate--USED CO2-
C21-C21-C31 4/29/10 
CO5 C21 C21 C01 0.1100 4 0.00 
LIPID methylbutyrate--USED CO2-
C21-C21-C31 4/29/10 
CO5 C21 C21 C01 0.0900 6 180.00 
LIPID methylbutyrate--USED CO2-
C21-C21-C31 4/29/10 
HG2 C21 C21 HG2 0.2200 3 0.00 LIPID alkanes 
C01 C21 C21 HG2 0.1950 3 0.00 PROT alkane update, adm jr., 3/2/92 
HG2 C21 C24 HG2 0.1950 3 0.00 FLAVOP PIP1,2,3 
HG2 C21 C24 NP1 0.1950 3 0.00 FLAVOP PIP1,2,3 
C21 C24 NP1 HP2 0.1000 3 0.00 FLAVOP PIP1,2,3 
HG2 C24 NP1 C14 0.1000 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED HG2-C24-NP2-C14 4/30/10 
C21 C24 NP1 C14 0.1000 3 0.00 
3MRB, Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED C21-C24-NP2-C14 4/30/10 
HG2 C24 NP1 C24 0.1000 3 0.00 FLAVOP PIP1,2,3 
C61 C61 C61 CC0 3.0000 2 180.00 INDO/TRP 
C01 C14 C21 HG2 0.1950 1 0.00 
3MRB,Gamma-3 methyl piperidine, 
alpha-benzyl GA CDCA amide, chayan-
-USED C21-C14-C21-HG2 4/30/10 
HG4 CD1 CD2 HG5 5.2000 2 180.00 LIPID propene, yin,adm jr., 12/95 
OD3  CO5  C3C1 HG1 0.0000 1 0.00 
PROT Alanine Dipeptide ab initio calc's 
(LK) unmodified--USED OD1-CO5-
C11-HG1 5/4/10 
     
 
167 
 
Dihedral K n δ Source 
C3C1 CO5  C21  HG2 0.1000 3 0.00 
ketone, RIMP2/cc-pVTZ//MP2/6-
31G(d), adm 11/08--USED C31-CO5-
C31-HG3 5/4/10 
C3C1 CO5  C21  C21 0.1000 3 0.00 
ketone, RIMP2/cc-pVTZ//MP2/6-
31G(d), adm 11/08--USED C31-CO5-
C31-HG3 5/4/10 
OD3  CO5  C3C1 C3C1 0.0000 1 0.00 
PROT Alanine Dipeptide ab initio calc's 
(LK) unmodified--USED OD3-CO5-
C11-HG1 5/4/10 
OD3  CO5  C3C1 C3C1 0.0000 1 0.00 
PROT Alanine Dipeptide ab initio calc's 
(LK) unmodified--USED OD3-CO5-
C11-HG1 5/4/10 
C61  C61  CC0  O351 0.0000 2 180.00 
ZFUR, benzofuran, kevo--USED C61-
C61-CC0-O351 5/5/10 
C61  C61  C3C1 C01 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C11 5/5/10 
C61  C61  C3C1 C3C1 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C11 5/5/10 
C61  C61  C3C1 C21 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C21 5/5/10 
C61  C61  C21  C14 0.2300 2 180.00 
PROT ethylbenzene ethyl rotation, adm 
jr. 3/7/92 
C61  C61  C21  HG2 0.0000 2 0.00 
3ALP, nicotinaldehyde (PYRIDINE 
pyr-CH2OH) 
C61  C61  C61  C61 3.1000 2 180.00 PROT JES 8/25/89 
C61  C61  C61  C21 3.1000 2 180.00 
PROT JES 8/25/89 toluene and 
ethylbenzene 
C61  C61  C61  C3C1 3.1000 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C61-C11 5/5/10 
C21  C61  C61  H61 2.4000 2 180.00 
PROT JES 8/25/89 toluene and 
ethylbenzene Kenno: 4.2 -> 2.4 
C21  C61  C61  C3C1 2.4000 2 180.00 
OXYL, o-xylene, kevo for gsk/ibm--
USED C31-C61-C61-C31 5/5/10 
C61  C61  CC0  C61 3.0000 2 180.00 
INDO/TRP--USED C61-C61-CC0-CC0 
5/5/10 
C61  CC0  C61  O11 3.1000 2 180.00 
PYRIDINE phenol--USED C61-C61-
C61-O11 5/5/10 
C61  CC0  C61  C3C1 3.1000 2 180.00 NAMODEL difluorotoluene 
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Dihedral K n δ Source 
CC0  C61  C3C1 C01 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C11 5/5/10 
CC0  C61  C3C1 C11 0.2300 2 180.00 
NAMODEL difluorotoluene--USED 
C61-C61-C11-C11 5/5/10 
C3C1 C01  C21  C21 0.1580 3 0.00 
CA, Cholic Acid, chayan, 03/06--USED 
C11-C01-C21-C21 5/5/10 
C3C1 C01  C21  HG2 0.1580 3 0.00 
CA, Cholic Acid, chayan, 03/06--USED 
C11-C01-C21-HG2 5/5/10 
C14  C01  C3C1 C21 0.0500 3 0.00 
CA, Cholic Acid, chayan, 03/06--USED 
C11-C01-C11-C21 5/5/10 
HG1  C14  C21  C61 0.0400 3 0.00 
PROT 2.7 kcal/mole CH3 rot in 
ethylbenzene, adm jr, 3/7/92 
NP1  C14  C21  C61 0.2000 3 0.00 
PROT alkane update, adm jr., 3/2/92--
USED NP3-C14-C21-C61 5/5/10 
C61  C3C1 C21  HG2 0.0000 3 0.00 
NAMODEL difluorotoluene--USED 
C61-C11-C21-HG2 5/5/10 
C01  C3C1 C21  HG2 0.2000 3 0.00 
CA, Cholic Acid, chayan, 03/06--USED 
C01-C11-C21-HG2 5/5/10 
C01  C3C1 C21  C24 0.2000 3 0.00 
DCA, Deoxycholic Acid, chayan, 
03/06--USED C01-C11-C21-C21 5/5/10 
C01  C3C1 C3C1 HG1 0.1500 3 0.00 
CARBOCY carbocyclic sugars--USED 
C11-C3C1-C3C1-HG1 5/5/10 
C21  C3C1 C3C1 HG1 0.1500 3 0.00 CARBOCY carbocyclic sugars 
C61  C3C1 C3C1 HG1 0.0400 3 0.00 
NAMODEL difluorotoluene--USED 
C61-C11-C11-HG1 5/5/10 
O11  C01  C3C1 C21 0.4500 2 0.00 
CARBOCY carbocyclic sugars--USED 
O11-C11-C3C1-C21 5/5/10 
C21  C01  C3C1 C21 2.2000 2 180.00 
CARBOCY carbocyclic sugars--USED 
C21-C11-C3C1-C21 5/5/10 
C21  C01  C3C1 C21 4.0000 3 0.00 
CARBOCY carbocyclic sugars--USED 
C21-C11-C3C1-C21 5/5/10 
C21  C01  C3C1 C21 0.5500 6 180.00 
CARBOCY carbocyclic sugars--USED 
C21-C11-C3C1-C21 5/5/10 
C21  C01  C3C1 C3C1 0.1500 3 0.00 
CARBOCY carbocyclic sugars--USED 
C21-C11-C3C1-C3C1 5/5/10 
O11  C01  C3C1 C3C1 0.4500 2 0.00 CARBOCY carbocyclic sugars 
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Dihedral K n δ Source 
C14  C01  C3C1 C3C1 0.1500 3 0.00 
CARBOCY carbocyclic sugars--USED 
C11-C11-C3C1-C3C1 5/5/10H 
HG2  C21  C3C1 C3C1 0.1500 3 0.00 CARBOCY carbocyclic sugars 
C24  C21  C3C1 C3C1 0.1500 3 0.00 
CARBOCY carbocyclic sugars--USED 
C21-C21-C3C1-C3C1 5/5/10 
CC0  C61  C61  C21 3.1000 2 180.00 
PROT JES 8/25/89 toluene and 
ethylbenzene--USED C61-C61-C61-
C21 5/5/10 
C21  CO5  C3C1 O351 0.7500 1 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 O351 0.1800 2 180.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 O351 0.0650 3 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 O351 0.0300 6 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 C3C1 0.7500 1 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 C3C1 0.1800 2 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 C3C1 0.0650 3 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 C3C1 0.0300 6 0.00 
TAKEN FROM C21 CO5 C21 C21 
EAP 3/9/12 
C21  CO5  C3C1 HG1 0.1000 3 0.00 
TAKEN FROM C21 CO5 C21 HG2 
EAP 3/9/12 
C3C1 C61  CC0  O351 6.0000 2 180.00 
TAKEN FROM C352 CC0 CC0 N351 
EAP 3/9/12 
CC0  C61  O351 C3C1 0.3000 2 180.00 
TAKEN FROM CC0 CC0 O351 C352 
EAP 3/9/12 
C14  C01  C3C1 C61 0.5000 4 180.00 
TAKEN FROM C21 C11 C3C1 C352 
(CC0) EAP 3/9/12 
O11  C01  C3C1 C61 0.1580 3 0.00 
TAKEN FROM O11 C11 C3C1 
C3C1(CC0) EAP 3/9/12 
C21  C01  C3C1 C61 0.5000 4 180.00 
TAKEN FROM C21 C11 C3C1 
C352(CC0) EAP 3/9/12 
C3C1 C01  C14  NP1 0.2000 3 0.00 
TAKEN FROM C21 C11 C14 NP3  
EAP 3/9/12 
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Dihedral K n δ Source 
C3C1 C01  C14  C21 0.1500 3 0.00 
TAKEN FROM C21 C11 C11 C3C1 
EAP 3/9/12 
C3C1 C01  C14  HG1 0.1500 3 0.00 
TAKEN FROM C3C1 C11 C11 HG1 
EAP 3/9/12 
C3C1 C01  O11  HP1 1.5000 1 0.00 
TAKEN FROM C3C1 C11 O11 HP1 
EAP 3/9/12 
C3C1 C01  O11  HP1 0.3000 2 180.00 
TAKEN FROM C3C1 C11 O11 HP1 
EAP 3/9/12 
C3C1 C01  O11  HP1 0.5000 3 0.00 
TAKEN FROM C3C1 C11 O11 HP1 
EAP 3/9/12 
C01  C14  C21  C61 0.0400 3 0.00 
TAKEN FROM C31 C11 C21 C61  
EAP 3/9/12 
C24  C21  C3C1 C61 0.2000 3 0.00 
TAKEN FROM C21 C21 C3C1 
C352(CC0) EAP 3/9/12 
C3C1 C21  C24  NP1 1.0000 3 0.00 
TAKEN FROM C21 C21 C24 NP1 
EAP 3/9/12 
C3C1 C21  C24  HG2 0.1950 3 0.00 
TAKEN FROM C3C1 C21 C21 HG2 
EAP 3/9/12 
C61  C3C1 C3C1 O351 1.2000 3 0.00 
TAKEN FROM C352(CC0) C3C1 
C3C1 O351 EAP 3/9/12 
C61  C3C1 C3C1 CO5 0.1500 3 0.00 
TAKEN FROM C352(CC0) C3C1 
C3C1 N61 EAP 3/9/12 
C3C1 C3C1 O351 CC0 0.0000 3 0.00 
TAKEN FROM C3C1 C3C1 O351 
C352 EAP 3/9/12 
C01  C3C1 C3C1 O351 1.2000 3 0.00 
TAKEN FROM C352 C3C1 C3C1 
O351 EAP 3/9/12 
CC0  O351 C3C1 HG1 0.3000 3 0.00 
TAKEN FROM CC0 O351 C352 HG2 
EAP 3/9/12 
O11  C61  CC0  O351 2.5800 2 180.00 
TAKEN FROM N11 C61 C61 O60 4 
EAP 3/9/12 
O351 C3C1 C3C1 C21 1.2000 3 0.00 
TAKEN FROM C352 C3C1 C3C1 
O351 EAP 3/9/12 
C61  CC0  O351 C3C1 0.3000 2 0.00 
TAKEN FROM C61 CC0 O351 C352 
EAP 3/9/12 
CC0  C61  C3C1 C3C1 1.0300 3 180.00 
TAKEN FROM CC0 CC0 C352 C352 
EAP 3/9/12 
CC0  C61  C3C1 C21 1.0300 3 180.00 
TAKEN FROM CC0 CC0 C352 C351 
EAP 3/9/12 
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Dihedral K n δ Source 
O351 C3C1 CO5  OD3 0.0000 2 0.00 
TAKEN FROM OD3 CO5 C11 C11  
EAP 3/13/12 
CO5  C3C1 C3C1 C01 4.0000 3 0.00 
TAKEN FROM C11 C3C1 C3C1 C21 
EAP 3/13/12 
CO5  C3C1 C3C1 C21 0.1500 3 0.00 
TAKEN FROM C21 C3C1 C3C1 C21 
EAP 3/13/12 
CC0  O351 C3C1 CO5 0.7300 3 0.00 
TAKEN FROM C352 C352 O351 C51 
EAP 3/13/12 
C14  NP1  C24  CD1 0.4700 1 0.00 
TAKEN FROM CD1 C24 NP1 C24 
PIPA EAP 3/13/12 
CD1 C24 NP1 C24 0.4700 1 0.00 
CNCC_1_100000_2nd_round PIPA 
EBP 5/18/10 
CD1 C24 NP1 HP2 0.7000 3 0.00 
CNCC_2_003000_1st_round PIPA EBP 
5/13/10 
CD2 CD1 C24 NP1 0.8400 2 0.00 
NCCC_1_023000_1st_ROUND PIPA 
EBP 10/5/10 
CD2 CD1 C24 NP1 1.3500 3 180.00 
NCCC_1_023000_1st_ROUND PIPA 
EBP 10/5/10 
HG4 CD1 C24 NP1 0.4100 4 180.00 
NCCC_2_000450_1st_round PIPA EBP 
10/13/10 
HG4 CD1 C24 NP1 0.1100 5 0.00 
NCCC_2_000450_1st_round PIPA EBP 
10/13/10 
CD2 CD1 C24 HG2 0.0200 5 180.00 
NCCC_3_000050_2nd_round PIPA 
EBP 10/18/10 
HG4 CD1 C24 HG2 1.2800 1 0.00 
NCCC_4_100400_1st_round PIPA EBP 
10/15/10 
HG4 CD1 C24 HG2 0.2300 4 180.00 
NCCC_4_100400_1st_round PIPA EBP 
10/15/10 
C24 CD1 CD2 HG5 5.2000 2 180.00 
TAKEN FROM C21-CD1-CD2-HG5 
3/9/12 
 
